Andrew Charlwood
2342 lines
470 KiB
CSV
2342 lines
470 KiB
CSV
Rec no.,TA ID,Year of Publication,STA/MTA process,Technology,Technology type,Indication,Categorisation (for specific recommendation),Comment
|
||
1,TA001,1999/00,MTA,Prophylactic removal,Surgical procedure,Wisdom teeth,Recommended,Recommendation in line with clinical practice. Moved to static list (review in 2011).
|
||
2,TA002,2000/01,MTA,Hip prostheses,Medical device,Hip disease,Recommended,Recommendation in line with clinical practice. Moved to static list.
|
||
3,TA003,2000/01,MTA,Paclitaxel,Pharmaceutical,Ovarian cancer,Recommended,Guidance has been replaced by TA55. Recommendation in line with marketing authorisation.
|
||
4,TA004,2000/01,MTA,Coronary artery stents ,Medical device,Ischaemic heart disease,Recommended,Guidance has been replaced by TA71. Recommendation in line with clinical practice.
|
||
5,TA005,2000/01,MTA,Liquid Based Cytology (LBC),Other therapeutic therapies,Cervical cancer,Only in Research,"Guidance has been replaced by TA69. At the time of appraisal the Committee advised that there was insufficient evidence to justify the nationwide introduction of LBC technology. However they recommended that large-scale pilot implementation studies should be carried out to evaluate the effectiveness, costs and practical implications of the introduction of LBC technology into the cervical screening programme. "
|
||
6,TA006,2000/01,MTA,Docetaxel,Pharmaceutical,Advanced breast cancer,Recommended,Guidance has been replaced by TA30. Recommendation in line with marketing authorisation.
|
||
7,TA006,2000/01,MTA,Paclitaxel,Pharmaceutical,Advanced breast cancer,Recommended,Guidance has been replaced by TA30. Recommendation in line with marketing authorisation.
|
||
8,TA007,2000/01,MTA,Lansoprazole,Pharmaceutical,Dyspepsia ,Recommended,Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
|
||
9,TA007,2000/01,MTA,Omeprazole,Pharmaceutical,Dyspepsia ,Recommended,Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
|
||
10,TA007,2000/01,MTA,Pantoprazole,Pharmaceutical,Dyspepsia ,Recommended,Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
|
||
11,TA007,2000/01,MTA,Rabeprazole,Pharmaceutical,Dyspepsia ,Recommended,Guidance has been incorporated in CG17. Recommendation in line with marketing authorisation.
|
||
12,TA008,2000/01,MTA,Analogue hearing aids,Medical device,Deafness,Recommended,The Department of Health made digital hearing aid technology available across the NHS after TA008 was published which made guidance obsolete. Guidance withdrawn from May 2003.
|
||
13,TA008,2000/01,MTA,Digital hearing aids,Medical device,Deafness,Not Recommended,The Department of Health made digital hearing aid technology available across the NHS after TA008 was published which made guidance obsolete. Guidance withdrawn from May 2003.
|
||
14,TA009,2000/01,MTA,Rosiglitazone ,Pharmaceutical,Type 2 diabetes,Recommended,Guidance has been replaced by TA63 and incorporated in CG66. Recommendation in line with marketing authorisation.
|
||
15,TA010,2000/01,MTA,Dry powder inhalers (DPI),Medical device,Asthma (children under 5 years),Recommended,Recommendation in line with marketing authorisation.
|
||
16,TA010,2000/01,MTA,Nebulised therapy,Other therapeutic therapies,Asthma (children under 5 years),Recommended,Recommendation in line with marketing authorisation.
|
||
17,TA010,2000/01,MTA,Pressurised metered dose inhalers (pMDI) and spacer system,Medical device,Asthma (children under 5 years),Recommended,Recommendation in line with marketing authorisation.
|
||
18,TA011,2000/01,MTA,Implantable cardioverter defibrillators (ICDs),Medical device,Arrhythmias,Recommended,Guidance has been replaced by TA95. Recommendation in line with clinical practice.
|
||
19,TA012,2000/01,MTA,Abciximab (intravenous),Pharmaceutical,Acute coronary syndromes,Recommended,Guidance has been replaced by TA47. Recommendation in line with marketing authorisation.
|
||
20,TA012,2000/01,MTA,Eptifibatide (intravenous),Pharmaceutical,Acute coronary syndromes,Recommended,Guidance has been replaced by TA47. Recommendation in line with marketing authorisation.
|
||
21,TA012,2000/01,MTA,Tirofiban (intravenous),Pharmaceutical,Acute coronary syndromes,Recommended,Guidance has been replaced by TA47. Recommendation in line with marketing authorisation.
|
||
22,TA013,2000/01,MTA,Methylphenidate,Pharmaceutical,Attention-Deficit Hyperactivity Disorder,Recommended,Guidance has been replaced by TA98. Recommendation in line with marketing authorisation
|
||
23,TA014,2000/01,MTA,Interferon alpha,Pharmaceutical,Hepatitis C ,Recommended,Guidance has been replaced by TA75 & TA106. Recommendation in line with marketing authorisation.
|
||
24,TA014,2000/01,MTA,Ribavirin and interferon alpha combination therapy,Pharmaceutical,Hepatitis C ,Recommended,Guidance has been replaced by TA75 & TA106. Recommendation in line with marketing authorisation.
|
||
25,TA015,2000/01,MTA,Zanamivir,Pharmaceutical,Influenza,Recommended,Guidance has been replaced by TA58 and then TA168. Recommendation in line with national influenza guidelines.
|
||
26,TA016,2000/01,MTA,Autologous Cartilage Transplantation (ACT),Surgical procedure,Knee joints (defective),Only in Research,"Guidance has been replaced by TA89. At the time of appraisal it was recommended that ACT should only be performed as part of a properly structured clinical trial, which, wherever possible, is randomised and adequately powered."
|
||
27,TA017,2000/01,MTA,Laparoscopic surgery ,Surgical procedure,Colorectal cancer ,Only in Research,Guidance replaced by TA105. At the time of appraisal it was recommended that laparoscopic surgery for colorectal cancer should be limited to use in a randomised controlled trial setting.
|
||
28,TA018,2000/01,MTA,Laparoscopic surgery,Surgical procedure,Hernia,Recommended,Recommendation in line with clinical practice.
|
||
29,TA019,2000/01,MTA,Donepezil,Pharmaceutical,Alzheimer's disease,Optimised,Guidance has been replaced by TA111. Optimised recommendation for use in specific circumstances in people with Alzheimer’s disease whose mini mental state examination (MMSE) score is above 12 points at the start of treatment and remains at least this high after every 6 months of treatment.
|
||
30,TA019,2000/01,MTA,Galantamine,Pharmaceutical,Alzheimer's disease,Optimised,Guidance has been replaced by TA111. Optimised recommendation for use in specific circumstances in people with Alzheimer’s disease whose mini mental state examination (MMSE) score is above 12 points at the start of treatment and remains at least this high after every 6 months of treatment.
|
||
31,TA019,2000/01,MTA,Rivastigmine,Pharmaceutical,Alzheimer's disease,Optimised,Guidance has been replaced by TA111. Optimised recommendation for use in specific circumstances in people with Alzheimer’s disease whose mini mental state examination (MMSE) score is above 12 points at the start of treatment and remains at least this high after every 6 months of treatment.
|
||
32,TA020,2000/01,MTA,Riluzole,Pharmaceutical,Motor neurone disease,Recommended,Recommendation in line with marketing authorisation.
|
||
33,TA021,2000/01,MTA,Pioglitazone,Pharmaceutical,Type 2 Diabetes,Recommended,Guidance has been replaced by TA63. Recommendation in line with marketing authorisation.
|
||
34,TA022,2000/01,MTA,Orlistat,Pharmaceutical,Obesity,Recommended,Guidance has been incorporated in CG43. Recommendation in line with marketing authorisation.
|
||
35,TA023,2001/02,MTA,Temozolomide,Pharmaceutical,Brain cancer (recurrent),Recommended,Recommendation in line with marketing authorisation.
|
||
36,TA024,2001/02,MTA,Alginate dressings,Other therapeutic therapies,Wound care,Recommended,Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
|
||
37,TA024,2001/02,MTA,Debriding agents - bio-surgical techniques (sterile maggots),Other therapeutic therapies,Wound care,Recommended,Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
|
||
38,TA024,2001/02,MTA,Foam dressings,Other therapeutic therapies,Wound care,Recommended,Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
|
||
39,TA024,2001/02,MTA,Hydrocolloids,Medical device,Wound care,Recommended,Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
|
||
40,TA024,2001/02,MTA,Hydrogels,Medical device,Wound care,Recommended,Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
|
||
41,TA024,2001/02,MTA,Polysaccharide beads/paste,Medical device,Wound care,Recommended,Guidance has been incorporated in CG74. Recommendation in line with clinical practice.
|
||
42,TA025,2001/02,MTA,Gemcitabine (1st line),Pharmaceutical,Pancreatic cancer ,Recommended,Recommended in line with clinical practice.
|
||
43,TA025,2001/02,MTA,Gemcitabine (2nd line),Pharmaceutical,Pancreatic cancer ,Not Recommended,At the time of appraisal there was insufficient evidence to support the use of gemcitabine as a second-line treatment in patients with pancreatic adenocarcinoma.
|
||
44,TA026,2001/02,MTA,Docetaxel (2nd line),Pharmaceutical,Non-small cell lung cancer ,Recommended,Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
|
||
45,TA026,2001/02,MTA,Gemcitabine (1st line),Pharmaceutical,Non-small cell lung cancer ,Recommended,Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
|
||
46,TA026,2001/02,MTA,Paclitaxel (1st line),Pharmaceutical,Non-small cell lung cancer ,Recommended,Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
|
||
47,TA026,2001/02,MTA,Vinorelbine (1st line),Pharmaceutical,Non-small cell lung cancer ,Recommended,Guidance has been incorporated in CG24. Recommendation in line with marketing authorisation.
|
||
48,TA027,2001/02,MTA,Celecoxib,Pharmaceutical,Osteoarthritis and rheumatoid arthritis,Optimised,Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at ‘high risk’ of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients.
|
||
49,TA027,2001/02,MTA,Etodolac,Pharmaceutical,Osteoarthritis and rheumatoid arthritis,Optimised,Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at ‘high risk’ of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients.
|
||
50,TA027,2001/02,MTA,Meloxicam,Pharmaceutical,Osteoarthritis and rheumatoid arthritis,Optimised,Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at ‘high risk’ of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients.
|
||
51,TA027,2001/02,MTA,Rofecoxib,Pharmaceutical,Osteoarthritis and rheumatoid arthritis,Optimised,Guidance has been incorporated in CG59 and CG79. Optimised recommendation for use in specific circumstances for people who may be at ‘high risk’ of developing serious gastrointestinal adverse effects. Guidance also highlighted uncertainty over the use of Cox II selective inhibitors in people with cardiovascular disease and indicated that they should not be prescribed routinely in preference to standard NSAIDs where these are indicated in this group of patients. Marketing authorisation for this technology was withdrawn by EMA after TA027 was published.
|
||
52,TA028,2001/02,MTA,Topotecan (2nd and subsequent lines of treatment),Pharmaceutical,Advanced ovarian cancer ,Recommended,Guidance has been replaced by TA91. Recommendation in line with marketing authorisation.
|
||
53,TA029,2001/02,MTA,Fludarabine - Intravenous formulation (2nd line),Pharmaceutical,Leukaemia (B-cell chronic lymphocytic),Recommended,Recommendation in line with marketing authorisation.
|
||
54,TA029,2001/02,MTA,Fludarabine - Oral formulation (2nd line),Pharmaceutical,Leukaemia (B-cell chronic lymphocytic),Recommended,Recommendation in line with marketing authorisation.
|
||
55,TA030,2001/02,MTA,Docetaxel (2nd line),Pharmaceutical,Advanced breast cancer ,Recommended,Update of guidance TA6. Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
|
||
56,TA030,2001/02,MTA,Docetaxel in combination with an anthracycline (1st line),Pharmaceutical,Advanced breast cancer ,Not Recommended,"Update of guidance TA6. Guidance has been incorporated in CG81. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
57,TA030,2001/02,MTA,Paclitaxel (2nd line),Pharmaceutical,Advanced breast cancer ,Recommended,Update of guidance TA6. Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
|
||
58,TA031,2001/02,MTA,Sibutramine ,Pharmaceutical,Obesity,Recommended,Guidance has been incorporated in CG43. Recommendation in line with marketing authorisation.
|
||
59,TA032,2001/02,MTA,Beta interferon,Pharmaceutical,Multiple sclerosis,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Moved to static list."
|
||
60,TA032,2001/02,MTA,Glatiramer acetate,Pharmaceutical,Multiple sclerosis,Not Recommended,"At the time of appraisal, the technology was not considered to be a good use of NHS resources based on the data available. Moved to static list."
|
||
61,TA033,2001/02,MTA,Irinotecan in combination with 5-fluorouracil and folinic acid (5FU/FA) (1st-line),Pharmaceutical,Colorectal cancer (advanced),Not Recommended,"Guidance replaced by TA93. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
62,TA033,2001/02,MTA,Irinotecan monotherapy (2nd line),Pharmaceutical,Colorectal cancer (advanced),Recommended,Guidance replaced by TA93. Recommendation in line with marketing authorisation.
|
||
63,TA033,2001/02,MTA,Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA) (1st-line),Pharmaceutical,Colorectal cancer (advanced),Optimised,Guidance has been replaced by TA93. Optimised recommendation for use in specific circumstances in patients with advanced colorectal cancer in patients with metastases that are confined solely to the liver and may become resectable (‘down staged’) following treatment.
|
||
64,TA033,2001/02,MTA,Raltitrexed,Pharmaceutical,Colorectal cancer (advanced),Only in Research,"Guidance replaced by TA93. At the time of appraisal, the Committee concluded from the available evidence that the need for rigorous monitoring and possibility of increased mortality outweigh any benefits of convenience of administration with raltitrexed. Therefore the technology was only recommended for use in the context of appropriately designed clinical trials."
|
||
65,TA034,2001/02,MTA,Trastuzumab in combination with paclitaxel,Pharmaceutical,Breast cancer,Recommended,Recommendation in line with marketing authorisation.
|
||
66,TA034,2001/02,MTA,Trastuzumab monotherapy,Pharmaceutical,Breast cancer,Recommended,Recommendation in line with marketing authorisation.
|
||
67,TA035,2001/02,MTA,Etanercept ,Pharmaceutical,Arthritis (juvenile idiopathic),Recommended,Recommendation in line with marketing authorisation.
|
||
68,TA036,2001/02,MTA,Etanercept,Pharmaceutical,Rheumatoid arthritis,Optimised,"Guidance has been partially replaced by TA130 and TA195. Optimised recommendation for use under specific circumstances in people who have not responded adequately to at least two DMARDs, including methotrexate (unless contraindicated). "
|
||
69,TA036,2001/02,MTA,Infliximab in combination with methotrexate,Pharmaceutical,Rheumatoid arthritis,Optimised,"Guidance has been replaced by TA130. Optimised recommendation for use under specific circumstances in people who have not responded adequately to at least two DMARDs, including methotrexate (unless contraindicated)."
|
||
70,TA037,2001/02,MTA,Rituximab (3rd and subsequent lines of treatment),Pharmaceutical,Lymphoma (follicular non-Hodgkin's) ,Not recommended,"Guidance replaced by TA137. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
71,TA037,2001/02,MTA,Rituximab (last line),Pharmaceutical,Lymphoma (follicular non-Hodgkin's) ,Only in Research,"Guidance replaced by TA137. At the time of appraisal, the technology was only recommended for last-line therapy in the context of the construction of a case series of past and new patients, to determine with more certainty its effectiveness in this indication."
|
||
72,TA038,2001/02,MTA,Breath actuated pressurised metered dose aerosol inhalers,Medical device,Asthma (older children),Recommended,Recommendation in line with marketing authorisations.
|
||
73,TA038,2001/02,MTA,Dry powder inhalers (DPI),Medical device,Asthma (older children),Recommended,Recommendation in line with marketing authorisations.
|
||
74,TA038,2001/02,MTA,Pressurised metered dose inhalers (pMDIs),Medical device,Asthma (older children) ,Recommended,Recommendation in line with marketing authorisations.
|
||
75,TA039,2001/02,MTA,Nicotine replacement therapy (NRT) and bupropion in combination,Pharmaceutical,Smoking cessation,Recommended,Guidance has been incorporated in PH10. Recommendation in line with marketing authorisation.
|
||
76,TA039,2001/02,MTA,Bupropion,Pharmaceutical,Smoking cessation,Recommended,Guidance has been incorporated in PH10. Recommendation in line with marketing authorisations.
|
||
77,TA039,2001/02,MTA,Nicotine replacement therapy (NRT),Pharmaceutical,Smoking cessation,Recommended,Guidance has been incorporated in PH10. Recommendation in line with marketing authorisations.
|
||
78,TA040,2002/03,MTA,Infliximab ,Pharmaceutical,Crohn's disease (active severe),Recommended,Recommendation in line with marketing authorisation.
|
||
79,TA040,2002/03,MTA,Infliximab ,Pharmaceutical,Crohn's disease (fistulising),Recommended,Recommendation in line with marketing authorisation.
|
||
80,TA041,2002/03,MTA,Routine antenatal anti-D prophylaxis (RAADP),Pharmaceutical,Pregnancy,Recommended,Guidance has been replaced by TA156. Recommendation in line with marketing authorisation and clinical practice.
|
||
81,TA042,2002/03,MTA,Somatropin ,Pharmaceutical,Growth hormone deficiency (children),Recommended,Guidance has been replaced by TA188. Recommendation in line with marketing authorisation.
|
||
82,TA043,2002/03,MTA,Amisulpride,Pharmaceutical,Schizophrenia,Recommended,Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
|
||
83,TA043,2002/03,MTA,Olanzapine,Pharmaceutical,Schizophrenia,Recommended,Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
|
||
84,TA043,2002/03,MTA,Quetiapine,Pharmaceutical,Schizophrenia,Recommended,Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
|
||
85,TA043,2002/03,MTA,Risperidone,Pharmaceutical,Schizophrenia,Recommended,Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
|
||
86,TA043,2002/03,MTA,Sertindole,Pharmaceutical,Schizophrenia,Recommended,Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
|
||
87,TA043,2002/03,MTA,Zotepine,Pharmaceutical,Schizophrenia,Recommended,Guidance has been incorporated in CG82. Recommendation in line with marketing authorisation.
|
||
88,TA044,2002/03,MTA,Metal on metal (MoM) hip resurfacing arthroplasty,Surgical procedure,Hip disease,Only in Research,"At the time of appraisal, it was recommended that where hip resurfacing arthroplasty is considered appropriate, the procedure should only be performed in the context of the ongoing collection of data on both the clinical effectiveness and cost-effectiveness of this technology. Ideally this data collection should form part of a UK national joint registry."
|
||
89,TA045,2002/03,MTA,Pegylated liposomal doxorubicin hydrochloride (PLDH) ,Pharmaceutical,Ovarian cancer (advanced),Recommended,Guidance has been replaced by TA91. Recommendation in line with marketing authorisation.
|
||
90,TA046,2002/03,MTA,Malabsorptive Surgery,Surgical procedure,Obesity (morbid),Recommended,Guidance has been incorporated in CG43. Recommendation in line with clinical practice.
|
||
91,TA046,2002/03,MTA,Restrictive Surgery,Surgical procedure,Obesity (morbid),Recommended,Guidance has been incorporated in CG43. Recommendation in line with clinical practice.
|
||
92,TA047,2002/03,MTA,Abciximab,Pharmaceutical,Acute coronary syndromes,Recommended,Update of guidance TA12. Recommendation in line with marketing authorisation.
|
||
93,TA047,2002/03,MTA,Eptifibitide,Pharmaceutical,Acute coronary syndromes,Recommended,Update of guidance TA12. Recommendation in line with marketing authorisation.
|
||
94,TA047,2002/03,MTA,Tirofiban,Pharmaceutical,Acute coronary syndromes,Recommended,Update of guidance TA12. Recommendation in line with marketing authorisation.
|
||
95,TA048,2002/03,MTA,Home haemodialysis,Other therapeutic therapies,Renal failure,Recommended,Recommendation in line with clinical practice.
|
||
96,TA049,2002/03,MTA,Audio-guided Doppler ultrasound guidance,Other therapeutic therapies,Central venous catheters,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
97,TA049,2002/03,MTA,Two-dimensional (2-D) imaging ultrasound guidance,Other therapeutic therapies,Central venous catheters,Optimised,Optimised recommendation for use in specific circumstances for adults and children in elective or emergency situations.
|
||
98,TA050,2002/03,MTA,Imatinib,Pharmaceutical,Leukaemia (CML),Recommended,Guidance has been replaced by TA70. Recommendation in line with marketing authorisation.
|
||
99,TA051,2002/03,MTA,Beating the Blues - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Only in Research,"Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. The evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects. "
|
||
100,TA051,2002/03,MTA,Calipso Overcoming Depression Self-Help Materials - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Only in Research,"Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient basis to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects."
|
||
101,TA051,2002/03,MTA,COPE - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Only in Research,"Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects."
|
||
102,TA051,2002/03,MTA,FearFighter - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Only in Research,"Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects."
|
||
103,TA051,2002/03,MTA,Restoring the Balance - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Only in Research,"Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects."
|
||
104,TA051,2002/03,MTA,StressPac - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Only in Research,"Guidance has been replaced by TA97. At the time of appraisal, research suggested that the delivery of cognitive behavioural therapy via a computer interface (CCBT) may be of value in the management of anxiety and depressive disorders. This evidence was, however, insufficient to recommend the general introduction of this technology into the NHS. To establish the contribution and place of CCBT in the management of anxiety and depressive disorders, including its role within ‘stepped care’ approaches, the NHS was advised to consider supporting an independent programme of research into CCBT, including carefully monitored pilot implementation projects."
|
||
105,TA052,2002/03,MTA,Alteplase,Pharmaceutical,Myocardial infarction,Recommended,Recommendation in line with clinical practice.
|
||
106,TA052,2002/03,MTA,Reteplase,Pharmaceutical,Myocardial infarction,Recommended,Recommendation in line with clinical practice.
|
||
107,TA052,2002/03,MTA,Streptokinase,Pharmaceutical,Myocardial infarction,Recommended,Recommendation in line with clinical practice.
|
||
108,TA052,2002/03,MTA,Tenecteplase,Pharmaceutical,Myocardial infarction,Recommended,Recommendation in line with clinical practice.
|
||
109,TA053,2002/03,MTA,Insulin glargine,Pharmaceutical,Type 1 diabetes ,Recommended,Recommendation in line with clinical practice.
|
||
110,TA053,2002/03,MTA,Insulin glargine,Pharmaceutical,Type 2 diabetes,Optimised,"Optimised recommendation for use in specific circumstances for people who require assistance with their treatment administration, or whose lifestyle is significantly restricted by recurrent symptomatic hypoglycaemic episodes, or for those who would otherwise need twice daily basal insulin injections in combination with oral anti-diabetic drugs."
|
||
111,TA054,2002/03,MTA,Vinorelbine combination therapies,Pharmaceutical,Breast cancer,Not Recommended,"Guidance has been incorporated in CG81. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
112,TA054,2002/03,MTA,Vinorelbine monotherapy,Pharmaceutical,Breast cancer,Recommended,Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
|
||
113,TA055,2002/03,MTA,Paclitaxel (1st line),Pharmaceutical,Ovarian cancer ,Recommended,Update of guidance TA3. Recommendation in line with marketing authorisation.
|
||
114,TA055,2002/03,MTA,Paclitaxel (2nd line),Pharmaceutical,Ovarian cancer ,Recommended,"Update of guidance TA3. Recommendation in line with clinical practice. In view of the limited evidence available on the clinical effectiveness of paclitaxel as a second-line treatment, the Committee concluded that paclitaxel should be considered as an option for second-line treatment only for women who do not receive it as part of their first-line therapy. For such women, it should be offered alongside other drugs that are licensed for second-lien treatment of ovarian cancer."
|
||
115,TA056,2002/03,MTA,Tension-free vaginal tape (Gynecare TVT) ,Medical device,Stress incontinence,Recommended,Guidance has been incorporated in CG40. Recommendation in line with clinical practice.
|
||
116,TA057,2002/03,MTA,Continuous subcutaneous insulin infusion (CSII or ‘insulin pump therapy'),Pharmaceutical,Type 1 diabetes,Optimised,"Guidance has been replaced by TA151. Optimised recommended for use in specific circumstances, for people whose HbA1c levels have remained high (at 8.5% or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care. "
|
||
117,TA057,2002/03,MTA,Continuous subcutaneous insulin infusion (CSII or ‘insulin pump therapy'),Pharmaceutical,Type 2 diabetes,Not Recommended,"Guidance has been replaced by TA151. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
118,TA058,2002/03,MTA,Amantadine,Pharmaceutical,Influenza (treatment),Not Recommended,"Guidance has been replaced by TA168. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
119,TA058,2002/03,MTA,Oseltamivir,Pharmaceutical,Influenza (treatment),Recommended,Update of guidance TA15. Guidance has been replaced by TA168. Recommendation in line with national influenza guidelines.
|
||
120,TA058,2002/03,MTA,Zanamivir,Pharmaceutical,Influenza (treatment),Recommended,Update of guidance TA15. Guidance has been replaced by TA168. Recommendation in line with national influenza guidelines.
|
||
121,TA059,2003/04,MTA,Electroconvulsive therapy (ECT) ,Other therapeutic therapies,Electroconvulsive therapy (ECT) ,Optimised,"Optimised recommendation for use in specific circumstances as a last-line treatment option for those with severe depressive illness, catatonia and prolonged or severe manic episode. "
|
||
122,TA060,2003/04,MTA,Structured patient education,Health promotion activities,Diabetes (types 1 and 2),Recommended,Recommendation in line with clinical practice.
|
||
123,TA061,2003/04,MTA,Capecitabine,Pharmaceutical,Colorectal cancer,Recommended,Recommendation in line with marketing authorisation.
|
||
124,TA061,2003/04,MTA,Tegafur with uracil,Pharmaceutical,Colorectal cancer,Recommended,Recommendation in line with marketing authorisation.
|
||
125,TA062,2003/04,MTA,Capecitabine,Pharmaceutical,Breast cancer (locally advanced or metastatic),Recommended,Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
|
||
126,TA062,2003/04,MTA,"Capecitabine, plus docetaxel",Pharmaceutical,Breast cancer (locally advanced or metastatic),Recommended,Guidance has been incorporated in CG81. Recommendation in line with marketing authorisation.
|
||
127,TA063,2003/04,MTA,Pioglitazone in combination with a sulphonylurea,Pharmaceutical,Type 2 diabetes,Optimised,"Update of guidance TA21. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances, for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated."
|
||
128,TA063,2003/04,MTA,Pioglitazone in combination with metformin,Pharmaceutical,Type 2 diabetes,Optimised,"Update of guidance TA21. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated."
|
||
129,TA063,2003/04,MTA,Rosiglitazone in combination with a sulphonylurea,Pharmaceutical,Type 2 diabetes,Optimised,"Update of guidance TA9. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated."
|
||
130,TA063,2003/04,MTA,Rosiglitazone in combination with metformin,Pharmaceutical,Type 2 diabetes,Optimised,"Update of guidance TA9. Guidance has been incorporated in CG66. Optimised recommendation for use in specific circumstances for people with type 2 diabetes who are unable to take metformin and a sulphonylurea in combination because of intolerance or a contraindication to one of the drugs; in this instance, the glitazone should replace in the combination the drug that is poorly tolerated or contraindicated."
|
||
131,TA064,2003/04,MTA,Somatropin,Pharmaceutical,Growth hormone deficiency (adults),Optimised,"Optimised recommendation for use in specific circumstances for people who have severe GH deficiency and they have a perceived impairment of quality of life (QoL), as demonstrated by a reported score of at least 11 in the disease-specific ‘Quality of life assessment of growth hormone deficiency in adults’ (QoL-AGHDA) questionnaire; and they are already receiving treatment for any other pituitary hormone deficiencies as required."
|
||
132,TA065,2003/04,MTA,Rituximab,Pharmaceutical,Non-Hodgkin's lymphoma - stage II - IV,Recommended,Recommendation in line with marketing authorisation.
|
||
133,TA065,2003/04,MTA,Rituximab,Pharmaceutical,Non-Hodgkin's lymphoma - stage I,Only in Research,"At the time of appraisal, the clinical and cost-effectiveness of rituximab in patients with localised (stage 1) disease had not been established. Therefore use in these circumstances was only recommended as part of ongoing or new clinical studies. "
|
||
134,TA066,2003/04,MTA,Olanzapine,Pharmaceutical,Bipolar disorder,Recommended,Guidance has been incorporated in CG38. Recommendation in line with marketing authorisation.
|
||
135,TA066,2003/04,MTA,Valproate semisodium,Pharmaceutical,Bipolar disorder,Recommended,Guidance has been incorporated in CG38. Recommendation in line with marketing authorisation.
|
||
136,TA067,2003/04,MTA,Amantadine,Pharmaceutical,Influenza (prevention),Not recommended,"Guidance has been replaced by TA158. At the time of appraisal, no direct evidence was available on the clinical effectiveness of amantadine at a dose of 100 mg for at-risk groups. "
|
||
137,TA067,2003/04,MTA,Oseltamivir,Pharmaceutical,Influenza (prevention),Recommended,Guidance has been replaced by TA158. Recommendation in line with national influenza guidelines.
|
||
138,TA068,2003/04,MTA,Photodynamic therapy (PDT),Other therapeutic therapies,Macular degeneration,Optimised,Optimised recommendation for use in specific circumstances for people with wet age-related macular degeneration who have a confirmed diagnosis of classic with no occult subfoveal CNV and best-corrected visual acuity 6/60 or better.
|
||
139,TA069,2003/04,MTA,Liquid Based Cytology (LBC),Other therapeutic therapies,Cervical cancer,Recommended,Update of guidance TA5. Moved to static list in 2007. Recommendation in line with clinical practice.
|
||
140,TA070,2003/04,MTA,Imatinib,Pharmaceutical,Leukaemia (CML),Recommended,Update of guidance TA50. Guidance has been partially updated by TA241 and TA251. Recommendation in line with marketing authorisation.
|
||
141,TA071,2003/04,MTA,Bare-metal stent (BMS),Medical device,Ischaemic heart disease,Recommended,Update of guidance TA4. Recommendation in line with clinical practice.
|
||
142,TA071,2003/04,MTA,Drug-eluting stent (DES) - paclitaxel-eluting,Medical device,Ischaemic heart disease,Optimised,Update of guidance TA4. Optimised recommendation for use under specific circumstances depending on vessel anatomy.
|
||
143,TA071,2003/04,MTA,Drug-eluting stent (DES) - sirolimus-eluting,Medical device,Ischaemic heart disease,Optimised,Update of guidance TA4. Optimised recommendation for use under specific circumstances depending on vessel anatomy.
|
||
144,TA072,2003/04,MTA,Anakinra,Pharmaceutical,Rheumatoid arthritis,Only in Research,"Guidance has been incorporated in CG79. At the time of appraisal, there was insufficient evidence to recommend anakinra for the treatment of rheumatoid arthritis, except in the context of a controlled, long-term clinical study. "
|
||
145,TA073,2003/04,MTA,Myocardial perfusion scintigraphy (MPS) using single photon emission computed tomography (SPECT),Other therapeutic therapies,Angina and myocardial infarction,Recommended,Guidance has been partially incorporated in CG95. Recommendation in line with clinical practice.
|
||
146,TA074,2003/04,MTA,Pre-hospital fluid replacement therapy - crystalloid solutions,Other therapeutic therapies,Trauma,Recommended,Recommendation in line with clinical practice.
|
||
147,TA075,2003/04,MTA,Peginterferon alfa and ribavirin – combination therapy,Pharmaceutical,Hepatitis C,Recommended,Update of guidance TA14. Recommendation in line with marketing authorisation.
|
||
148,TA075,2003/04,MTA,Peginterferon alfa monotherapy,Pharmaceutical,Hepatitis C,Recommended,Update of guidance TA14. Recommendation in line with marketing authorisation.
|
||
149,TA076,2003/04,MTA,Gabapentin,Pharmaceutical,Epilepsy (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
150,TA076,2003/04,MTA,Lamotrigine,Pharmaceutical,Epilepsy (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
151,TA076,2003/04,MTA,Levetiracetam,Pharmaceutical,Epilepsy (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
152,TA076,2003/04,MTA,Oxcarbazepine,Pharmaceutical,Epilepsy (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
153,TA076,2003/04,MTA,Tiagabine,Pharmaceutical,Epilepsy (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
154,TA076,2003/04,MTA,Topiramate,Pharmaceutical,Epilepsy (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
155,TA076,2003/04,MTA,Vigabatrin,Pharmaceutical,Epilepsy (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
156,TA077,2004/05,MTA,Zaleplon,Pharmaceutical,Insomnia ,Recommended,Recommendation in line with marketing authorisation.
|
||
157,TA077,2004/05,MTA,Zolpidem,Pharmaceutical,Insomnia ,Recommended,Recommendation in line with marketing authorisation.
|
||
158,TA077,2004/05,MTA,Zopiclone,Pharmaceutical,Insomnia ,Recommended,Recommendation in line with marketing authorisation.
|
||
159,TA078,2003/04,MTA,Fluid-filled thermal balloon endometrial ablation,Surgical procedure,Menstrual bleeding,Recommended,Recommendation in line with clinical practice.
|
||
160,TA078,2003/04,MTA,Microwave endometrial ablation,Surgical procedure,Menstrual bleeding,Recommended,Recommendation in line with clinical practice.
|
||
161,TA079,2004/05,MTA,Gabapentin,Pharmaceutical,Epilepsy (children),Recommended,Recommendation in line with marketing authorisation.
|
||
162,TA079,2004/05,MTA,Lamotrigine,Pharmaceutical,Epilepsy (children),Recommended,Recommendation in line with marketing authorisation.
|
||
163,TA079,2004/05,MTA,Oxcarbazepine,Pharmaceutical,Epilepsy (children),Recommended,Recommendation in line with marketing authorisation.
|
||
164,TA079,2004/05,MTA,Tiagabine,Pharmaceutical,Epilepsy (children),Recommended,Recommendation in line with marketing authorisation.
|
||
165,TA079,2004/05,MTA,Topiramate,Pharmaceutical,Epilepsy (children),Recommended,Recommendation in line with marketing authorisation.
|
||
166,TA079,2004/05,MTA,Vigabatrin,Pharmaceutical,Epilepsy (children),Recommended,Recommendation in line with marketing authorisation.
|
||
167,TA080,2004/05,MTA,Clopidogrel,Pharmaceutical,Acute coronary syndromes,Optimised,Guidance has been incorporated in CG94. Optimised recommendation for use in specific circumstances for people who are at moderate to high risk of myocardial infarction or death.
|
||
168,TA081,2004/05,MTA,Alclometasone dipropionate,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
169,TA081,2004/05,MTA,Beclometasone dipropionate,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
170,TA081,2004/05,MTA,Betamethasone Esters (in guidance: Betamethasone valerate),Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
171,TA081,2004/05,MTA,Clobetasol propionate,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
172,TA081,2004/05,MTA,Clobetasone butyrate,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
173,TA081,2004/05,MTA,Desoximetasone (old name: desoxymethasone) ,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
174,TA081,2004/05,MTA,Diflucortolone valerate,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
175,TA081,2004/05,MTA,Fludroxycortide,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
176,TA081,2004/05,MTA,Fluocinolone acetonide,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
177,TA081,2004/05,MTA,Fluocinonide,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
178,TA081,2004/05,MTA,Fluocortolone,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
179,TA081,2004/05,MTA,Fluticasone propionate,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
180,TA081,2004/05,MTA,Halcinonide,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
181,TA081,2004/05,MTA,Hydrocortisone,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
182,TA081,2004/05,MTA,Hydrocortisone butyrate,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
183,TA081,2004/05,MTA,Mometasone furoate,Pharmaceutical,Atopic dermatitis (eczema) ,Recommended,Recommendation in line with clinical practice.
|
||
184,TA082,2004/05,MTA,Pimecrolimus,Pharmaceutical,Atopic dermatitis (eczema),Recommended,Recommendation in line with clinical practice.
|
||
185,TA082,2004/05,MTA,Tacrolimus,Pharmaceutical,Atopic dermatitis (eczema),Recommended,Recommendation in line with clinical practice.
|
||
186,TA083,2004/05,MTA,Laparoscopic surgery - totally extraperitonea procedurel [TEP],Surgical procedure,Hernia,Recommended,Recommendation in line with clinical practice.
|
||
187,TA083,2004/05,MTA,Laparoscopic surgery - transabdominal preperitoneal procedure [TAPP],Surgical procedure,Hernia,Recommended,Recommendation in line with clinical practice.
|
||
188,TA084,2004/05,MTA,Drotrecogin ,Pharmaceutical,Sepsis (severe),Recommended,Recommendation in line with marketing authorisation.
|
||
189,TA085,2004/05,MTA,Induction therapy (basiliximab),Pharmaceutical,Renal transplantation (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
190,TA085,2004/05,MTA,Induction therapy (daclizumab),Pharmaceutical,Renal transplantation (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
191,TA085,2004/05,MTA,Mycophenolate mofetil (MMF),Pharmaceutical,Renal transplantation (adults),Optimised,"Optimised recommendation for use in specific circumstances for people with proven intolerance to calcineurin inhibitors, particularly nephrotoxicity leading to risk of chronic allograft dysfunction, or; in situations where there is a very high risk of nephrotoxicity necessitating minimisation or avoidance of a calcineurin inhibitor. "
|
||
192,TA085,2004/05,MTA,Sirolimus,Pharmaceutical,Renal transplantation (adults),Optimised,Optimised recommendation for use in specific circumstances for people with proven intolerance to calcineurin inhibitors (including nephrotoxicity) necessitating complete withdrawal of these treatments.
|
||
193,TA085,2004/05,MTA,Tacrolimus,Pharmaceutical,Renal transplantation (adults),Recommended,Recommendation in line with marketing authorisation.
|
||
194,TA086,2004/05,MTA,Imatinib,Pharmaceutical,"Gastrointestinal stromal tumours (unresectable, metastatic)",Recommended,Guidance has been partially updated by TA209. Recommendation in line with marketing authorisation.
|
||
195,TA087,2004/05,MTA,Alendronate,Pharmaceutical,Osteoporosis - secondary prevention,Optimised,"Guidance has been replaced by TA161. Optimised recommendation for use in specific circumstances for women aged 75 years and older, without the need for prior dual energy X-ray absorptiometry (DEXA) scanning; or in women aged between 65 and 74 years if the presence of osteoporosis is confirmed by DEXA scanning; or in postmenopausal women younger than 65 years of age, if they have a very low bone mineral density or if they have confirmed osteoporosis plus one, or more, additional age-independent risk factor."
|
||
196,TA087,2004/05,MTA,Etidronate,Pharmaceutical,Osteoporosis - secondary prevention,Optimised,"Guidance has been replaced by TA161. Optimised recommendation for use in specific circumstances for women aged 75 years and older, without the need for prior dual energy X-ray absorptiometry (DEXA) scanning; or in women aged between 65 and 74 years if the presence of osteoporosis is confirmed by DEXA scanning; or in postmenopausal women younger than 65 years of age, if they have a very low bone mineral density or if they have confirmed osteoporosis plus one, or more, additional age-independent risk factor."
|
||
197,TA087,2004/05,MTA,Raloxifene,Pharmaceutical,Osteoporosis - secondary prevention,Optimised,"Guidance has been replaced by TA161. Optimised recommendation for use under specific circumstances for women in whom bisphosphonates are contraindicated or who are physically unable to comply with the special recommendations for use of bisphosphonates, or who have had an unsatisfactory response to bisphosphonates, or who are intolerant of bisphosphonates."
|
||
198,TA087,2004/05,MTA,Risedronate,Pharmaceutical,Osteoporosis - secondary prevention,Optimised,"Guidance has been replaced by TA161. Optimised recommendation for use in specific circumstances for women aged 75 years and older, without the need for prior dual energy X-ray absorptiometry (DEXA) scanning; or in women aged between 65 and 74 years if the presence of osteoporosis is confirmed by DEXA scanning; or in postmenopausal women younger than 65 years of age, if they have a very low bone mineral density or if they have confirmed osteoporosis plus one, or more, additional age-independent risk factor."
|
||
199,TA087,2004/05,MTA,Teriparatide,Pharmaceutical,Osteoporosis - secondary prevention,Optimised,"Guidance has been replaced by TA161. Optimised recommendation for use under specific circumstances for women aged 65 years and older who have had an unsatisfactory response to bisphosphonates or intolerance to bisphosphonates, and who have an extremely low BMD (with a T-score of approximately –4 SD or below), or who have a very low BMD (with a T-score of approximately –3 SD or below) plus multiple fractures (that is, more than two) plus one, or more, additional age-independent risk factor: low body mass index (< 19 kg/m2); family history of maternal hip fracture before the age of 75 years; untreated premature menopause; conditions associated with prolonged immobility."
|
||
200,TA088,2004/05,MTA,Dual chamber pacemakers,Medical device,Bradycardia,Recommended,Recommendation in line with clinical practice.
|
||
201,TA089,2005/06,MTA,Autologous chondrocyte implantation (ACI),Surgical procedure,Cartilage injury,Only in Research,"Update of guidance TA16. At the time of appraisal, there was insufficient evidence on the effectiveness of ACI for it to be recommended, except in the context of new or ongoing clinical studies designed to generate robust and relevant outcome data including the measurement of health related quality of life and long term follow up. "
|
||
202,TA090,2005/06,MTA,Modified-release (MR) dipyridamole,Pharmaceutical,Vascular disease,Optimised,Guidance has been replaced by TA210. Optimised recommendation for use in specific circumstances for people who are intolerant of low-dose aspirin and either have experienced an occlusive vascular event or have symptomatic peripheral arterial disease.
|
||
203,TA090,2005/06,MTA,Clopidogrel,Pharmaceutical,Vascular disease,Optimised,Guidance has been replaced by TA210. Optimised recommendation for use in specific circumstances in combination with aspirin for people who have had an ischaemic stroke or a transient ischaemic attack for a period of 2 years from the most recent event.
|
||
204,TA091,2005/06,MTA,Pegylated liposomal doxorubicin hydrochloride (PLDH),Pharmaceutical,Ovarian cancer (advanced),Recommended,Recommendation in line with marketing authorisation.
|
||
205,TA091,2005/06,MTA,Topotecan,Pharmaceutical,Ovarian cancer (advanced),Recommended,Recommendation in line with marketing authorisation.
|
||
206,TA091,2005/06,MTA,Paclitaxel,Pharmaceutical,Ovarian cancer (advanced),Recommended,Update of guidance TA45. Recommendation in line with marketing authorisation.
|
||
207,TA091,2005/06,MTA,Paclitaxel in combination with a platinum-based compound,Pharmaceutical,Ovarian cancer (advanced),Recommended,"Update of guidance TA28. Recommendation in line with clinical practice for women in whom PLDH and single-agent paclitaxel are considered inappropriate because they have previously been exposed to PLDH and single-agent paclitaxel, or if the impact of the adverse effects of treatment with these drugs is considered unacceptable. "
|
||
208,TA092,2005/06,MTA,HealOzone,Medical device,Tooth decay,Only in Research,"At the time of appraisal, the Committee concluded that there was insufficient evidence on the effectiveness of HealOzone treatment for this technology to be recommended, except as part of well designed randomised controlled trials."
|
||
209,TA093,2005/06,MTA,Irinotecan,Pharmaceutical,Colorectal cancer (advanced),Recommended,Update of guidance TA33. Recommendation in line with marketing authorisation.
|
||
210,TA093,2005/06,MTA,Irinotecan in combination with 5-fluorouracil and folinic acid,Pharmaceutical,Colorectal cancer (advanced),Recommended,Update of guidance TA33. Recommendation in line with marketing authorisation.
|
||
211,TA093,2005/06,MTA,Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA),Pharmaceutical,Colorectal cancer (advanced),Recommended,Update of guidance TA33. Recommendation in line with marketing authorisation.
|
||
212,TA093,2005/06,MTA,Raltitrexed,Pharmaceutical,Colorectal cancer (advanced),Only in Research,"Update of guidance TA33. At the time of appraisal, the Committee concluded from the available evidence that the need for rigorous monitoring and possibility of increased mortality outweigh any benefits of convenience of administration with raltitrexed. Therefore the technology was only recommended for use in the context of appropriately designed clinical trials. "
|
||
213,TA094,2005/06,MTA,Atorvastatin,Pharmaceutical,Cardiovascular disease,Recommended,Recommendation in line with clinical practice.
|
||
214,TA094,2005/06,MTA,Fluvastatin,Pharmaceutical,Cardiovascular disease,Recommended,Recommendation in line with clinical practice.
|
||
215,TA094,2005/06,MTA,Pravastatin,Pharmaceutical,Cardiovascular disease,Recommended,Recommendation in line with clinical practice.
|
||
216,TA094,2005/06,MTA,Rosuvastatin,Pharmaceutical,Cardiovascular disease,Recommended,Recommendation in line with clinical practice.
|
||
217,TA094,2005/06,MTA,Simvastatin,Pharmaceutical,Cardiovascular disease,Recommended,Recommendation in line with clinical practice.
|
||
218,TA095,2005/06,MTA,Implantable cardioverter defibrillators (ICDs),Medical device,Arrhythmia (secondary prevention),Recommended,Update of guidance TA11. Recommendation in line with clinical practice.
|
||
219,TA095,2005/06,MTA,Implantable cardioverter defibrillators (ICDs),Medical device,Arrhythmia (primary prevention),Recommended,Update of guidance TA11. Recommendation in line with clinical practice.
|
||
220,TA096,2005/06,MTA,Adefovir dipivoxil,Pharmaceutical,Hepatitis B (chronic),Optimised,"Optimised recommendation for use under specific circumstances if treatment with interferon alfa or peginterferon alfa-2a has been unsuccessful, or a relapse occurs after successful initial treatment, or treatment with interferon alfa or peginterferon alfa-2a is poorly tolerated or contraindicated."
|
||
221,TA096,2005/06,MTA,Adefovir dipivoxil in combination with lamivudine,Pharmaceutical,Hepatitis B (chronic),Optimised,"Optimised recommendation for use under specific circumstances either alone or in combination with lamivudine when: treatment with lamivudine has resulted in viral resistance, or lamivudine resistance is likely to occur rapidly (for example, in the presence of highly replicative hepatitis B disease), and development of lamivudine resistance is likely to have an adverse outcome (for example, if a flare of the infection is likely to precipitate decompensated liver disease."
|
||
222,TA096,2005/06,MTA,Peginterferon alfa-2a,Pharmaceutical,Hepatitis B (chronic),Recommended,Recommendation in line with marketing authorisation.
|
||
223,TA097,2005/06,MTA,OCFighter (previously known as BTSteps) - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Not Recommended,"Update of guidance TA51. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
224,TA097,2005/06,MTA,Beating the Blues - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Recommended,Update of guidance TA51. Recommendation in line with clinical practice.
|
||
225,TA097,2005/06,MTA,FearFighter - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Recommended,Update of guidance TA51. Recommendation in line with clinical practice.
|
||
226,TA097,2005/06,MTA,COPE - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Only in Research,Update of guidance TA51. At the time of appraisal there was insufficient evidence to recommend the technology as an option for the management of depression except as part of new or ongoing clinical trials designed to generate robust and relevant clinical effectiveness data.
|
||
227,TA097,2005/06,MTA,Overcoming Depression - computerised cognitive behavioural therapy (CCBT) package,Other therapeutic therapies,Depression and anxiety,Only in Research,Update of guidance TA51. At the time of appraisal there was insufficient evidence to recommend the technology as an option for the management of depression except as part of new or ongoing clinical trials designed to generate robust and relevant clinical effectiveness data.
|
||
228,TA098,2005/06,MTA,Atomoxetine,Pharmaceutical,Attention deficit hyperactivity disorder (ADHD) ,Recommended,Update of guidance TA13. Recommendation in line with marketing authorisation.
|
||
229,TA098,2005/06,MTA,Dexamfetamine,Pharmaceutical,Attention deficit hyperactivity disorder (ADHD) ,Recommended,Update of guidance TA13. Recommendation in line with marketing authorisation.
|
||
230,TA098,2005/06,MTA,Methylphenidate,Pharmaceutical,Attention deficit hyperactivity disorder (ADHD) ,Recommended,Update of guidance TA13. Recommendation in line with marketing authorisation.
|
||
231,TA099,2006/07,MTA,Basiliximab,Pharmaceutical,Renal transplantation - children and adolescents ,Recommended,Recommendation in line with marketing authorisation.
|
||
232,TA099,2006/07,MTA,Daclizumab,Pharmaceutical,Renal transplantation - children and adolescents ,Recommended,Recommendation in line with marketing authorisation.
|
||
233,TA099,2006/07,MTA,Mycophenolate mofetil (MMF),Pharmaceutical,Renal transplantation (children),Optimised,"Optimised recommendation for use in specific circumstances when there is proven intolerance to calcineurin inhibitors, particularly nephrotoxicity which could lead to risk of chronic allograft dysfunction, or there is a very high risk of nephrotoxicity necessitating the minimisation or avoidance of a calcineurin inhibitor until the period of high risk has passed. "
|
||
234,TA099,2006/07,MTA,Mycophenolate sodium (MPS),Pharmaceutical,Renal transplantation (children),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
235,TA099,2006/07,MTA,Sirolimus,Pharmaceutical,Renal transplantation (children),Optimised,Optimised recommendation for use in specific circumstances for children or adolescents undergoing renal transplantation except proven intolerance to calcineurin inhibitors (including nephrotoxicity) necessitates the complete withdrawal of these treatments.
|
||
236,TA099,2006/07,MTA,Tacrolimus,Pharmaceutical,Renal transplantation (children),Recommended,Recommendation in line with marketing authorisation.
|
||
237,TA100,2006/07,MTA,Capecitabine (adjuvant),Pharmaceutical,Colon cancer ,Recommended,Recommendation in line with marketing authorisation. Moved to static list.
|
||
238,TA100,2006/07,MTA,Oxaliplatin in combination with 5-fluorouracil and folinic acid (5FU/FA) (adjuvant),Pharmaceutical,Colon cancer ,Recommended,Recommendation in line with marketing authorisation. Moved to static list.
|
||
239,TA101,2006/07,MTA,Docetaxel,Pharmaceutical,Prostate cancer (hormone-refractory),Recommended,Recommendation in line with marketing authorisation.
|
||
240,TA102,2006/07,MTA,Group-based parent-training/education programmes,Health promotion activities,Conduct disorder in children,Recommended,Recommendation in line with clinical practice.
|
||
241,TA102,2006/07,MTA,Individual-based parent-training/education programmes,Health promotion activities,Conduct disorder in children,Recommended,Recommendation in line with clinical practice.
|
||
242,TA103,2006/07,MTA,Efaluzimab,Pharmaceutical,Psoriasis,Optimised,Optimised recommendation for use in specific circumstances in people with severe disease defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 after failure or intolerance to etanercept. Marketing authorisation was withdrawn by EMA after publication of TA103.
|
||
243,TA103,2006/07,MTA,Etanercept,Pharmaceutical,Psoriasis,Recommended,Recommendation in line with clinical practice.
|
||
244,TA104,2006/07,MTA,Etanercept,Pharmaceutical,Psoriatic arthritis,Recommended,Guidance has been replaced by TA199. Recommendation in line with clinical practice.
|
||
245,TA104,2006/07,MTA,Infliximab,Pharmaceutical,Psoriatic arthritis,Optimised,"Guidance has been replaced by TA199. Optimised recommendation for use in specific circumstances when a person has peripheral arthritis with three or more tender joints and three or more swollen joints; the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying anti-rheumatic drugs (DMARDs), administered either individually or in combination; the person has been shown to be intolerant of, or have contraindications to, treatment with etanercept or has major difficulties with self administered injections. "
|
||
246,TA105,2006/07,MTA,Laparoscopic resection,Surgical procedure,Colorectal cancer,Recommended,Update of guidance TA17. Recommendation in line with clinical practice.
|
||
247,TA106,2006/07,MTA,Peginterferon alfa-2a and ribavirin or peginterferon alfa-2b and ribavirin Combination therapy,Pharmaceutical,Hepatitis C,Recommended,Recommendation in line with marketing authorisation.
|
||
248,TA106,2006/07,MTA,Peginterferon alfa-2a or peginterferon alfa-2b,Pharmaceutical,Hepatitis C,Recommended,Recommendation in line with marketing authorisation.
|
||
249,TA107,2006/07,STA,Trastuzumab,Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.
|
||
250,TA108,2006/07,STA,Paclitaxel,Pharmaceutical,Breast cancer (early),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
251,TA109,2006/07,STA,Docetaxel with doxorubicin and cyclophosphamide (the TAC regimen),Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.
|
||
252,TA110,2006/07,STA,Rituximab,Pharmaceutical,Follicular lymphoma,Recommended,Guidance has been replaced by TA243. Recommendation in line with marketing authorisation.
|
||
253,TA111,2006/07,MTA,Donepezil,Pharmaceutical,Alzheimer's disease,Optimised,Guidance has been replaced by TA217. Previously was update of guidance TA19. Optimised recommendation for use in specific circumstances for people with Alzheimer’s disease with an MMSE score between 10 and 20 at the start of treatment. Treatment should only be continued while the patient has a score at or above 10.
|
||
254,TA111,2006/07,MTA,Galantamine,Pharmaceutical,Alzheimer's disease,Optimised,Guidance has been replaced by TA217. Previously was update of guidance TA19. Optimised recommendation for use in specific circumstances for people with Alzheimer’s disease with an MMSE score between 10 and 20 at the start of treatment. Treatment should only be continued while the patient has a score at or above 10.
|
||
255,TA111,2006/07,MTA,Memantine,Pharmaceutical,Alzheimer's disease,Only in research,Guidance has been replaced by TA217. Previously was update of guidance TA19. Only recommended in the context of well designed clinical trials.
|
||
256,TA111,2006/07,MTA,Rivastigmine,Pharmaceutical,Alzheimer's disease,Optimised,"Guidance has been replaced by TA217. Previously was update of guidance TA19. Optimised recommendation for use in specific circumstances, for people with Alzheimer’s disease only with an MMSE score between 10 and 20 at the start of treatment. Treatment should only be continued while the patient has a score at or above 10."
|
||
257,TA112,2006/07,MTA,Anastrozole,Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.
|
||
258,TA112,2006/07,MTA,Exemestane,Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.
|
||
259,TA112,2006/07,MTA,Letrozole,Pharmaceutical,Breast cancer (early),Recommended,Recommendation in line with marketing authorisation.
|
||
260,TA113,2006/07,MTA,Inhaled insulin (Exubera),Pharmaceutical,Diabetes (types 1 and 2),Optimised,"Optimised recommendation for use in specific circumstances for people with type 1 or type 2 diabetes mellitus who show evidence of poor glycaemic control despite other therapeutic interventions (including, where appropriate, diet, oral hypoglycaemic agents [OHAs] and subcutaneous insulin) and adequate educational support, and who are unable to initiate or intensify pre-prandial subcutaneous insulin therapy because of either: a marked and persistent fear of injections that meet DSM-IV criteria for specific phobia ‘blood injection injury type’ diagnosed by a diabetes specialist or mental health professional; severe and persistent problems with injection sites (for example, as a consequence of lipohypertrophy) despite support with injection site rotation. Guidance now obsolete because manufacturer has ceased production of this technology. "
|
||
261,TA114,2006/07,MTA,Buprenorphine (oral formulations),Pharmaceutical,Drug misuse,Recommended,Recommendation in line with clinical practice.
|
||
262,TA114,2006/07,MTA,Methadone (oral formulations),Pharmaceutical,Drug misuse,Recommended,Recommendation in line with clinical practice.
|
||
263,TA115,2006/07,MTA,Naltrexone,Pharmaceutical,Drug misuse,Recommended,Recommendation in line with clinical practice.
|
||
264,TA116,2006/07,STA,Gemcitabine,Pharmaceutical,Breast cancer,Recommended,Recommendation in line with marketing authorisation.
|
||
265,TA117,2006/07,MTA,Cinacalcet,Pharmaceutical,Hyperparathyroidism (refractory),Optimised,"Optimised recommendation for use in specific circumstances for people with end-stage renal disease (including those with calciphylaxis) who have ‘very uncontrolled’ plasma levels of intact parathyroid hormone (defined as greater than 85 pmol/litre [800 pg/ml]) that are refractory to standard therapy; and a normal or high adjusted serum calcium level, and in whom surgical parathyroidectomy is contraindicated, in that the risks of surgery are considered to outweigh the benefits. "
|
||
266,TA118,2006/07,MTA,Bevacizumab in combination with 5-fluorouracil plus folinic acid (with or without irinotecan),Pharmaceutical,Colorectal cancer (metastatic),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
267,TA118,2006/07,MTA,Cetuximab in combination with irinotecan,Pharmaceutical,Colorectal cancer (metastatic),Not Recommended,"Guidance has been partially replaced by TA242. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
268,TA119,2006/07,STA,Fludarabine (monotherapy),Pharmaceutical,Leukaemia (lymphocytic),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
269,TA120,2007/08,MTA,Cardiac resynchronisation therapy with a defibrillator device (CRT-D),Medical device,Heart failure,Recommended,Recommendation in line with clinical practice.
|
||
270,TA120,2007/08,MTA,Cardiac resynchronisation therapy with a pacing device (CRT-P),Medical device,Heart failure,Recommended,Recommendation in line with clinical practice.
|
||
271,TA121,2007/08,MTA,Carmustine implants,Pharmaceutical,Glioma (newly diagnosed),Recommended,Recommendation in line with clinical practice.
|
||
272,TA121,2007/08,MTA,Temozolomide,Pharmaceutical,Glioma (newly diagnosed),Recommended,Recommendation in line with clinical practice.
|
||
273,TA122,2007/08,STA,Alteplase,Pharmaceutical,Ischaemic stroke (acute),Recommended,Guidance has been replaced by TA264. Recommendation in line with marketing authorisation.
|
||
274,TA123,2007/08,STA,Varenicline,Pharmaceutical,Smoking cessation,Recommended,Recommendation in line with marketing authorisation.
|
||
275,TA124,2007/08,STA,Pemetrexed (2nd line),Pharmaceutical,Non-small cell lung cancer ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
276,TA125,2007/08,STA,Adalimumab,Pharmaceutical,Psoriatic arthritis ,Recommended,Guidance has been replaced by TA199. Recommendation in line with clinical practice.
|
||
277,TA126,2007/08,STA,Rituximab,Pharmaceutical,Rheumatoid arthritis (refractory),Recommended,Guidance has been replaced by TA195. Recommendation in line with clinical practice.
|
||
278,TA127,2007/08,STA,Natalizumab,Pharmaceutical,Multiple sclerosis,Optimised,Optimised recommendation for use in specific circumstances for people with rapidly evolving severe relapsing–remitting multiple sclerosis (RES) only.
|
||
279,TA128,2007/08,MTA,Stapled haemorroidopexy,Surgical procedure,Haemorrhoid,Recommended, Recommendation in line with clinical practice.
|
||
280,TA129,2007/08,STA,Bortezomib,Pharmaceutical,Multiple myeloma,Recommended,Recommended after agreement of Patient Access Scheme.
|
||
281,TA130,2007/08,MTA,Adalimumab (1st line),Pharmaceutical,Rheumatoid arthritis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Replaced by TA375."
|
||
282,TA130,2007/08,MTA,Etanercept (1st line),Pharmaceutical,Rheumatoid arthritis,Not recommended,"Update of guidance TA36. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Replaced by TA375."
|
||
283,TA130,2007/08,MTA,Infliximab (1st line),Pharmaceutical,Rheumatoid arthritis,Not recommended,"Update of guidance TA36. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Replaced by TA375."
|
||
284,TA130,2007/08,MTA,Adalimumab (after DMARD failure),Pharmaceutical,Rheumatoid arthritis,Optimised,"Optimised recommendation for use in specific circumstances for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated). Replaced by TA375."
|
||
285,TA130,2007/08,MTA,Etanercept (after DMARD failure),Pharmaceutical,Rheumatoid arthritis,Optimised,"Update of guidance TA36. Optimised recommendation for use in specific circumstances, for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated). Replaced by TA375."
|
||
286,TA130,2007/08,MTA,Infliximab (after DMARD failure),Pharmaceutical,Rheumatoid arthritis,Optimised,"Update of guidance TA36. Optimised recommendation for use in specific circumstances for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated). Replaced by TA375."
|
||
287,TA131,2007/08,MTA,"Inhaled corticosteroids (ICS) including beclometasone, budesonide, fluticasone, budesonide/formoterol combination, fluticasone/salmeterol combination",Pharmaceutical,Asthma (in children),Recommended,Recommendation in line with marketing authorisation.
|
||
288,TA132,2007/08,MTA,Ezetimibe monotherapy,Pharmaceutical,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,Recommended,Recommendation in line with marketing authorisation.
|
||
289,TA132,2007/08,MTA,Ezetimibe (in combination with a statin),Pharmaceutical,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,Recommended,Recommendation in line with marketing authorisation.
|
||
290,TA133,2007/08,STA,Omalizumab,Pharmaceutical,Severe persistent allergic (IgE mediated) asthma,Recommended,Recommendation in line with marketing authorisation.
|
||
291,TA134,2007/08,STA,Infliximab (2nd line),Pharmaceutical,Plaque psoriasis ,Optimised,Optimised recommendation for use in specific circumstances when the psoriasis is very severe and has failed to respond to standard systemic therapies or the person is intolerant to or has a contraindication to these treatments. Treatment with infliximab should only be continued beyond 10 weeks if an adequate response to treatment is achieved.
|
||
292,TA135,2007/08,MTA,Pemetrexed disodium,Pharmaceutical,Malignant pleural mesothelioma,Recommended,Recommendation in line with clinical practice.
|
||
293,TA136,2007/08,MTA,Structural neuroimaging techniques (either magnetic resonance imaging [MRI] or computed axial tomography [CT] scanning),Surgical procedure,Psychosis (first episode),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
294,TA137,2007/08,STA,Rituximab (3rd line),Pharmaceutical,Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,Recommended,Update of guidance TA37. Recommendation in line with marketing authorisation.
|
||
295,TA138,2007/08,MTA,"Inhaled corticosteroids (ICS) including beclometasone, budesonide, fluticasone, budesonide/formoterol combination, fluticasone/salmeterol combination",Pharmaceutical,Asthma (in adults) ,Recommended,Recommendation in line with clinical practice.
|
||
296,TA139,2007/08,MTA,Fixed or autotitrating continuous positive airway pressure (CPAP) device,Medical device,Obstructive sleep apnoea/hypopnoea syndrome (mild),Recommended,Recommendation in line with clinical practice.
|
||
297,TA139,2007/08,MTA,Fixed or autotitrating continuous positive airway pressure (CPAP) device,Medical device,Obstructive sleep apnoea/hypopnoea syndrome (moderate - severe),Recommended,Recommendation in line with clinical practice.
|
||
298,TA140,2008/09,STA,Infliximab ,Pharmaceutical,"Subacute, moderately to severely active ulcerative colitis",Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
299,TA141,2008/09,STA,Abatacept,Pharmaceutical,Rheumatoid arthritis,Not Recommended,"Guidance has been replaced by TA195. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
300,TA142,2008/09,MTA,"Erythropoietin analogues (epoetin alpha, epoetin beta, darbepoetin) ",Pharmaceutical,Cancer treatment-induced anaemia,Optimised,Optimised recommendation for use in specific circumstances for cancer treatment-induced anaemia in women receiving platinum-based chemotherapy for ovarian cancer who have symptomatic anaemia with a haemoglobin level of 8 g/100 ml or lower.
|
||
301,TA143,2008/09,MTA,Adalimumab,Pharmaceutical,Severe ankylosing spondylitis (adults),Recommended,Recommendation in line with clinical practice.
|
||
302,TA143,2008/09,MTA,Etanercept,Pharmaceutical,Severe ankylosing spondylitis (adults),Recommended,Recommendation in line with clinical practice.
|
||
303,TA143,2008/09,MTA,Infliximab,Pharmaceutical,Severe ankylosing spondylitis (adults),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
304,TA144,2008/09,STA,Rimonabant,Pharmaceutical,Overweight and obese adults,Optimised,"Optimised recommendation for use in specific circumstances for adults who are obese or overweight and who have had an inadequate response to, are intolerant of, or are contraindicated to orlistat and sibutramine. EMA withdrew the marketing authorisation for this product after TA144 was published."
|
||
305,TA145,2008/09,STA,Cetuximab,Pharmaceutical,Locally advanced squamous cell cancer of the head and neck,Optimised,Optimised recommendation for use in specific circumstances for people with locally advanced squamous cell cancer of the head and neck whose Karnofsky performance-status score is 90% or greater and for whom all forms of platinum-based chemoradiotherapy treatment are contraindicated.
|
||
306,TA146,2008/09,STA,Adalimumab,Pharmaceutical,Plaque psoriasis,Recommended,Recommendation in line with clinical practice.
|
||
307,TA147,2008/09,STA,Bevacizumab (1st line),Pharmaceutical,Metastatic breast cancer ,Terminated Appraisal - non submission,Guidance has been replaced by TA214. The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
308,TA148,2008/09,STA,Bevacizumab (1st line),Pharmaceutical,"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer ",Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
309,TA149,2008/09,STA,Carmustine implants,Pharmaceutical,Recurrent glioblastoma multiforme,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
310,TA150,2008/09,STA,Cetuximab (2nd-3rd line),Pharmaceutical,Metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy,Terminated Appraisal - non submission,Guidance has been replaced by TA242. The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
311,TA151,2008/09,MTA,Continuous subcutaneous insulin infusion (CSII or ‘insulin pump’) therapy,Pharmaceutical,Type 1 diabetes ,Optimised,"Update of guidance TA57. Optimised recommendation for use in specific circumstances for people with type 1 diabetes whose HbA1c levels have remained high (at 8.5% or above) on MDI therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care. "
|
||
312,TA152,2008/09,MTA,Drug-eluting stents,Medical device,Coronary artery disease ,Optimised,Update of recommendations 1.2 – 1.4 in guidance TA71. Optimised recommendation for use in specific circumstances if a patient’s target artery to be treated has less than a 3-mm calibre or the lesion is longer than 15 mm.
|
||
313,TA153,2008/09,STA,Entecavir,Pharmaceutical,Chronic Hepatitis B,Recommended,Recommendation in line with marketing authorisation.
|
||
314,TA154,2008/09,STA,Telbivudine,Pharmaceutical,Chronic Hepatitis B,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
315,TA155,2008/09,MTA,Ranibizumab,Pharmaceutical,Wet age-related macular degeneration,Recommended,Recommended after agreement of Patient Access Scheme.
|
||
316,TA155,2008/09,MTA,Pegaptanib,Pharmaceutical,Wet age-related macular degeneration,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
317,TA156,2008/09,MTA,Routine antenatal anti-D prophylaxis,Pharmaceutical,Pregnancy (rhesus negative women) ,Recommended,Update of guidance TA41. Recommendation in line with marketing authorisation.
|
||
318,TA157,2008/09,STA,Dabigatran etexilate,Pharmaceutical,Venous thromboembolism after hip or knee replacement surgery ,Recommended,Recommendation in line with marketing authorisation.
|
||
319,TA158,2008/09,MTA,Amantadine,Pharmaceutical,Influenza (post-exposure prophylaxis),Not Recommended,"Update of guidance TA67. At the time of appraisal, no direct evidence was available on the clinical effectiveness of amantadine at a dose of 100 mg for at-risk groups."
|
||
320,TA158,2008/09,MTA,Oseltamivir,Pharmaceutical,Influenza (post-exposure prophylaxis),Recommended,Update of guidance TA67. Recommendation in line with national influenza guidelines.
|
||
321,TA158,2008/09,MTA,Zanamivir,Pharmaceutical,Influenza (post-exposure prophylaxis),Recommended,Recommendation in line with national influenza guidelines.
|
||
322,TA159,2008/09,MTA,Spinal cord stimulation,Other therapeutic therapies,Chronic pain of neuropathic origin ,Optimised,Optimised recommendation for use in specific circumstances for adults who continue to experience chronic pain for at least 6 months despite appropriate conventional medical management.
|
||
323,TA159,2008/09,MTA,Spinal cord stimulation,Other therapeutic therapies,Chronic pain of ischaemic origin,Only in Research,"Only recommended in the context of research designed to generate robust evidence about the benefits of spinal cord stimulation (including pain relief, functional outcomes and quality of life) compared with standard of care. "
|
||
324,TA160,2008/09,MTA,Alendronate,Pharmaceutical,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,Optimised,"Optimised recommendation for use under specific circumstances, for postmenopausal women aged 70 years or older who have an independent clinical risk factor for fracture or an indicator of low BMD and who are confirmed to have osteoporosis; In women aged 75 years or older who have two or more independent clinical risk factors for fracture or indicators of low BMD, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible; Women aged 65–69 years who have an independent clinical risk factor for fracture and who are confirmed to have osteoporosis; postmenopausal women younger than 65 years who have an independent clinical risk factor for fracture and at least one additional indicator of low BMD and who are confirmed to have osteoporosis (that is, a T-score of −2.5 SD or below. Replaced with TA464."
|
||
325,TA160,2008/09,MTA,Etidronate,Pharmaceutical,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,Optimised,"Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible. Withdrawn guidance - no longer marketed in the UK. "
|
||
326,TA160,2008/09,MTA,Risedronate,Pharmaceutical,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,Optimised,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Replaced with TA464."
|
||
327,TA160,2008/09,MTA,Strontium ranelate,Pharmaceutical,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,Optimised,"Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible. Withdrawn guidance - no longer marketed in the UK. "
|
||
328,TA160,2008/09,MTA,Raloxifene,Pharmaceutical,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,Not recommended,"Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. "
|
||
329,TA161,2008/09,MTA,Alendronate,Pharmaceutical,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),Recommended,Update of guidance TA87. Recommendation in line with marketing authorisation. Replaced with TA464.
|
||
330,TA161,2008/09,MTA,Etidronate,Pharmaceutical,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),Optimised,"Update of guidance TA87. Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible. Withdrawn guidance - no longer marketed in the UK."
|
||
331,TA161,2008/09,MTA,Raloxifene,Pharmaceutical,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),Optimised,"Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture."
|
||
332,TA161,2008/09,MTA,Risedronate,Pharmaceutical,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),Optimised,"Update of guidance TA87. Optimised recommendation for use under specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. If a woman aged 75 years or older who has two or more independent clinical risk factors for fracture or indicators of low BMD has not previously had her BMD measured, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible. Replaced with TA464."
|
||
333,TA161,2008/09,MTA,Strontium ranelate,Pharmaceutical,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),Optimised,"Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to comply with the special instructions for the administration of alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. Withdrawn guidance - no longer marketed in the UK."
|
||
334,TA161,2008/09,MTA,Teriparatide,Pharmaceutical,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),Optimised,"Update of guidance TA87. Optimised recommendation for use in specific circumstances in postmenopausal women who are unable to take alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate, or who have a contraindication to, or are intolerant of strontium ranelate, or who have had an unsatisfactory response to treatment with alendronate, risedronate or etidronate and who are 65 years or older and have a T-score of –4.0 SD or below, or a T-score of –3.5 SD or below plus more than two fractures, or who are aged 55–64 years and have a T-score of –4 SD or below plus more than two fractures."
|
||
335,TA162,2008/09,STA,Erlotinib (2nd-line treatment in patients for whom docetaxel is suitable),Pharmaceutical,Non-small-cell lung cancer,Recommended,Recommendation in line with marketing authorisation and following agreement of a Patient Access Scheme.
|
||
336,TA162,2008/09,STA,Erlotinib (2nd-line treatment in patients for whom docetaxel is unsuitable; or as a 3rd-line treatment after docetaxel therapy),Pharmaceutical,Non-small-cell lung cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
337,TA163,2008/09,STA,Infliximab,Pharmaceutical,"Acute, severely active ulcerative colitis",Recommended,Recommendation in line with marketing authorisation.
|
||
338,TA164,2008/09,STA,Febuxostat,Pharmaceutical,Chronic hyperuricaemia (in people with gout),Recommended,Recommendation in line with clinical practice.
|
||
339,TA165,2008/09,MTA,Cold Static Storage (Belzer UW storage solution or Marshall's hypertonic citrate solution),Medical device,Organ preservation (renal) ,Recommended,Recommendation in line with clinical practice.
|
||
340,TA165,2008/09,MTA,Machine perfusion systems (LifePort kidney transporter),Medical device,Organ preservation (renal) ,Recommended,Recommendation in line with clinical practice.
|
||
341,TA166,2008/09,MTA,Sequential bilateral cochlear implantation,Medical device,Severe to profound deafness in children and adults,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
342,TA166,2008/09,MTA,Simultaneous bilateral cochlear implantation,Medical device,Severe to profound deafness in children and adults,Optimised,Optimised recommendation for use in specific circumstances for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids; or children; or adults who are blind or who have other disabilities that increase their reliance on auditory stimuli as a primary sensory mechanism for spatial awareness.
|
||
343,TA166,2008/09,MTA,Unilateral cochlear implantation,Medical device,Severe to profound deafness in children and adults,Recommended,Recommendation in line with clinical practice.
|
||
344,TA167,2008/09,MTA,Endovascular stent-grafts,Medical device,Infra-renal abdominal aortic aneurysms (unruptured),Recommended,Recommendation in line with clinical practice.
|
||
345,TA167,2008/09,MTA,Endovascular stent-grafts,Medical device,Infra-renal abdominal aortic aneurysms (ruptured),Only in Research,Only recommended for use in the context of research.
|
||
346,TA168,2008/09,MTA,Zanamivir,Pharmaceutical,Influenza (treatment),Recommended,Update of guidance TA58. Recommendation In line with national influenza guidelines.
|
||
347,TA168,2008/09,MTA,Amantadine,Pharmaceutical,Influenza (treatment),Not Recommended,"Update of guidance TA58. At the time of appraisal, no direct evidence was available on the clinical effectiveness of amantadine at a dose of 100 mg for at-risk groups. "
|
||
348,TA168,2008/09,MTA,Oseltamivir,Pharmaceutical,Influenza (treatment),Recommended,Update of guidance TA58. Recommendation In line with national influenza guidelines.
|
||
349,TA169,2008/09,MTA,Sunitinib (1st line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Recommended,Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
|
||
350,TA170,2009/10,STA,Rivaroxaban,Pharmaceutical,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),Recommended,Recommendation in line with marketing authorisation.
|
||
351,TA171,2009/10,STA,Lenalidomide,Pharmaceutical,Multiple myeloma ,Recommended,Recommended following agreement on Patient Access Scheme.
|
||
352,TA172,2009/10,STA,Cetuximab,Pharmaceutical,Recurrent and/or metastatic squamous cell cancer of the head and neck,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
353,TA173,2009/10,STA,Tenofovir disoproxil fumarate,Pharmaceutical,Chronic hepatitis B ,Recommended,Recommendation in line with marketing authorisation.
|
||
354,TA174,2009/10,STA,Rituximab in combination with fludarabine and cyclophosphamide (1st line),Pharmaceutical,Chronic lymphocytic leukaemia ,Optimised,Optimised recommendation for use in specific circumstances in combination with fludarabine and cyclophosphamide.
|
||
355,TA175,2009/10,STA,Gefitinib (2nd line),Pharmaceutical,Locally advanced or metastatic non-small-cell-lung cancer ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
356,TA176,2009/10,STA,"Cetuximab in combination with 5-fluorouracil (5-FU), folinic acid and oxaliplatin (FOLFOX) (1st line)",Pharmaceutical,Metastatic colorectal cancer ,Recommended,Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
|
||
357,TA176,2009/10,STA,"Cetuximab in combination with 5-FU, folinic acid and irinotecan (FOLFIRI) (1st line)",Pharmaceutical,Metastatic colorectal cancer ,Recommended,Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
|
||
358,TA177,2009/10,STA,Alitretinoin,Pharmaceutical,Severe chronic hand eczema ,Recommended,Recommendation in line with clinical practice.
|
||
359,TA178,2009/10,MTA,Bevacizumab (1st line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
360,TA178,2009/10,MTA,Sorafenib (1st line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
361,TA178,2009/10,MTA,Temsirolimus (1st line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
362,TA178,2009/10,MTA,Sunitinib (2nd line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
363,TA178,2009/10,MTA,Sorafenib (2nd line),Pharmaceutical,Advanced and/or metastatic renal cell carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
364,TA179,2009/10,STA,Sunitinib,Pharmaceutical,Unresectable and/or metastatic malignant gastrointestinal stromal tumours,Recommended,Recommendation in line with marketing authorisation and following agreement of Patient Access Scheme.
|
||
365,TA180,2009/10,STA,Ustekinumab,Pharmaceutical,Plaque psoriasis,Recommended,Recommendation in line with clinical practice and following agreement of Patient Access Scheme.
|
||
366,TA181,2009/10,STA,Pemetrexed in combination with cisplatin (1st line),Pharmaceutical,Locally advanced or metastatic non-small-cell lung cancer ,Recommended,Recommendation in line with clinical practice.
|
||
367,TA182,2009/10,STA,Prasugrel in combination with aspirin,Pharmaceutical,Atherothrombotic events in people with acute coronary syndromes (prevention) ,Recommended,Recommendation in line with clinical practice.
|
||
368,TA183,2009/10,STA,Topotecan in combination with cisplatin,Pharmaceutical,Recurrent or stage IV cervical cancer ,Recommended,Recommended in line with marketing authorisation.
|
||
369,TA184,2009/10,MTA,Oral topotecan ,Pharmaceutical,Relapsed small-cell lung cancer,Recommended,Recommendation in line with clinical practice.
|
||
370,TA184,2009/10,MTA,Intravenous topotecan,Pharmaceutical,Relapsed small-cell lung cancer ,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
371,TA185,2009/10,STA,Intravenous trabectedin,Pharmaceutical,Advanced soft tissue sarcoma ,Recommended,Recommended following agreement of Patient Access Scheme.
|
||
372,TA186,2009/10,STA,Certolizumab (subcutaneous injection),Pharmaceutical,Rheumatoid arthritis,Optimised,"Optimised recommendation for use in specific circumstances in people who have not had an adequate response following the use of at least 2 DMARDs, and following agreement of Patient Access Scheme. "
|
||
373,TA187,2010/11,MTA,Infliximab,Pharmaceutical,Severe active Crohn's disease (adults),Recommended,Update of guidance TA40. Recommendation in line with clinical practice.
|
||
374,TA187,2010/11,MTA,Adalimumab,Pharmaceutical,Severe active Crohn's disease (adults),Recommended,Recommendation in line with clinical practice.
|
||
375,TA187,2010/11,MTA,Infliximab,Pharmaceutical,Active fistulising Crohn's disease (adults),Recommended,Update of guidance TA40. Recommendation in line with clinical practice.
|
||
376,TA187,2010/11,MTA,Infliximab,Pharmaceutical,Severe active Crohn's disease (children aged 6 - 17 years),Recommended,Update of guidance TA40. Recommendation in line with clinical practice.
|
||
377,TA188,2010/11,MTA,Somatropin,Pharmaceutical,Growth failure (children),Recommended,Update of guidance TA42. Recommendation in line with clinical practice.
|
||
378,TA189,2010/11,STA,Sorafenib (1st line),Pharmaceutical,Advanced and metastatic hepatocellular carcinoma ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
379,TA190,2010/11,STA,Pemetrexed (maintenance treatment),Pharmaceutical,Non-small-cell lung cancer,Recommended,Recommendation in line with marketing authorisation.
|
||
380,TA191,2010/11,STA,Capecitabine (1st line),Pharmaceutical,Inoperable advanced gastric cancer,Recommended,Recommendation in line with marketing authorisation
|
||
381,TA192,2010/11,STA,Gefitinib (1st line),Pharmaceutical,Locally advanced or metastatic non-small-cell lung cancer,Recommended,Recommendation in line with marketing authorisation and following agreement of Patient Access Scheme.
|
||
382,TA193,2010/11,STA,Rituximab in combination with chemotherapy (other than fludarabine and cyclophosphamide),Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia,Only in Research,"Due to a lack of clinical and cost effectiveness evidence, the Committee concluded that rituximab plus chemotherapy (other than fludarabine and cyclophosphamide) should only be used for the treatment of relapsed or refractory chronic lymphocytic leukaemia in the context of research."
|
||
383,TA193,2010/11,STA,Rituximab in combination with fludarabine and cyclophosphamide,Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia,Optimised,"Optimised recommendation for use in specific circumstances for the treatment of people who have not previously received rituximab (or who have only received rituximab in the context of a clinical trial at a dose lower than the licensed dose for chronic lymphocytic leukaemia, or in combination with chemotherapy other than fludarabine and cyclophosphamide) and whose disease is not refractory to fludarabine."
|
||
384,TA193,2010/11,STA,Rituximab in combination with fludarabine and cyclophosphamide,Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia,Only in Research,"For patients who have already received rituximab (in circumstances other than in the context of a clinical trial), rituximab in combination with fludarabine and cyclophosphamide should only be used in the context of research."
|
||
385,TA194,2010/11,STA,Denosumab,Pharmaceutical,Therapy-induced bone loss in non-metastatic prostate cancer,Terminated Appraisal - non submission,Guidance has been replaced by CG175The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
386,TA195,2010/11,MTA,Abatacept in combination with methotrexate (after TNF failure),Pharmaceutical,Rheumatoid arthritis,Optimised,"Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event."
|
||
387,TA195,2010/11,MTA,Adalimumab in combination with methotrexate (after TNF failure),Pharmaceutical,Rheumatoid arthritis,Optimised,"Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event."
|
||
388,TA195,2010/11,MTA,Adalimumab monotherapy (after TNF failure),Pharmaceutical,Rheumatoid arthritis,Optimised,"Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event."
|
||
389,TA195,2010/11,MTA,Etanercept in combination with methotrexate (after TNF failure),Pharmaceutical,Rheumatoid arthritis,Optimised,"Update of guidance TA36, TA126 and TA141. Recommendation in line with clinical practice."
|
||
390,TA195,2010/11,MTA,Etanercept monotherapy (after TNF failure) ,Pharmaceutical,Rheumatoid arthritis,Optimised,"Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event."
|
||
391,TA195,2010/11,MTA,Infliximab in combination with methotrexate (after TNF failure),Pharmaceutical,Rheumatoid arthritis,Optimised,"Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event."
|
||
392,TA195,2010/11,MTA,Rituximab in combination with methotrexate (after TNF failure),Pharmaceutical,Rheumatoid arthritis,Recommended,"Update of guidance TA36, TA126 and TA141. Optimised recommendation for use under specific circumstances in adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to rituximab, or when rituximab is withdrawn because of an adverse event."
|
||
393,TA196,2010/11,STA,Imatinib adjuvant,Pharmaceutical,Gastrointestinal stromal tumours (resectable),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
394,TA197,2010/11,STA,Dronedarone (2nd line),Pharmaceutical,Non-permanent atrial fibrillation,Optimised,Optimised recommendation for use under specific circumstances in people with atrial fibrillation not controlled by first line treatment who also have at least one cardiovascular risk factor.
|
||
395,TA198,2010/11,STA,Tocilizumab in combination with methotrexate,Pharmaceutical,Rheumatoid arthritis ,Optimised,Guidance has been replaced by TA247. Optimised recommendation for use under specific circumstances in people whose rheumatoid arthritis has responded inadequately to one or more tumour necrosis factor alpha (TNF-) inhibitors and whose rheumatoid arthritis has responded inadequately to rituximab or in whom rituximab is contraindicated or when rituximab is withdrawn because of an adverse effect.
|
||
396,TA199,2010/11,MTA,Adalimumab,Pharmaceutical,Psoriatic arthritis,Recommended,Update of guidance TA104 and TA125. Recommendation in line with clinical practice.
|
||
397,TA199,2010/11,MTA,Etanercept,Pharmaceutical,Psoriatic arthritis,Recommended,Update of guidance TA104 and TA125. Recommendation in line with clinical practice.
|
||
398,TA199,2010/11,MTA,Infliximab,Pharmaceutical,Psoriatic arthritis,Recommended,Update of guidance TA104 and TA125. Recommendation in line with clinical practice.
|
||
399,TA200,2010/11,MTA,Pegylated interferon (2a and 2b) in combination with ribavirin ,Pharmaceutical,Chronic hepatitis C ,Recommended,Partial update of guidance TA75 and TA106. Recommendation in line with marketing authorisation for people who have been treated previously and whose condition either did not respond to treatment or responded initially to treatment but subsequently relapsed or who are co-infected with HIV.
|
||
400,TA200,2010/11,MTA,Pegylated interferon (2a and 2b) in combination with ribavirin – shortened treatment course,Pharmaceutical,Chronic hepatitis C,Recommended,Partial update of guidance TA75 and TA106. Recommendation in line with marketing authorisation.
|
||
401,TA201,2010/11,STA,Omalizumab ,Pharmaceutical,"Treatment of severe
|
||
persistent allergic asthma in
|
||
children aged 6 to 11 years",Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
402,TA202,2010/11,STA,Ofatumumab,Pharmaceutical,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available and the proposed Patient Access Scheme."
|
||
403,TA203,2010/11,STA,"Liraglutide 1.2 mg in triple therapy regimens (that is, in combination with metformin and a sulphonylurea, or in combination with metformin and a thiazolidinedione)",Pharmaceutical,Type 2 diabetes ,Recommended,Recommendation in line with clinical practice.
|
||
404,TA203,2010/11,STA,"Liraglutide 1.2 mg in dual therapy regimens (that is, in combination with metformin or a sulphonylurea)",Pharmaceutical,Type 2 diabetes ,Optimised,"Optimised recommendation for use under specific circumstances for people are intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and they are intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated "
|
||
405,TA203,2010/11,STA,Liraglutide 1.8 mg ,Pharmaceutical,Type 2 diabetes ,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
406,TA204,2010/11,STA,Denosumab,Pharmaceutical,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),Optimised,"Optimised recommendation for use under specific circumstances for postmenopausal women who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture. "
|
||
407,TA204,2010/11,STA,Denosumab,Pharmaceutical,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),Optimised,"Optimised recommendation for use under specific circumstances for postmenopausal women who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments and who also have a specific combination of T-score, age and number of independent clinical risk factors for fracture."
|
||
408,TA205,2010/11,STA,Eltrombopag,Pharmaceutical,Chronic immune (idiopathic) thrombocytopenic purpura,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
409,TA206,2010/11,STA,Bendamustine,Pharmaceutical,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
410,TA207,2010/11,STA,Temsirolimus,Pharmaceutical,Mantle cell lymphoma (relapsed) ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
411,TA208,2010/11,STA,Trastuzumab in combination with cisplatin and capecitabine or 5-fluorouracil,Pharmaceutical,"Gastric cancer (HER2-positive, metastatic)",Optimised,Optimised recommendation for use under specific circumstances for people with human epidermal growth factor receptor 2 (HER2)-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior treatment for their metastatic disease and have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3 (IHC3 positive).
|
||
412,TA209,2010/11,MTA,Imatinib (dose escalation to 600mg/day or 800mg/day following disease progression on 400 mg/day imatinib),Pharmaceutical,"Gastrointestinal stromal tumours (unresectable, metastatic)",Not Recommended,"Partial update of guidance TA86 (recommendation 1.4). At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
413,TA210,2010/11,MTA,Clopidogrel,Pharmaceutical,Vascular disease,Optimised,Update of guidance TA90. Optimised recommendation for use in specific circumstances for clinical practice for people who have had a myocardial infarction only if aspirin is contraindicated or not tolerated.
|
||
414,TA210,2010/11,MTA,Clopidogrel ,Pharmaceutical,Vascular disease,Recommended,Update of guidance TA90. Recommended in line with clinical practice for people who have had an ischaemic stroke or who have peripheral arterial disease or multivascular disease.
|
||
415,TA210,2010/11,MTA,Modified-release dipyridamole,Pharmaceutical,Vascular disease,Optimised,Update of guidance TA90. Optimised recommendation for use in specific circumstances for people who have had an ischaemic stroke only if aspirin and clopidogrel are contraindicated or not tolerated.
|
||
416,TA210,2010/11,MTA,Modified-release dipyridamole,Pharmaceutical,Vascular disease,Recommended,Update of guidance TA90. Recommended in line with clinical practice for people who have had an ischaemic stroke and aspirin is contraindicated or not tolerated.
|
||
417,TA210,2010/11,MTA,Modified-release dipyridamole in combination with aspirin,Pharmaceutical,Vascular disease,Recommended,Update of guidance TA90. Recommended in line with clinical practice for people who have had a transient ischaemic attack.
|
||
418,TA210,2010/11,MTA,Modified-release dipyridamole in combination with aspirin,Pharmaceutical,Vascular disease,Optimised,Update of guidance TA90. Optimised recommendation for use in specific circumstances for people who have had an ischaemic stroke only if clopidogrel is contraindicated or not tolerated.
|
||
419,TA211,2010/11,STA,Prucalopride,Pharmaceutical,Chronic constipation (in women),Recommended,Recommendation in line with clinical practice
|
||
420,TA212,2010/11,STA,Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine,Pharmaceutical,Metastatic colorectal cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
421,TA213,2010/11,STA,Aripiprazole,Pharmaceutical,Schizophrenia in people aged 15-17 years,Recommended,Recommended in line with clinical practice.
|
||
422,TA214,2010/11,STA,Bevacizumab in combination with a taxane (1st line),Pharmaceutical,Metastatic breast cancer,Not Recommended,"Update of guidance TA147. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
423,TA215,2010/11,STA,Pazopanib (1st line),Pharmaceutical,Metastatic renal cell carcinoma,Recommended,Recommended in line with clinical practice and after agreement of Patient Access Scheme.
|
||
424,TA216,2010/11,STA,Bendamustine (1st line),Pharmaceutical,Chronic lymphocytic leukaemia (Binet stage B or C),Recommended,Recommendation in line with marketing authorisation.
|
||
425,TA217,2010/11,MTA,Donepezil ,Pharmaceutical,Alzheimer's disease (mild to moderate),Recommended,Recommendation in line with marketing authorisation.
|
||
426,TA217,2010/11,MTA,Galantamine,Pharmaceutical,Alzheimer's disease (mild to moderate),Recommended,Recommendation in line with marketing authorisation.
|
||
427,TA217,2010/11,MTA,Memantine,Pharmaceutical,Alzheimer's disease (moderate),Optimised,Optimised recommendation for use under specific circumstances for people with moderate Alzheimer’s disease who are intolerant of or have a contraindication to AChE inhibitors.
|
||
428,TA217,2010/11,MTA,Memantine,Pharmaceutical,Alzheimer's disease (severe),Recommended,Recommendation in line with marketing authorisation.
|
||
429,TA217,2010/11,MTA,Rivastigmine,Pharmaceutical,Alzheimer's disease (mild to moderate),Recommended,Recommendation in line with marketing authorisation.
|
||
430,TA218,2010/11,STA,Azacitidine,Pharmaceutical,"Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia",Recommended,Recommendation in line with marketing authorisation and after agreement of Patient Access Scheme.
|
||
431,TA219,2011/12,STA,Everolimus,Pharmaceutical,Advanced renal cell carcinoma (2nd line),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
432,TA220,2011/12,STA,Golimumab,Pharmaceutical,Psoriatic arthritis (active and progressive disease),Recommended,Recommended in line with clinical practice and after agreement of Patient Access Scheme.
|
||
433,TA221,2011/12,STA,Romiplostim,Pharmaceutical,Chronic immune (idiopathic) thrombocytopenic purpura,Recommended,Recommended in line with clinical practice and after agreement of Patient Access Scheme.
|
||
434,TA222,2011/12,STA,Trabectedin in combination with pegylated liposomal doxorubicin hydrochloride,Pharmaceutical,Relapsed platinum-sensitive ovarian cancer in women,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
435,TA223,2011/12,MTA,Naftidrofyryl oxalate,Pharmaceutical,Intermittent claudication in people with peripheral arterial disease,Recommended,Recommended in line with clinical practice.
|
||
436,TA223,2011/12,MTA,Cilostazol,Pharmaceutical,Intermittent claudication in people with peripheral arterial disease,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
437,TA223,2011/12,MTA,Pentoxifylline ,Pharmaceutical,Intermittent claudication in people with peripheral arterial disease,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
438,TA223,2011/12,MTA,Inositol nicotinate,Pharmaceutical,Intermittent claudication in people with peripheral arterial disease,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
439,TA224,2011/12,STA,Golimumab,Pharmaceutical,Methotrexate-naïve rheumatoid arthritis,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
440,TA225,2011/12,STA,Golimumab in combination with methotrexate,Pharmaceutical,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",Optimised,"Optimised recommendation for use in specific circumstances in line with TA130, for those who have active rheumatoid arthritis as measured by disease activity score (DAS28) greater than 5.1 confirmed on at least two occasions, 1 month apart; and have undergone trials of two disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate (unless contraindicated). Recommendation made after agreement of patient access scheme."
|
||
441,TA225,2011/12,STA,Golimumab in combination with methotrexate,Pharmaceutical,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",Optimised,"Optimised recommendation for use in specific circumstances in line with TA195, for adults with severe active rheumatoid arthritis who have had an inadequate response to, or have an intolerance of, other DMARDs, including at least one TNF inhibitor, and who cannot receive rituximab therapy because they have a contraindication to methotrexate, or when methotrexate is withdrawn because of an adverse event. Recommendation made after agreement of patient access scheme."
|
||
442,TA226,2011/12,STA,Rituximab (1st line maintenance treatment),Pharmaceutical,Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,Recommended,Recommended in line with marketing authorisation.
|
||
443,TA227,2011/12,STA,Erlotinib (1st line maintenance treatment),Pharmaceutical,Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available, despite agreement of a patient access scheme."
|
||
444,TA228,2011/12,MTA,Thalidomide in combination with an alkylating agent and a corticosteroid,Pharmaceutical,Multiple myeloma,Recommended,Recommended in line with marketing authorisation.
|
||
445,TA228,2011/12,MTA,Bortezomib in combination with an alkylating agent and a corticosteroid,Pharmaceutical,Multiple myeloma,Optimised,Optimised recommendation for use in specific circumstances for people with multiple myeloma if high-dose chemotherapy with stem cell transplantation is considered inappropriate and they are unable to tolerate or have contraindications to thalidomide.
|
||
446,TA229,2011/12,STA,Dexamethasone intravitreal implant,Pharmaceutical,Macular oedema caused following central retinal vein occlusion ,Recommended,Recommended in line with marketing authorisation.
|
||
447,TA229,2011/12,STA,Dexamethasone intravitreal implant,Pharmaceutical,Macular oedema following branch retinal vein occlusion,Optimised,Optimised recommendation for use in specific circumstances for people with macular oedema following branch retinal vein occlusion when treatment with laser photocoagulation has not been beneficial or is not considered suitable because of the extent of macular haemorrhage.
|
||
448,TA230,2011/12,STA,Bivalirudin in combination with aspirin and clopidogrel,Pharmaceutical,ST-segment-elevation myocardial infarction,Recommended,Recommended in line with marketing authorisation.
|
||
449,TA231,2011/12,STA,Agomelatine,Pharmaceutical,Major depressive episodes,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
450,TA232,2011/12,STA,Retigabine (adjuvant),Pharmaceutical,Partial onset seizures in epilepsy,Recommended,Recommended in line with clinical practice.
|
||
451,TA233,2011/12,STA,Golimumab,Pharmaceutical,Severe ankylosing spondylitis (adults),Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
452,TA234,2011/12,STA,Abatacept in combination with methotrexate (2nd line),Pharmaceutical,"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",Not Recommended,"Guidance has been replaced by TA280. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
453,TA235,2011/12,STA,Mifamurtide,Pharmaceutical,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
454,TA236,2011/12,STA,Ticagrelor in combination with low-dose aspirin,Pharmaceutical,Treatment of acute coronary syndromes,Recommended,Recommended in line with clinical practice.
|
||
455,TA237,2011/12,STA,Ranibizumab,Pharmaceutical,Treatment of visual impairment due to diabetic macular oedema,Not Recommended,Guidance has been replaced by TA274. Optimised recommendation for use in specific circumstances for people with retinal thickness of 400 micrometres or more at the start of treatment and following agreement of patient access scheme.
|
||
456,TA238,2011/12,STA,Tocilizumab,Pharmaceutical,"Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease has responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and methotrexate",Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
457,TA238,2011/12,STA,Tocilizumab,Pharmaceutical,Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease continues to respond to methotrexate or who have not been previously treated with methotrexate,Not Recommended,"At the time of appraisal, no clinical evidence was provided to assess the effect of tocilizumab in children whose disease continues to respond to methotrexate, or in whom methotrexate has not been previously administered."
|
||
458,TA239,2011/12,STA,Fulvestrant,Pharmaceutical,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
459,TA240,2011/12,STA,Panitumumab in combination with chemotherapy,Pharmaceutical,Treatment of metastatic colorectal cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
460,TA241,2011/12,MTA,Nilotinib,Pharmaceutical,Treatment of chronic or accelerated phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults whose CML is resistant to treatment with standard-dose imatinib or who have imatinib intolerance,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
461,TA241,2011/12,MTA,Dasatinib,Pharmaceutical,"Treatment of chronic, accelerated or blast-crisis phase CML in adults with imatinib intolerance or whose CML is resistant to treatment with standard-dose imatinib",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
462,TA241,2011/12,MTA,High dose imatinib,Pharmaceutical,"Treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
463,TA242,2011/12,MTA,Cetuximab monotherapy or combination chemotherapy,Pharmaceutical,Treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy,Not Recommended,The guidance updates and replaces recommendations in TA150. This guidance also partially updates recommendations TA118.
|
||
464,TA242,2011/12,MTA,Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy,Pharmaceutical,Treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
465,TA242,2011/12,MTA,Panitumumab monotherapy,Pharmaceutical,Treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
466,TA243,2011/12,MTA,Rituximab in combination with chemotherapy,Pharmaceutical,First-line treatment of stage III-IV follicular lymphoma,Recommended,This guidance updates and replaces TA110. Recommendation in line with marketing authorisation.
|
||
467,TA244,2011/12,STA,Roflumilast,Pharmaceutical,Management of severe chronic obstructive pulmonary disease,Only in Research,Only recommended for use in the context of research.
|
||
468,TA245,2011/12,STA,Apixaban,Pharmaceutical,Prevention of venous thromboembolism after total hip or knee replacement,Recommended,Recommendation in line with marketing authorisation.
|
||
469,TA246,2011/12,MTA,Pharmalgen,Pharmaceutical,Treatment of bee and wasp venom allergy,Recommended,Recommendation in line with clinical practice.
|
||
470,TA247,2011/12,STA,Tocilizumab in combination with methotrexate,Pharmaceutical,Treatment of rheumatoid arthritis ,Recommended,"Update of guidance TA198. Recommendation in line with clinical practice and following agreement of patient access scheme for adults with rheumatoid arthritis if the disease has responded inadequately to DMARDs or the disease has responded inadequately to DMARDs and a TNF inhibitor and the person cannot receive rituximab because of a contraindication to rituximab, or because rituximab is withdrawn because of an adverse event; or the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab."
|
||
471,TA248,2011/12,STA,"Exenatide prolonged-release suspension for injection in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione (triple therapy regimen)",Pharmaceutical,Treatment of type 2 diabetes,Recommended,Recommendation in line with clinical practice.
|
||
472,TA248,2011/12,STA,Exenatide prolonged-release suspension for injection in combination with metformin or a sulphonylurea (dual therapy regimen),Pharmaceutical,Treatment of type 2 diabetes,Recommended,Recommendation in line with clinical practice.
|
||
473,TA249,2011/12,STA,Dabigatran etexilate,Pharmaceutical,Prevention of stroke and systemic embolism in atrial fibrillation,Recommended,Recommendation in line with marketing authorisation.
|
||
474,TA250,2012/13,STA,Eribulin,Pharmaceutical,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available despite agreement of a patient access scheme."
|
||
475,TA251,2012/13,MTA,Standard-dose imatinib (400mg/day),Pharmaceutical,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia ,Recommended,Partially updates TA70. Recommended in line with marketing authorisation.
|
||
476,TA251,2012/13,MTA,Nilotinib,Pharmaceutical,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia ,Recommended,Recommended in line with marketing authorisation and following agreement of PAS.
|
||
477,TA251,2012/13,MTA,Dasatinib,Pharmaceutical,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia ,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available"
|
||
478,TA252,2012/13,STA,Telaprevir in combination with peginterferon alfa and ribavirin,Pharmaceutical,Treatment of genotype 1 chronic hepatitis C,Recommended,"Withdrawn guidance, telaprevir is no longer marketed in the UK. Recommended in line with marketing authorisation"
|
||
479,TA253,2012/13,STA,Boceprevir in combination with peginterferon alfa and ribavirin,Pharmaceutical,Treatment of genotype 1 chronic hepatitis C,Recommended,Recommendation in line with marketing authorisation.
|
||
480,TA254,2012/13,STA,Fingolimod,Pharmaceutical,Treatment of highly active relapsing-remitting multiple sclerosis,Recommended,Recommendation in line with marketing authorisation and following agreement of patient access scheme.
|
||
481,TA255,2012/13,STA,Cabazitaxel in combination with prednisone or prednisolone,Pharmaceutical,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
482,TA256,2012/13,STA,Rivaroxaban,Pharmaceutical,Prevention of stroke and systemic embolism in atrial fibrillation,Recommended,Recommendation in line with marketing authorisation.
|
||
483,TA257,2012/13,MTA,Lapatinib in combination with an aromatase inhibitor (1st line),Pharmaceutical,Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
484,TA257,2012/13,MTA,Trastuzumab in combination with an aromatase inhibitor (1st line),Pharmaceutical,Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
485,TA258,2012/13,STA,Erlotinib (1st line),Pharmaceutical,Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
486,TA259,2012/13,STA,Abiraterone in combination with prednisolone or prednisone (2nd line),Pharmaceutical,Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
487,TA260,2012/13,STA,Botulinum toxin type A,Pharmaceutical,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,Recommended,Recommended in line with clinical practice.
|
||
488,TA261,2012/13,STA,Rivaroxaban,Pharmaceutical,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,Recommended,Recommended in line with marketing authorisation.
|
||
489,TA262,2012/13,STA,Adalimumab,Pharmaceutical,Treatment of moderate to severe ulcerative colitis,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
490,TA263,2012/13,STA,Bevacizumab in combination with capecitabine (1st line),Pharmaceutical,First-line treatment of metastatic breast cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
491,TA264,2012/13,STA,Alteplase,Pharmaceutical,Ischaemic stroke (acute),Recommended,Update of guidance TA122. Recommended in line with marketing authorisation.
|
||
492,TA265,2012/13,MTA,Denosumab,Pharmaceutical,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,Recommended,Recommended in line with clinical practice following agreement of patient access scheme.
|
||
493,TA265,2012/13,MTA,Denosumab,Pharmaceutical,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available despite agreement of a patient access scheme."
|
||
494,TA266,2012/13,STA,Mannitol dry powder for inhalation,Pharmaceutical,Cystic fibrosis,Optimised,"Optimised recommendation for use in specific circumstances in people who cannot use rhDNase because of ineligibility, intolerance or inadequate response to rhDNase and whose lung function is rapidly declining (forced expiratory volume in 1 second [FEV1] decline greater than 2% annually) and for whom other osmotic agents are not considered appropriate."
|
||
495,TA267,2012/13,STA,Ivabradine,Pharmaceutical,Chronic heart failure,Recommended,Recommended in line with clinical practice.
|
||
496,TA268,2012/13,STA,Ipilimumab,Pharmaceutical,Previously treated advanced (unresectable or metastatic) melanoma ,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
497,TA269,2012/13,STA,Vemurafenib,Pharmaceutical,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma ,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
498,TA270,2012/13,STA,Decitabine,Pharmaceutical,Acute myeloid leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
499,TA271,2012/13,STA,Fluocinolone acetonide intravitreal implant,Medical device,Chronic diabetic macular oedema after an inadequate response to prior therapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
500,TA272,2012/13,STA,Vinflunine,Pharmaceutical,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
501,TA273,2012/13,STA,Tadalafil,Pharmaceutical,Hyperplasia (benign prostatic),Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
502,TA274,2012/13,STA,Ranibizumab,Pharmaceutical,Treatment of visual impairment due to diabetic macular oedema,Optimised,Update of guidance TA237. Optimised recommendation for use in specific circumstances for people with retinal thickness of 400 micrometres or more at the start of treatment and following agreement of patient access scheme.
|
||
503,TA275,2012/13,STA,Apixaban,Pharmaceutical,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,Recommended,Recommended in line with marketing authorisation.
|
||
504,TA276,2012/13,MTA,Colistimethate sodium,Pharmaceutical,Pseudomonas lung infection in cystic fibrosis,Optimised,"Optimised recommendation for use in people with cystic fibrosis only if they would clinically benefit from continued colistimethate sodium but do not tolerate it in its nebulised form and thus tobramycin therapy would otherwise be considered, and following agreement of a patient access scheme."
|
||
505,TA276,2012/13,MTA,Tobramycin,Pharmaceutical,Pseudomonas lung infection in cystic fibrosis,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
506,TA277,2012/13,STA,Methylnaltrexone,Pharmaceutical,Treatment of opioid-induced bowel dysfunction in people with advanced illness receiving palliative care,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
507,TA278,2013/14,MTA,Omalizumab,Pharmaceutical,Add-on treatment for severe persistent allergic asthma,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
508,TA279,2013/14,MTA,Percutaneous vertebroplasty,Medical device,Vertebral compression fractures,Recommended,Recommended in line with clinical practice.
|
||
509,TA279,2013/14,MTA,Percutaneous balloon kyphoplasty (without stenting),Medical device,Vertebral compression fractures,Recommended,Recommended in line with clinical practice.
|
||
510,TA280,2013/14,STA,Abatacept in combination with methotrexate (2nd line),Pharmaceutical,Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,Optimised,"Update of guidance TA234. Optimised recommendation for use under specific circumstances in people who have not responded adequately to at least two DMARDs, including methotrexate (unless contraindicated) and following agreement of patient access scheme."
|
||
511,TA281,2013/14,STA,Canakinumab,Pharmaceutical,Gouty arthritis attacks,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
512,TA282,2013/14,STA,Pirfenidone,Pharmaceutical,Idiopathic pulmonary fibrosis,Optimised,"Optimised recommendation for use under specific circumstances in people who have a forced vital capacity (FVC) between 50% and 80% predicted, and following agreement of a patient access scheme."
|
||
513,TA283,2013/14,STA,Ranibizumab,Pharmaceutical,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
514,TA283,2013/14,STA,Ranibizumab,Pharmaceutical,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,Optimised,"Optimised recommendation for treating visual impairment caused by macular oedema following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage, and following agreement of a patient access scheme."
|
||
515,TA284,2013/14,STA,Bevacizumab in combination with paclitaxel and carboplatin,Pharmaceutical,Advanced ovarian cancer (1st line),Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
516,TA285,2013/14,STA,Bevacizumab in combination with gemcitabine and carboplatin,Pharmaceutical,First recurrence of platinum-sensitive advanced ovarian cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
517,TA286,2013/14,STA,Loxapine inhalation,Pharmaceutical,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
518,TA287,2013/14,STA,Rivaroxaban,Pharmaceutical,Treating pulmonary embolism and preventing recurrent venous thromboembolism,Recommended,Recommended in line with marketing authorisation.
|
||
519,TA288,2013/14,STA,Dapagliflozin in a dual therapy regimen in combination with metformin ,Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with clinical practice.
|
||
520,TA288,2013/14,STA,Dapagliflozin in combination with insulin with or without other antidiabetic drugs ,Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with marketing authorisation.
|
||
521,TA288,2013/14,STA,Dapagliflozin in a triple therapy regimen in combination with metformin and a sulfonylurea ,Pharmaceutical,Type 2 diabetes,Only in Research,Only recommended as part of a clinical trial.
|
||
522,TA289,2013/14,STA,Ruxolitinib,Pharmaceutical,Disease-related splenomegaly or symptoms in adults with myelofibrosis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
523,TA290,2013/14,STA,Mirabegron,Pharmaceutical,Symptoms of overactive bladder,Optimised,"Optimised recommendation for treating the symptoms of overactive bladder only for people in whom antimuscarinic drugs are contraindicated or clinically ineffective, or have unacceptable side effects."
|
||
524,TA291,2013/14,STA,Pegloticase,Pharmaceutical,Severe debilitating chronic tophaceous gout,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
525,TA292,2013/14,STA,Aripiprazole,Pharmaceutical,Moderate to severe manic episodes in adolescents with bipolar I disorder,Recommended,Recommended in line with marketing authorisation.
|
||
526,TA293,2013/14,STA,Eltrombopag,Pharmaceutical,Chronic immune (idiopathic) thrombocytopenic purpura,Optimised,"Optimised recommendation for treating adults with chronic immune (idiopathic) thrombocytopenic purpura, within its marketing authorisation, only if: their condition is refractory to standard active treatments and rescue therapies, or they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies and the manufacturer provides eltrombopag with the discount agreed in the patient access scheme."
|
||
527,TA294,2013/14,STA,Aflibercept solution for injection,Pharmaceutical,Wet age‑related macular degeneration,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
528,TA295,2013/14,STA,Everolimus in combination with exemestane,Pharmaceutical,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
529,TA296,2013/14,STA,Crizotinib,Pharmaceutical,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
530,TA297,2013/14,STA,Ocriplasmin,Pharmaceutical,Vitreomacular traction,Optimised,"Optimised recommendation for treating vitreomacular traction in adults, only if: an epiretinal membrane is not present and they have a stage II full-thickness macular hole with a diameter of 400 micrometres or less and/or they have severe symptoms."
|
||
531,TA298,2013/14,STA,Ranibizumab,Pharmaceutical,Choroidal neovascularisation associated with pathological myopia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
532,TA299,2013/14,STA,Bosutinib,Pharmaceutical,Previously treated chronic myeloid leukaemia,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Guidance has been replaced."
|
||
533,TA300,2013/14,MTA,Peginterferon alfa in combination with ribavirin ,Pharmaceutical,Chronic hepatitis C in children and young people,Recommended,Recommended in line with marketing authorisation.
|
||
534,TA301,2013/14,STA,Fluocinolone acetonide intravitreal implant ,Medical device,Chronic diabetic macular oedema after an inadequate response to prior therapy,Optimised,Optimised recommendation for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if the implant is to be used in an eye with an intraocular (pseudophakic) lens and the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme.
|
||
535,TA302,2013/14,STA,Canakinumab,Pharmaceutical,Systemic juvenile idiopathic arthritis,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
536,TA303,2013/14,STA,Teriflunomide,Pharmaceutical,Relapsing-remitting multiple sclerosis,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme
|
||
537,TA304,2013/14,MTA,Total hip replacement,Medical device,End-stage arthritis of the hip,Recommended,Recommended in line with clinical practice
|
||
538,TA304,2013/14,MTA,Resurfacing anthroplasty,Medical device,End-stage arthritis of the hip,Recommended,Recommended in line with clinical practice
|
||
539,TA305,2013/14,STA,Aflibercept solution for injection,Pharmaceutical,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
540,TA306,2013/14,STA,Pixantrone monotherapy,Pharmaceutical,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,Optimised,Optimised recommendation for treating adults with multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma only if: the person has previously been treated with rituximab and the person is receiving third- or fourth-line treatment and the manufacturer provides pixantrone with the discount agreed in the patient access scheme.
|
||
541,TA307,2013/14,STA,Aflibercept in combination with irinotecan and fluorouracil-based therapy,Pharmaceutical,Metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
542,TA308,2013/14,STA,Rituximab in combination with glucocorticoids,Pharmaceutical,Anti-neutrophil cytoplasmic antibody-associated vasculitis,Optimised,"Optimised recommendation for inducing remission in adults with ANCA-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if:
|
||
further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose or
|
||
cyclophosphamide is contraindicated or not tolerated or
|
||
the person has not completed their family and treatment with cyclophosphamide may materially affect their fertility or
|
||
the disease has remained active or progressed despite a course of cyclophosphamide lasting 3–6 months or
|
||
the person has had uroepithelial malignancy.
|
||
"
|
||
543,TA309,2014/15,STA,Pemetrexed,Pharmaceutical,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
544,TA310,2014/15,STA,Afatinib,Pharmaceutical,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
545,TA311,2014/15,STA,"Bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide",Pharmaceutical,For induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,Recommended,Recommended in line with marketing authorisation.
|
||
546,TA312,2014/15,STA,Alemtuzumab,Pharmaceutical,Relapsing-remitting multiple sclerosis,Recommended,Recommended in line with marketing authorisation.
|
||
547,TA313,2014/15,STA,Ustekinumab alone or in combination with methotrexate,Pharmaceutical,Active psoriatic arthritis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
548,TA314,2014/15,MTA,Implantable cardioverter defibrillators ,Medical device,Arrhythmias and heart failure,Optimised,"Optimised recommendation. The Committee looked at 20 subgroups of patients for all combinations of New York Heart Association (NYHA) class, QRS duration and presence of left bundle branch block (LBBB). Please see table 1 in TA314 for the recommendations for each subgroup.
|
||
The Committee also concluded that the recommendation in NICE technology appraisal guidance 95 regarding previous serious ventricular arrhythmia, certain familial cardiac conditions and after surgical repair of congenital heart disease did not need to be changed."
|
||
549,TA314,2014/15,MTA,Cardiac resynchronisation therapy (CRT-D and CRT-P),Medical device,Arrhythmias and heart failure,Optimised,"Optimised recommendation. The Committee looked at 20 subgroups of patients for all combinations of New York Heart Association (NYHA) class, QRS duration and presence of left bundle branch block (LBBB). Please see table 1 in TA314 for the recommendations for each subgroup."
|
||
550,TA315,2014/15,STA,Canagliflozin in combination with metformin (dual therapy),Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with marketing authorisation.
|
||
551,TA315,2014/15,STA,Canagliflozin in combination with metformin and a sulfonylurea/thiazolidinedione (triple therapy),Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with clinical practice.
|
||
552,TA315,2014/15,STA,Canagliflozin in combination with insulin with or without other antidiabetic drugs ,Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with clinical practice.
|
||
553,TA316,2014/15,STA,Enzalutamide,Pharmaceutical,Metastatic hormone-relapsed prostate cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
554,TA317,2014/15,MTA,Prasugrel in combination with aspirin,Pharmaceutical,Acute coronary syndromes,Recommended,Recommended in line with marketing authorisation
|
||
555,TA318,2014/15,STA,Lubiprostone,Pharmaceutical,Chronic idiopathic constipation,Recommended,Recommended in line with clinical practice
|
||
556,TA319,2014/15,STA,Ipilimumab,Pharmaceutical,Previously untreated advanced (unresectable or metastatic) melanoma,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
557,TA320,2014/15,STA,Dimethyl fumarate,Pharmaceutical,Relapsing-remitting multiple sclerosis,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme
|
||
558,TA321,2014/15,STA,Dabrafenib,Pharmaceutical,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
559,TA322,2014/15,STA,Lenalidomide,Pharmaceutical,Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
560,TA323,2014/15,MTA,"Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa)",Pharmaceutical,Treating anaemia in people with cancer having chemotherapy ,Recommended,Recommended in line with marketing authorisation
|
||
561,TA324,2014/15,MTA,Dual chamber pacemakers,Medical device,Symptomatic bradycardia due to sick sinus syndrome without atrioventricular block ,Recommended,Recommended in line with clinical practice
|
||
562,TA325,2014/15,STA,Nalmefene,Pharmaceutical,Reducing alcohol consumption in people with alcohol dependence,Recommended,Recommended in line with marketing authorisation
|
||
563,TA326,2014/15,STA,Imatinib,Pharmaceutical,Adjuvant treatment of gastrointestinal stromal tumours ,Recommended,Recommended in line with clinical practice
|
||
564,TA327,2014/15,STA,Dabigatran etexilate,Pharmaceutical,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,Recommended,Recommended in line with marketing authorisation
|
||
565,TA328,2014/15,STA,Idelalisib,Pharmaceutical,follicular lymphoma that is refractory to 2 prior treatments,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
566,TA329,2014/15,MTA,Infliximab,Pharmaceutical,moderately to severely active ulcerative colitis after the failure of conventional therapy ,Recommended,Recommended in line with marketing authorisation
|
||
567,TA329,2014/15,MTA,Adalimumab,Pharmaceutical,moderately to severely active ulcerative colitis after the failure of conventional therapy ,Recommended,Recommended in line with marketing authorisation
|
||
568,TA329,2014/15,MTA,Golimumab,Pharmaceutical,moderately to severely active ulcerative colitis after the failure of conventional therapy ,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
569,TA330,2014/15,STA,Sofosbuvir,Pharmaceutical,Chronic hepatitis C,Optimised,Optimised recommendation. Sofosbuvir was recommended only for some groups depending on genotype combined with treatment history.
|
||
570,TA331,2014/15,STA,Simeprevir in combination with peginterferon alfa and ribavirin,Pharmaceutical,Treating genotypes 1 and 4 chronic hepatitis C,Recommended,Recommended in line with marketing authorisation. Simeprevir also has a marketing authorisation for use in combination with sofosbuvir. Recommendations for simeprevir in combination with sofosbuvir will be developed in separate guidance.
|
||
571,TA332,2014/15,STA,Sipuleucel-T,Pharmaceutical,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. This guidance has been withdrawn after publication, because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015."
|
||
572,TA333,2014/15,STA,Axitinib,Pharmaceutical,treating advanced renal cell carcinoma after failure of prior systemic treatment,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
573,TA334,2014/15,STA,Regorafenib,Pharmaceutical,Metastatic colorectal cancer after treatment for metastatic disease,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
574,TA335,2014/15,STA,Rivaroxaban in combination with aspirin plus clopidogrel or aspirin alone,Pharmaceutical,Preventing adverse outcomes after acute management of acute coronary syndrome,Recommended,Recommended in line with marketing authorisation.
|
||
575,TA336,2014/15,STA,Empagliflozin in a dual therapy regimen in combination with metformin,Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with clinical practice.
|
||
576,TA336,2014/15,STA,Empagliflozin in a triple therapy regimen in combination with metformin and either a sulfonylurea or a thiazolidinedione,Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with clinical practice.
|
||
577,TA336,2014/15,STA,Empagliflozin in combination with insulin with or without other antidiabetic drugs,Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with clinical practice.
|
||
578,TA337,2014/15,STA,Rifaximin,Pharmaceutical,Preventing episodes of overt hepatic encephalopathy,Recommended,Recommended in line with marketing authorisation.
|
||
579,TA338,2014/15,STA,Pomalidomide in combination with dexamethasone,Pharmaceutical,Relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
580,TA339,2015/16,STA,Omalizumab,Pharmaceutical,Previously treated chronic spontaneous urticaria,Optimised,"Optimised recommendation for omalizumab as an option as add‑on therapy for treating severe chronic spontaneous urticaria in adults and young people aged 12 years and over only if:
|
||
• the severity of the condition is assessed objectively, for example, using a weekly urticaria activity score of 28 or morethe person's condition has not responded to standard treatment with H1‑antihistamines and leukotriene receptor antagonists;
|
||
• omalizumab is stopped at or before the fourth dose if the condition has not responded;
|
||
• omalizumab is stopped at the end of a course of treatment (6 doses) if the condition has responded, to establish whether the condition has gone into spontaneous remission, and is restarted only if the condition relapses;
|
||
• omalizumab is administered under the management of a secondary care specialist in dermatology, immunology or allergy;
|
||
and the company provides omalizumab with the discount agreed in the patient access scheme.
|
||
"
|
||
581,TA340,2015/16,STA,"Ustekinumab, alone or in combination with methotrexate",Pharmaceutical,Active psoriatic arthritis,Optimised,"Optimised recommendation for ustekinumab, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when:
|
||
|
||
• treatment with tumour necrosis factor (TNF) alpha inhibitors is contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis and golimumab for the treatment of psoriatic arthritis) or
|
||
|
||
• the person has had treatment with 1 or more TNF‑alpha inhibitors.
|
||
|
||
and if the company provides the 90 mg dose of ustekinumab for people who weigh more than 100 kg at the same cost as the 45 mg dose, as agreed in the patient access scheme.
|
||
"
|
||
582,TA341,2015/16,STA,Apixaban,Pharmaceutical,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,Recommended,Recommended in line with marketing authorisation
|
||
583,TA342,2015/16,STA,Vedolizumab,Pharmaceutical,Moderately to severely active ulcerative colitis,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
584,TA343,2015/16,STA,Obinutuzumab in combination with chlorambucil,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Optimised,"Optimised recommendation for obinutuzumab in combination with chlorambucil as an option for adults with untreated chronic lymphocytic leukaemia who have comorbidities that make full‑dose fludarabine‑based therapy unsuitable for them, only if: bendamustine‑based therapy is not suitable
|
||
|
||
and the company provides obinutuzumab with the discount agreed in the patient access scheme.
|
||
"
|
||
585,TA344,2015/16,STA,Ofatumumab in combination with chlorambucil,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
586,TA345,2015/16,STA,Naloxegol ,Pharmaceutical,Opioid‑induced constipation,Recommended,Recommended in line with marketing authorisation.
|
||
587,TA346,2015/16,STA,Aflibercept,Pharmaceutical,Diabetic macular oedema,Optimised,"Optimised recommendation for aflibercept solution for injection as an option for treating visual impairment caused by diabetic macular oedema only if the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and the company provides aflibercept with the discount agreed in the patient access scheme.
|
||
|
||
"
|
||
588,TA347,2015/16,STA,Nintedanib in combination with docetaxel ,Pharmaceutical,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
589,TA348,2015/16,STA,Everolimus,Pharmaceutical,Preventing organ rejection in liver transplantation,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
590,TA349,2015/16,STA,Dexamethasone intravitreal implant ,Pharmaceutical,Diabetic macular oedema,Optimised,"Optimised recommendation for dexamethasone intravitreal implant as an option for treating diabetic macular oedema only if:
|
||
the implant is to be used in an eye with an intraocular (pseudophakic) lens and
|
||
the diabetic macular oedema does not respond to non‑corticosteroid treatment, or such treatment is unsuitable.
|
||
|
||
"
|
||
591,TA350,2015/16,STA,Secukinumab,Pharmaceutical,Moderate to severe plaque psoriasis,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
592,TA351,2015/16,STA,Cangrelor,Pharmaceutical,Reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
593,TA352,2015/16,STA,Vedolizumab,Pharmaceutical,Treating moderately to severely active Crohn's disease after prior therapy,Optimised,"Optimised recommendation for vedolizumab for treating moderately to severely active Crohn's disease only if:
|
||
a tumour necrosis factor‑alpha inhibitor has failed (that is, the disease has responded inadequately or has lost response to treatment) or
|
||
a tumour necrosis factor‑alpha inhibitor cannot be tolerated or is contraindicated.
|
||
|
||
Vedolizumab is recommended only if the company provides it with the discount agreed in the patient access scheme.
|
||
|
||
"
|
||
594,TA353,2015/16,STA,Bevacizumab,Pharmaceutical,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
595,TA354,2015/16,STA,Edoxaban,Pharmaceutical,Treating and preventing deep vein thrombosis and pulmonary embolism,Recommended,Recommended in line with marketing authorisation.
|
||
596,TA355,2015/16,STA,Edoxaban,Pharmaceutical,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,Recommended,Recommended in line with marketing authorisation.
|
||
597,TA356,2015/16,STA,Ruxolitinib,Pharmaceutical,Treating polycythaemia vera ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
598,TA357,2015/16,STA,Pembrolizumab,Pharmaceutical,Treating advanced melanoma after disease progression with ipilimumab,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
599,TA358,2015/16,STA,Tolvaptan,Pharmaceutical,Treating autosomal dominant polycystic kidney disease,Optimised,"Optimised recommendation for tolvaptan as an option for treating autosomal dominant polycystic kidney disease (ADPKD) in adults to slow the progression of cyst development and renal insufficiency only if:
|
||
• they have chronic kidney disease stage 2 or 3 at the start of treatment
|
||
• there is evidence of rapidly progressing disease and
|
||
• the company provides it with the discount agreed in the patient access scheme.
|
||
"
|
||
600,TA359,2015/16,STA,Idelalisib in combination with rituximab,Pharmaceutical,Treating chronic lymphocytic leukaemia,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme. Note: no evidence presented for population not recommended.
|
||
601,TA360,2015/16,STA,Paclitaxel as albumin‑bound nanoparticles in combination with gemcitabine,Pharmaceutical,Previously untreated metastatic pancreatic cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
602,TA361,2015/16,STA,Simeprevir in combination with sofosbuvir,Pharmaceutical,Treating genotype 1 or 4 chronic hepatitis C,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
603,TA362,2015/16,STA,Paclitaxel as albumin-bound nanoparticles with carboplatin,Pharmaceutical,Untreated non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
604,TA363,2015/16,STA,Ledipasvir–sofosbuvir,Pharmaceutical,Chronic hepatitis C,Optimised,"Optimised recommendation for ledipasvir–sofosbuvir for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history. Please see the final guidance section 1 for the detailed recommendations."
|
||
605,TA363,2015/16,STA,Ledipasvir–sofosbuvir plus ribavirin,Pharmaceutical,Chronic hepatitis C,Optimised,"Optimised recommendation for ledipasvir–sofosbuvir plus ribavirin for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history. Please see the final guidance section 1 for the detailed recommendations."
|
||
606,TA364,2015/16,STA,Daclatasvir plus sofosbuvir,Pharmaceutical,Chronic hepatitis C,Optimised,"Optimised recommendation for daclatasvir plus sofosbuvir for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history and only if the company provides daclatasvir at the same price or lower than that agreed with the Commercial Medicines Unit. Please see the final guidance section 1 for the detailed recommendations."
|
||
607,TA364,2015/16,STA,Daclatasvir plus sofosbuvir and ribavirin,Pharmaceutical,Chronic hepatitis C,Optimised,"Optimised recommendation for daclatasvir plus sofosbuvir and ribavirin for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history and only if the company provides daclatasvir at the same price or lower than that agreed with the Commercial Medicines Unit. Please see the final guidance section 1 for the detailed recommendations."
|
||
608,TA364,2015/16,STA,Daclatasvir plus peginterferon alfa and ribavirin,Pharmaceutical,Chronic hepatitis C,Optimised,"Optimised recommendation for daclatasvir plus peginterferon alfa and ribavirin for treating chronic hepatitis C based on HCV genotype, liver disease stage, duration and treatment history and only if the company provides daclatasvir at the same price or lower than that agreed with the Commercial Medicines Unit. Please see the final guidance section 1 for the detailed recommendations."
|
||
609,TA365,2015/16,STA,Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin,Pharmaceutical,Chronic hepatitis C,Recommended,Recommended in line with marketing authorisation and only if only if the company provides ombitasvir–paritaprevir–ritonavir and dasabuvir at the same price or lower than that agreed with the Commercial Medicines Unit
|
||
610,TA365,2015/16,STA,Ombitasvir–paritaprevir–ritonavir with ribavirin,Pharmaceutical,Chronic hepatitis C,Recommended,Recommended in line with marketing authorisation and only if only if the company provides ombitasvir–paritaprevir–ritonavir and ribavirin at the same price or lower than that agreed with the Commercial Medicines Unit
|
||
611,TA366,2015/16,STA,Pembrolizumab,Pharmaceutical,Advanced melanoma not previously treated with ipilimumab,Recommended,"Recommended in line with marketing authorisation and following agreement of patient access scheme. Note: The MA was appraised across 2 separate appraisals, both recommended (see TA357)."
|
||
612,TA367,2015/16,STA,Vortioxetine,Pharmaceutical,Major depressive episodes,Recommended,Recommended in line with clinical practice.
|
||
613,TA368,2015/16,STA,Apremilast,Pharmaceutical,Moderate to severe plaque psoriasis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
614,TA369,2015/16,STA,Ciclosporin,Pharmaceutical,Treating dry eye disease that has not improved despite treatment with artificial tears,Recommended,Recommended in line with marketing authorisation
|
||
615,TA370,2015/16,STA,Bortezomib,Pharmaceutical,Previously untreated mantle cell lymphoma,Recommended,Recommended in line with marketing authorisation
|
||
616,TA371,2015/16,STA,Trastuzumab emtansine,Pharmaceutical,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
617,TA372,2015/16,STA,Apremilast alone or in combination with disease‑modifying antirheumatic drug (DMARD) therapy,Pharmaceutical,Treating active psoriatic arthritis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
618,TA373,2015/16,MTA,Abatecept,Pharmaceutical,Treating juvenile idiopathic arthritis,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
619,TA373,2015/16,MTA,Adalimumab,Pharmaceutical,Treating juvenile idiopathic arthritis,Recommended,Recommended in line with marketing authorisation.
|
||
620,TA373,2015/16,MTA,Etanercept,Pharmaceutical,Treating juvenile idiopathic arthritis,Recommended,Recommended in line with marketing authorisation.
|
||
621,TA373,2015/16,MTA,Tocilizumab,Pharmaceutical,Treating juvenile idiopathic arthritis,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
622,TA374,2015/16,MTA,Erlotinib,Pharmaceutical,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,Optimised,"Optimised recommendation for erlotinib, only if the company provides erlotinib with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 258: Erlotinib is recommended as an option for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed in people who have had non‑targeted chemotherapy because of delayed confirmation that their tumour is epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation‑positive. Erlotinib is recommended as an option for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed after non‑targeted chemotherapy in people with tumours of unknown EGFR‑TK mutation status, only if: the result of an EGFR‑TK mutation diagnostic test is unobtainable because of an inadequate tissue sample or poor‑quality DNA and the treating clinician considers that the tumour is very likely to be EGFR‑TK mutation‑positive and the person's disease responds to the first 2 cycles of treatment with erlotinib. Erlotinib is not recommended for treating locally advanced or metastatic non‑small‑cell lung cancer that has progressed after non‑targeted chemotherapy in people with tumours that are EGFR‑TK mutation‑negative."
|
||
623,TA374,2015/16,MTA,Gefitinib,Pharmaceutical,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
624,TA375,2015/16,MTA,Adalimumab,Pharmaceutical,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,Optimised,"Optimised recommendation for adalimumab in combination with methotrexate only if:
|
||
disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and
|
||
disease has not responded to intensive therapy with a combination of conventional DMARDs
|
||
|
||
Adalimumab as monotherapy is recommended for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in section 1.1 are met."
|
||
625,TA375,2015/16,MTA,Etanercept,Pharmaceutical,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,Optimised,"Optimised recommendation for etanercept in combination with methotrexate only if:
|
||
disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and
|
||
disease has not responded to intensive therapy with a combination of conventional DMARDs
|
||
|
||
Etanercept as monotherapy is recommended for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in section 1.1 are met."
|
||
626,TA375,2015/16,MTA,Infliximab in combination with methotrexate,Pharmaceutical,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,Optimised,"Optimised recommendation for infliximab in combination with methotrexate only if:
|
||
disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and
|
||
disease has not responded to intensive therapy with a combination of conventional DMARDs"
|
||
627,TA375,2015/16,MTA,Certolizumab Pegol,Pharmaceutical,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,Optimised,"Optimised recommendation for Certolizumab pegol in combination with methotrexate only if:
|
||
disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and
|
||
disease has not responded to intensive therapy with a combination of conventional DMARDs
|
||
the company provides certolizumab pegol as agreed in the patient access scheme
|
||
Certolizumab pegol as monotherapy is recommended for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in section 1.1 are met."
|
||
628,TA375,2015/16,MTA,Golimumab in combination with methotrexate,Pharmaceutical,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,Optimised,"Optimised recommendation for golimumab in combination with methotrexate only if:
|
||
disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and
|
||
disease has not responded to intensive therapy with a combination of conventional DMARDs
|
||
the company provides golimumab as agreed in the patient access scheme"
|
||
629,TA375,2015/16,MTA,Tocilizumab,Pharmaceutical,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,Optimised,"Optimised recommendation for tocilizumab in combination with methotrexate only if:
|
||
disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and
|
||
disease has not responded to intensive therapy with a combination of conventional DMARDs
|
||
the company provides tocilizumab as agreed in the patient access scheme
|
||
Tocilizumab as monotherapy is recommended for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in section 1.1 are met."
|
||
630,TA375,2015/16,MTA,Abatacept in combination with methotrexate,Pharmaceutical,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,Optimised,"Optimised recommendation for abatacept in combination with methotrexate only if:
|
||
disease is severe, that is, a disease activity score (DAS28) greater than 5.1 and
|
||
disease has not responded to intensive therapy with a combination of conventional DMARDs
|
||
the company provides abatacept as agreed in the patient access scheme"
|
||
631,TA376,2015/16,STA,Radium-223 dichloride,Pharmaceutical,Treating hormone-relapsed prostate cancer with bone metastases,Optimised,"Optimised recommendation for Radium‑223 dichloride as an option for treating adults with hormone‑relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, only if:
|
||
|
||
• they have had treatment with docetaxel, and
|
||
|
||
• the company provides radium‑223 dichloride with the discount agreed in the patient access scheme."
|
||
632,TA377,2015/16,STA,Enzalutamide,Pharmaceutical,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
633,TA378,2015/16,STA,Ramucirumab alone or with paclitaxel,Pharmaceutical,Treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
634,TA379,2015/16,STA,Nintedanib ,Pharmaceutical,Treating idiopathic pulmonary fibrosis,Optimised,"Optimised recommendation for nintedanib as an option for treating idiopathic pulmonary fibrosis, only if:
|
||
the person has a forced vital capacity (FVC) between 50% and 80% of predicted
|
||
the company provides nintedanib with the discount agreed in the patient access scheme
|
||
treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12‑month period."
|
||
635,TA380,2015/16,STA,Panobinostat in combination with bortezomib and dexamethasone,Pharmaceutical,Treating multiple myeloma after at least 2 previous treatments,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
636,TA381,2015/16,STA,Olaparib,Pharmaceutical,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",Optimised,"Optimised recommendation for olaparib as an option for treating adults with relapsed, platinum‑sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum‑based chemotherapy only if:
|
||
they have had 3 or more courses of platinum-based chemotherapy and the drug cost of olaparib for people who remain on treatment after 15 months will be met by the company."
|
||
637,TA382,2015/16,STA,Eltrombopag,Pharmaceutical,Treating severe aplastic anaemia refractory to immunosuppressive therapy,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
638,TA383,2015/16,MTA,Adalimumab,Pharmaceutical,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,Recommended,Recommended in line with marketing authorisation.
|
||
639,TA383,2015/16,MTA,Certolizumab pegol,Pharmaceutical,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
640,TA383,2015/16,MTA,Etanercept,Pharmaceutical,Ankylosing spondylitis,Recommended,Recommended in line with marketing authorisation.
|
||
641,TA383,2015/16,MTA,Golimumab,Pharmaceutical,Ankylosing spondylitis,Recommended,"Recommended in line with marketing authorisation and following agreement of patient access scheme. Golimumab has a marketing authorisation for non‑radiographic axial spondyloarthritis. However, regulatory approval was received at a late stage in the appraisal process so golimumab was not included for this indication."
|
||
642,TA383,2015/16,MTA,Infliximab,Pharmaceutical,Ankylosing spondylitis,Recommended,Recommended in line with marketing authorisation.
|
||
643,TA384,2015/16,STA,Nivolumab,Pharmaceutical,Advanced (unresectable or metastatic) melanoma,Recommended,Recommended in line with marketing authorisation.
|
||
644,TA385,2015/16,STA,Ezetimibe monotherapy,Pharmaceutical,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,Recommended,Recommended in line with marketing authorisation.
|
||
645,TA385,2015/16,STA,Ezetimibe co‑administered with initial statin therapy,Pharmaceutical,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,Recommended,Recommended in line with marketing authorisation.
|
||
646,TA386,2015/16,STA,Ruxolitinib,Pharmaceutical,Treating disease-related splenomegaly or symptoms in adults with myelofibrosis,Optimised,"Optimised recommendation for ruxolitinib for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only:
|
||
•in people with intermediate‑2 or high-risk disease, and
|
||
•if the company provides ruxolitinib with the discount agreed in the patient access scheme."
|
||
647,TA387,2016/17,STA,Abiraterone in combination with prednisone or prednisolone,Pharmaceutical,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,Recommended,"Recommended in line with the marketing authorisation, only if the company rebates the drug cost of abiraterone from the 11th month until the end of treatment for people who remain on treatment for more than 10 months."
|
||
648,TA388,2016/17,STA,Sacubitril valsartan,Pharmaceutical,Treating symptomatic chronic heart failure with reduced ejection fraction,Optimised,"Optimised recommendation for treating symptomatic chronic heart failure with reduced ejection fraction, only in people:
|
||
•with New York Heart Association (NYHA) class II to IV symptoms and
|
||
•with a left ventricular ejection fraction of 35% or less and
|
||
•who are already taking a stable dose of angiotensin‑converting enzyme (ACE) inhibitors or angiotensin II receptor‑blockers (ARBs)."
|
||
649,TA389,2016/17,MTA,Paclitaxel in combination with platinum or as monotherapy,Pharmaceutical,Treating recurrent ovarian cancer,Recommended,Recommended in line with marketing authorisation.
|
||
650,TA389,2016/17,MTA,Pegylated liposomal doxorubicin hydrochloride (PLDH) monotherapy,Pharmaceutical,Treating recurrent ovarian cancer,Recommended,Recommended in line with marketing authorisation.
|
||
651,TA389,2016/17,MTA,PLDH in combination with platinum,Pharmaceutical,Treating recurrent ovarian cancer,Recommended,Recommended in line with clinical practice. The use of PLDH (Caelyx) in combination with platinum is outside the terms of the marketing authorisation. Consequently the statutory funding requirement does not apply to this recommendation.
|
||
652,TA389,2016/17,MTA,Gemcitabine in combination with carboplatin ,Pharmaceutical,Treating recurrent ovarian cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
653,TA389,2016/17,MTA,Trabectedin in combination with PLDH,Pharmaceutical,Treating recurrent ovarian cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
654,TA389,2016/17,MTA,Topotecan,Pharmaceutical,Treating recurrent ovarian cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
655,TA390,2016/17,MTA,Canagliflozin monotherapy,Pharmaceutical,Treating type 2 diabetes,Optimised,"Optimised recommendation for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:
|
||
• a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and
|
||
• a sulfonylurea or pioglitazone is not appropriate."
|
||
656,TA390,2016/17,MTA,Dapagliflozin monotherapy,Pharmaceutical,Treating type 2 diabetes,Optimised,"Optimised recommendation for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:
|
||
• a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and
|
||
• a sulfonylurea or pioglitazone is not appropriate."
|
||
657,TA390,2016/17,MTA,Empagliflozin monotherapy,Pharmaceutical,Treating type 2 diabetes,Optimised,"Optimised recommendation for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:
|
||
• a dipeptidyl peptidase‑4 (DPP‑4) inhibitor would otherwise be prescribed and
|
||
• a sulfonylurea or pioglitazone is not appropriate."
|
||
658,TA391,2016/17,STA,Cabazitaxel in combination with prednisone or prednisolone,Pharmaceutical,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
659,TA392,2016/17,STA,Adalimumab,Pharmaceutical,Treating moderate to severe hidradenitis suppurativa,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
660,TA393,2016/17,STA,Alirocumab,Pharmaceutical,Treating primary hypercholesterolaemia and mixed dyslipidaemia,Optimised,"Optimised recommendation for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
|
||
Low‑density lipoprotein concentrations are persistently above the thresholds specified despite maximal tolerated lipid‑lowering therapy. That is, either the maximum dose has been reached or further titration is limited by intolerance (as defined in NICE's guideline on familial hypercholesterolaemia: identification and management), and the company provides alirocumab with the discount agreed in the patient access scheme."
|
||
661,TA394,2016/17,STA,Evolocumab,Pharmaceutical,Treating primary hypercholesterolaemia and mixed dyslipidaemia,Optimised,"Optimised recommendation for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
|
||
The dosage is 140 mg every 2 weeks.
|
||
Low-density lipoprotein concentrations are persistently above the thresholds specified despite maximal tolerated lipid-lowering therapy. That is, either the maximum dose has been reached, or further titration is limited by intolerance (as defined in NICE's guideline on familial hypercholesterolaemia).
|
||
The company provides evolocumab with the discount agreed in the patient access scheme"
|
||
662,TA395,2016/17,STA,Ceritinib,Pharmaceutical,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
|
||
663,TA396,2016/17,STA,Trametinib in combination with dabrafenib,Pharmaceutical,Treating unresectable or metastatic melanoma,Recommended,Recommended in line with marketing authorisation
|
||
664,TA397,2016/17,STA,Belimumab,Pharmaceutical,Treating active autoantibody-positive systemic lupus erythematosus,Optimised,"Optimised recommendation for belimumab as an option as add-on treatment for active autoantibody-positive systemic lupus erythematosus in adults only if all of the following apply:
|
||
· There is evidence for serological disease activity (defined as positive anti-double-stranded DNA and low complement) and a Safety of Estrogen in Lupus National Assessment – Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of greater than or equal to 10 despite standard treatment.
|
||
· Treatment with belimumab is continued beyond 24 weeks only if the SELENA-SLEDAI score has improved by 4 points or more.
|
||
· The company provides belimumab with the discount agreed in the patient access scheme.
|
||
· Under the conditions for data collection, monitoring, patient eligibility and consent, ongoing treatment, cost to the NHS, and review by NICE as laid out in sections 5 and 6 of this document."
|
||
665,TA398,2016/17,STA,Lumacaftor–ivacaftor,Pharmaceutical,Treating cystic fibrosis homozygous for the F508del mutation,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
666,TA399,2016/17,STA,Azacitidine,Pharmaceutical,Treating acute myeloid leukaemia with more than 30% bone marrow blasts,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
667,TA400,2016/17,STA,Nivolumab in combination with ipilimumab,Pharmaceutical,Treating advanced melanoma,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
668,TA401,2016/17,STA,Bosutinib,Pharmaceutical,Previously treated chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
669,TA402,2016/17,STA,Pemetrexed,Pharmaceutical,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
|
||
670,TA403,2016/17,STA,Ramucirumab in combination with docetaxel,Pharmaceutical,Previously treated locally advanced or metastatic non-small-cell lung cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
671,TA404,2016/17,STA,Degarelix,Pharmaceutical,Advanced hormone-dependent prostate cancer,Optimised,"Optimised recommendation for degarelix as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016."
|
||
672,TA405,2016/17,STA,Trifluridine–tipiracil,Pharmaceutical,Previously treated metastatic colorectal cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
673,TA406,2016/17,STA,Crizotinib,Pharmaceutical,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
|
||
674,TA407,2016/17,STA,Secukinumab,Pharmaceutical,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
|
||
675,TA408,2016/17,STA,"Pegaspargase, as part of antineoplastic combination therapy",Pharmaceutical,Treating acute lymphoblastic leukaemia,Optimised,"Optimised recommendation for pegaspargase, as part of antineoplastic combination therapy, ias an option for treating acute lymphoblastic leukaemia in children, young people and adults only when they have untreated newly diagnosed disease."
|
||
676,TA409,2016/17,STA,Aflibercept,Pharmaceutical,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
|
||
677,TA410,2016/17,STA,Talimogene laherparepvec,Pharmaceutical,Treating unresectable metastatic melanoma,Optimised,"Optimised recommendation for talimogene laherparepvec an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if:
|
||
· treatment with systemically administered immunotherapies is not suitable and
|
||
· the company provides talimogene laherparepvec with the discount agreed in the patient access scheme."
|
||
678,TA411,2016/17,STA,"Necitumumab, in combination with gemcitabine and cisplatin",Pharmaceutical,Untreated advanced or metastatic squamous non-small-cell lung cancer ,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
679,TA412,2016/17,STA,Radium‑223 dichloride,Pharmaceutical,Treating hormone-relapsed prostate cancer with bone metastases,Optimised,"Optimised recommendation for radium‑223 dichloride as an option for treating hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases in adults, only if:
|
||
they have already had docetaxel or
|
||
docetaxel is contraindicated or is not suitable for them.
|
||
The drug is only recommended if the company provides radium‑223 dichloride with the discount agreed in the patient access scheme. "
|
||
680,TA413,2016/17,STA,Elbasvir–grazoprevir,Pharmaceutical,Chronic hepatitis C,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
681,TA414,2016/17,STA,Cobimetinib in combination with vemurafenib,Pharmaceutical,Unresectable or metastatic BRAF V600 mutation-positive melanoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
682,TA415,2016/17,STA,Certolizumab pegol in combination with methotrexate,Pharmaceutical,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,Optimised,"Optimised recommendation for certolizumab pegol, in combination with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor‑alpha (TNF‑alpha) inhibitor, only if: disease activity is severe and rituximab is contraindicated or not tolerated and the company provides certolizumab pegol with the agreed patient access scheme."
|
||
683,TA415,2016/17,STA,Certolizumab pegol monotherapy,Pharmaceutical,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,Optimised,"Optimised recommendation for certolizumab pegol, as monotherapy, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate, other DMARDs including at least 1 TNF‑alpha inhibitor, only if: disease activity is severe and rituximab therapy cannot be given because methotrexate is contraindicated or not tolerated and the company provides certolizumab pegol with the agreed patient access scheme."
|
||
684,TA416,2016/17,STA,Osimertinib,Pharmaceutical,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,Recommended (CDF),Recommended in line with clinical practice for use within the Cancer Drugs fund only if the conditions in the managed access agreement for osimertinib are followed.
|
||
685,TA417,2016/17,STA,Nivolumab,Pharmaceutical,Previously treated advanced renal cell carcinoma,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
|
||
686,TA418,2016/17,STA,Dapagliflozin in combinatin with metformin and a sulfonylurea,Pharmaceutical,Treating type 2 diabetes,Recommended,Recommended in line with clinical practice.
|
||
687,TA419,2016/17,STA,Apremilast,Pharmaceutical,Treating moderate to severe plaque psoriasis,Recommended,Recommended in line with clinical practice and following agreement of patient access scheme.
|
||
688,TA420,2016/17,STA,Ticagrelor in combination with aspirin,Pharmaceutical,Preventing atherothrombotic events after myocardial infarction,Recommended,Recommended in line with marketing authorisation
|
||
689,TA421,2016/17,STA,Everolimus in combination with exemestane,Pharmaceutical,Treating advanced breast cancer after endocrine therapy,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
690,TA422,2016/17,STA,Crizotinib,Pharmaceutical,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
691,TA423,2016/17,STA,Eribulin,Pharmaceutical,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,Optimised,"Optimised recommendation for eribulin as an option for treating locally advanced or metastatic breast cancer in adults, only when:
|
||
•it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine)
|
||
•the company provides eribulin with the discount agreed in the patient access scheme."
|
||
692,TA424,2016/17,STA,Pertuzumab in combination with trastuzumab and chemotherapy,Pharmaceutical,Neoadjuvant treatment of HER2-positive breast cancer,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
693,TA425,2016/17,STA,Dasitinib,Pharmaceutical,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,Optimised,"Optimised recommendation for dasatinib as an option for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if:
|
||
• they cannot have imatinib, or their disease is imatinib-resistant and
|
||
•the companies provide the drugs with the discounts agreed in the relevant patient access schemes."
|
||
694,TA425,2016/17,STA,Nilotinib,Pharmaceutical,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of patient access scheme.
|
||
695,TA425,2016/17,STA,High-dose imatinib,Pharmaceutical,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
696,TA426,2016/17,STA,Dasatinib,Pharmaceutical,Untreated chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
697,TA426,2016/17,STA,Nilotinib,Pharmaceutical,Untreated chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
698,TA426,2016/17,STA,Imatinib,Pharmaceutical,Untreated chronic myeloid leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
699,TA427,2016/17,STA,"Pomalidomide, in combination with low‑dose dexamethasone",Pharmaceutical,Multiple myeloma previously treated with lenalidomide and bortezomib,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
700,TA428,2016/17,STA,Pembrolizumab,Pharmaceutical,PD-L1-positive non-small-cell lung cancer after chemotherapy,Optimised,"Optimised recommendation for pempbrolizumab for treating locally advanced or metastatic PD‑L1‑positive non‑small‑cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermal growth factor receptor [EGFR]- or anaplastic lymphoma kinase [ALK]‑positive tumour), only if:
|
||
• pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression, and
|
||
• the company provides pembrolizumab with the discount agreed in the patient access scheme revised in the context of this appraisal."
|
||
701,TA429,2016/17,STA,Ibrutinib alone,Pharmaceutical,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
702,TA430,2016/17,STA,Sofosbuvir–velpatasvir,Pharmaceutical,Chronic hepatitis C,Optimised,"Optimised recommendation for sofosbuvir–velpatasvir for treating chronic hepatitis C based on HCV genotype, liver disease stage, and only if the company provides the drug with the discount agreed in the simple discount agreement. Please see the final guidance section 1 for the detailed recommendations."
|
||
703,TA431,2016/17,STA,Mepolizumab as an add-on to optimised standard therapy,Pharmaceutical,Severe refractory eosinophilic asthma,Optimised,"Optimised recommendation for mepolizumab, as an add-on to optimised standard therapy, for treating severe refractory eosinophilic asthma in adults, only if:
|
||
•the blood eosinophil count is 300 cells/microlitre or more in the previous 12 months and
|
||
•the person has agreed to and followed the optimised standard treatment plan and
|
||
◦has had 4 or more asthma exacerbations needing systemic corticosteroids in the previous 12 months or
|
||
◦has had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous 6 months and
|
||
•the company provides the drug with the discount agreed in the patient access scheme."
|
||
704,TA432,2016/17,STA,Everolimus,Pharmaceutical,Advanced renal cell carcinoma after previous treatment,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
705,TA433,2016/17,STA,"Apremilast, alone or in combination with disease-modifying antirheumatic drugs (DMARDs)",Pharmaceutical,Active psoriatic arthritis,Optimised,"Optimised recommendation for apremilast alone or in combination with disease-modifying antirheumatic drugs (DMARDs), as an option for treating active psoriatic arthritis in adults only if:
|
||
• they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and
|
||
• their disease has not responded to adequate trials of at least 2 standard DMARDs, given either alone or in combination and
|
||
• the company provides apremilast with the discount agreed in the patient access scheme."
|
||
706,TA434,2016/17,STA,Elotuzumab,Pharmaceutical,Previously treated multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
|
||
707,TA435,2016/17,STA,Tenofovir alafenamide,Pharmaceutical,Chronic hepatitis B,Terminated Appraisal - non submission,The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
|
||
708,TA436,2016/17,STA,Bevacizumab,Pharmaceutical,EGFR mutation-positive non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
|
||
709,TA437,2016/17,STA,Ibrutinib with bendamustine and rituximab,Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy ,Terminated Appraisal - non submission,The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
|
||
710,TA438,2016/17,STA,Alectinib,Pharmaceutical,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the company’s submission. In the absence of a submission from the company the appraisal was terminated and a recommendation could not be made.
|
||
711,TA439,2016/17,MTA,Cetuximab,Pharmaceutical,Previously untreated metastatic colorectal cancer,Recommended,Recommended in line with marketing authorisation.
|
||
712,TA439,2016/17,MTA,Panitumumab,Pharmaceutical,Previously untreated metastatic colorectal cancer,Recommended,Recommended in line with marketing authorisation.
|
||
713,TA440,2017/18,STA,Pegylated liposomal irinotecan in combination with 5‑fluorouracil and leucovorin,Pharmaceutical,Pancreatic cancer after gemcitabine,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
714,TA441,2017/18,STA,Daclizumab,Pharmaceutical,Relapsing–remitting multiple sclerosis,Optimised,"This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. Optimised recommendation for daclizumab for treating multiple sclerosis in adults, only if:
|
||
the person has active relapsing–remitting multiple sclerosis previously treated with disease-modifying therapy, or rapidly evolving severe relapsing–remitting multiple sclerosis (that is, at least 2 relapses in the previous year and at least 1 gadolinium-enhancing lesion at baseline MRI) and
|
||
|
||
alemtuzumab is contraindicated or otherwise unsuitable and
|
||
|
||
the company provides the drug with the discount agreed in the patient access scheme"
|
||
715,TA442,2017/18,STA,Ixekizumab,Pharmaceutical,Moderate to severe plaque psoriasis,Optimised,"Optimised recommendation for ixekizumab for treating plaque psoriasis in adults, only if:
|
||
|
||
•the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10
|
||
|
||
• the disease has not responded to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or these treatments are contraindicated or the person cannot tolerate them, and
|
||
|
||
• the company provides the drug with the discount agreed in the patient access scheme.
|
||
"
|
||
716,TA443,2017/18,STA,Obeticholic acid,Pharmaceutical,Primary biliary cholangitis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
717,TA444,2017/18,STA,Afatinib,Pharmaceutical,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,Terminated appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
718,TA445,2017/18,MTA,"Certolizumab pegol alone, or in combination with methotrexate",Pharmaceutical,Psoriatic arthritis after inadequate response to DMARDs,Optimised,"Optimised recommendation for certolizumab pegol alone, or in combination with methotrexate, for treating active psoriatic arthritis in adults only if:
|
||
•it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
|
||
|
||
•the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has stopped responding after the first 12 weeks.
|
||
|
||
Certolizumab pegol is only recommended if the company provides it as agreed in the patient access scheme."
|
||
719,TA445,2017/18,MTA,"Secukinumab alone, or in combination with methotrexate",Pharmaceutical,Psoriatic arthritis after inadequate response to DMARDs,Optimised,"Optimised recommendation for secukinumab alone, or in combination with methotrexate, for treating active psoriatic arthritis in adults only if:
|
||
•it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
|
||
|
||
•the person has had a TNF‑alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or
|
||
|
||
•TNF‑alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
|
||
|
||
Secukinumab is only recommended if the company provides it as agreed in the patient access scheme."
|
||
720,TA446,2017/18,STA,Brentuximab vedotin,Pharmaceutical,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,Optimised,"Optimised recommendation for brentuximab vedotin as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if:
|
||
•they have relapsed or refractory disease after autologous stem cell transplant and
|
||
•the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement."
|
||
721,TA446,2017/18,STA,Brentuximab vedotin,Pharmaceutical,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,Optimised (CDF),"Optimised recommendation for brentuximab vedotin for use within the Cancer Drugs Fund, as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if:
|
||
|
||
•they have relapsed or refractory disease after at least 2 previous therapies and
|
||
|
||
•they cannot have autologous stem cell transplant or multi-agent chemotherapy and
|
||
|
||
•the conditions of the managed access agreement are followed."
|
||
722,TA447,2017/18,STA,Pembrolizumab,Pharmaceutical,Untreated PD-L1-positive metastatic non-small-cell lung cancer,Optimised (CDF),"Optimised recommendation for pembrolizumab for use within the Cancer Drugs Fund as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults only if:
|
||
•their tumours express PD-L1 with at least a 50% tumour proportion score and have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations
|
||
•pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression
|
||
•the conditions in the managed access agreement for pembrolizumab are followed"
|
||
723,TA448,2017/18,STA,Etelcalcetide,Pharmaceutical,Secondary hyperparathyroidism,Optimised,"Optimised recommendation for etelcalcetide as an option for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis, only if:
|
||
|
||
•treatment with a calcimimetic is indicated but cinacalcet is not suitable and
|
||
|
||
•the company provides etelcalcetide with the discount agreed in the patient access scheme."
|
||
724,TA449,2017/18,MTA,Everolimus,Pharmaceutical,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
725,TA449,2017/18,MTA,Sunitinib,Pharmaceutical,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,Recommended,Recommended in line with marketing authorisation.
|
||
726,TA450,2017/18,STA,Blinatumomab,Pharmaceutical,Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
727,TA451,2017/18,STA,Ponatinib,Pharmaceutical,Chronic myeloid leukaemia and acute lymphoblastic leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
728,TA452,2017/18,STA,Ibrutinib,Pharmaceutical,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
729,TA453,2017/18,STA,Bortezomib,Pharmaceutical,Multiple myeloma after second or subsequent relapse,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
730,TA454,2017/18,STA,Daratumumab,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
731,TA455,2017/18,MTA,Adalimumab,Pharmaceutical,Plaque psoriasis in children and young people,Optimised,"Optimised recommendation for adalimumab as an option for treating plaque psoriasis in children and young people aged 4 years or older, only if the disease:
|
||
|
||
•is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and
|
||
•has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated.
|
||
"
|
||
732,TA455,2017/18,MTA,Etanercept,Pharmaceutical,Plaque psoriasis in children and young people,Optimised,"Optimised recommendation for etanercept as an option for treating plaque psoriasis in children and young people aged 6 years or older, only if the disease:
|
||
|
||
•is severe, as defined by a total PASI of 10 or more and
|
||
|
||
•has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated"
|
||
733,TA455,2017/18,MTA,Ustekinumab,Pharmaceutical,Plaque psoriasis in children and young people,Optimised,"Optimised recommendation for ustekinumab as an option for treating plaque psoriasis in children and young people aged 12 years or older, only if the disease:
|
||
|
||
•is severe, as defined by a total PASI of 10 or more
|
||
|
||
•has not responded to standard systemic therapy, such as ciclosporin, methotrexate or phototherapy, or these options are contraindicated or not tolerated"
|
||
734,TA456,2017/18,STA,Ustekinumab,Pharmaceutical,Moderately to severely active Crohn’s disease after previous treatment,Recommended,Recommended in line with marketing authorisation.
|
||
735,TA457,2017/18,STA,Carfilzomib in combination with dexamethasone,Pharmaceutical,Previously treated multiple myeloma,Optimised,"Optmised recommendation for carfilzomib in combination with dexamethasone as an option for treating multiple myeloma in adults, only if:
|
||
|
||
•they have had only 1 previous therapy, which did not include bortezomib and
|
||
•the company provides carfilzomib with the discount agreed in the patient access scheme
|
||
"
|
||
736,TA458,2017/18,STA,Trastuzumab emtansine,Pharmaceutical,HER2-positive advanced breast cancer after trastuzumab and a taxane,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access agreement.
|
||
737,TA459,2017/18,STA,Collagenase clostridium histolyticum,Pharmaceutical,Dupuytren's contracture,Optimised,"People who meet the inclusion criteria for the ongoing clinical trial (HTA-15/102/04), comparing collagenase clostridium histolyticum (CCH) with limited fasciectomy, are encouraged to participate in the study.
|
||
|
||
For people not taking part in the ongoing clinical trial, optimised recommendation for CCH for treating Dupuytren's contracture with a palpable cord in adults only if all of the following apply:
|
||
|
||
•There is evidence of moderate disease (functional problems and metacarpophalangeal joint contracture of 30° to 60° and proximal interphalangeal joint contracture of less than 30° or first web contracture) plus up to 2 affected joints.
|
||
|
||
•Percutaneous needle fasciotomy (PNF) is not considered appropriate, but limited fasciectomy is considered appropriate by the treating hand surgeon.
|
||
|
||
•The choice of treatment (CCH or limited fasciectomy) is made on an individual basis after discussion between the responsible hand surgeon and the patient about the risks and benefits of the treatments available.
|
||
|
||
•One injection is given per treatment session by a hand surgeon in an outpatient setting.
|
||
"
|
||
738,TA460,2017/18,MTA,Adalimumab,Pharmaceutical,Non-infectious uveitis,Optimised,"Optimised recommendation for dexamethasone intravitreal implant as an option for treating non-infectious uveitis in the posterior segment of the eye in adults, only if there is
|
||
|
||
•active disease (that is, current inflammation in the eye) and
|
||
•worsening vision with a risk of blindness.
|
||
"
|
||
739,TA460,2017/18,MTA,Dexamethasone intravitreal implant ,Pharmaceutical,Non-infectious uveitis,Optimised,"Optimised recommendation for dexamethasone intravitreal implant as an option for treating non-infectious uveitis in the posterior segment of the eye in adults, only if there is
|
||
•active disease (that is, current inflammation in the eye) and
|
||
•worsening vision with a risk of blindness."
|
||
740,TA461,2017/18,STA,Roflumilast as an add-on to bronchodilator therapy,Pharmaceutical,Chronic obstructive pulmonary disease,Optimised,"Optimised recommendation for Roflumilast as an add-on to bronchodilator therapy as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis, only if:
|
||
|
||
•the disease is severe, defined as a forced expiratory volume in 1 second (FEV1) after a bronchodilator of less than 50% of predicted normal, and
|
||
•the person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid.
|
||
"
|
||
741,TA462,2017/18,STA,Nivolumab ,Pharmaceutical,Relapsed or refractory classical Hodgkin lymphoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
742,TA463,2017/18,STA,Cabozantinib,Pharmaceutical,Previously treated advanced renal cell carcinoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
743,TA464,2017/18,MTA," Oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium)",Pharmaceutical,Osteoporosis,Optimised,"Optimised recommendation for oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium) as options for treating osteoporosis in adults only if:
|
||
•the person is eligible for risk assessment as defined in NICE's guideline on osteoporosis (recommendations 1.1 and 1.2) and
|
||
•the 10‑year probability of osteoporotic fragility fracture is at least 1%.
|
||
|
||
"
|
||
744,TA464,2017/18,MTA,Intravenous bisphosphonates (ibandronic acid and zoledronic acid),Pharmaceutical,Osteoporosis,Optimised,"Optimised recommendation for Intravenous bisphosphonates (ibandronic acid and zoledronic acid) as options for treating osteoporosis in adults only if:
|
||
•the person is eligible for risk assessment as defined in NICE's guideline on osteoporosis (recommendations 1.1 and 1.2) and
|
||
•the 10‑year probability of osteoporotic fragility fracture is at least 10% or
|
||
•the 10‑year probability of osteoporotic fragility fracture is at least 1% and the person has difficulty taking oral bisphosphonates (alendronic acid, ibandronic acid or risedronate sodium) or these drugs are contraindicated or not tolerated.
|
||
|
||
"
|
||
745,TA465,2017/18,STA,Olaratumab in combination with doxorubicin ,Pharmaceutical,Advanced soft tissue sarcoma,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for advanced soft tissue sarcoma in adults, only if:
|
||
|
||
•they have not had any previous systemic chemotherapy for advanced soft tissue sarcoma
|
||
|
||
•they cannot have curative treatment with surgery or their disease does not respond to radiotherapy
|
||
|
||
•the conditions in the managed access agreement for olaratumab are followed
|
||
|
||
"
|
||
746,TA466,2017/18,STA,Baricitinib with methotrexate,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for baricitinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if:
|
||
•disease is severe (a disease activity score [DAS28] of more than 5.1) and
|
||
•the company provides baricitinib with the discount agreed in the patient access scheme."
|
||
747,TA466,2017/18,STA,Baricitinib with methotrexate,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for baricitinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if:
|
||
•disease is severe (a DAS28 of more than 5.1) and
|
||
•they cannot have rituximab and
|
||
•the company provides baricitinib with the discount agreed in the patient access scheme
|
||
|
||
"
|
||
748,TA466,2017/18,STA,Baricitinib monotherapy,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,Optimised recommendation for baricitinib as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance when the criteria for combination treatment described in section 1.1 and 1.2 are met.
|
||
749,TA467,2017/18,STA,Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells),Pharmaceutical,Limbal stem cell deficiency after eye burns,Optimised,"Optimised recommendation for holoclar as an option in people with moderate to severe limbal stem cell deficiency after eye burns, only if:
|
||
•it is only used to treat 1 eye and
|
||
•people have already had a conjunctival limbal autograft or
|
||
•there is not enough tissue for a conjunctival limbal autograft or it is contraindicated and
|
||
•the company provides it with the discount agreed in the patient access scheme.
|
||
|
||
"
|
||
750,TA467,2017/18,STA,Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells),Pharmaceutical,Limbal stem cell deficiency after eye burns for treating both eyes ,Only in Research,"Only in research recommendation for holoclar in people with moderate to severe limbal stem cell deficiency after eye burns for treating both eyes, only when there is not enough tissue for a conjunctival limbal autograft.
|
||
|
||
"
|
||
751,TA468,2017/18,STA,Methylnaltrexone bromide,Pharmaceutical,Opioid-induced constipation,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
752,TA469,2017/18,STA,Idelalisib with ofatumumab,Pharmaceutical,Chronic lymphocytic leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
753,TA470,2017/18,STA,Ofatumumab with chemotherapy ,Pharmaceutical,Chronic lymphocytic leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
754,TA471,2017/18,STA,Eluxadoline,Pharmaceutical,Irritable bowel syndrome with diarrhoea,Recommended,Recommended in line with clinical practice.
|
||
755,TA472,2017/18,STA,Obinutuzumab with bendamustine,Pharmaceutical,Follicular lymphoma refractory to rituximab,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating adults with follicular lymphoma that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen, only if the conditions in the managed access agreement for obinutuzumab are followed."
|
||
756,TA473,2017/18,STA,Cetuximab in combination with platinum-based chemotherapy ,Pharmaceutical,Recurrent or metastatic squamous cell cancer of the head and neck,Optimised,"Optimised recommendation for cetuximab in combination with platinum-based chemotherapy as an option for treating recurrent or metastatic squamous cell cancer of the head and neck in adults only:
|
||
•if the cancer started in the oral cavity and
|
||
•when the company provides the drug in line with the commercial access agreement with NHS England.
|
||
|
||
"
|
||
757,TA474,2017/18,STA,Sorafenib,Pharmaceutical,Advanced hepatocellular carcinoma,Optimised,"Optmised recommendation for sorafenib only for people with Child-Pugh grade A liver impairment, only if the company provides sorafenib within the agreed commercial access arrangement."
|
||
758,TA475,2017/18,STA,Dimethyl fumarate ,Medical device,Moderate to severe plaque psoriasis,Optimised,"Optimised recommendation for dimethyl fumarate only if the disease:
|
||
•is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
|
||
•has not responded to other systemic therapies, including, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated.
|
||
|
||
"
|
||
759,TA476,2017/18,STA,Paclitaxel as albumin-bound nanoparticles (nab‑paclitaxel) with gemcitabine ,Pharmaceutical,Untreated metastatic pancreatic cancer,Optimised,"Optimised recommendation for nab‑paclitaxel with gemcitabine only if:
|
||
|
||
•other combination chemotherapies are unsuitable and they would otherwise have gemcitabine monotherapy and
|
||
|
||
•the company provides nab‑paclitaxel with the discount agreed in the patient access scheme.
|
||
|
||
"
|
||
760,TA477,2017/18,MTA,Autologous chondrocyte implantation,Pharmaceutical,Symptomatic articular cartilage defects of the knee,Optimised,"Optimised recommendation for autologous chondrocyte implantation (ACI) as an option for treating symptomatic articular cartilage defects of the knee, only if:
|
||
|
||
•the person has not had previous surgery to repair articular cartilage defects
|
||
•there is minimal osteoarthritic damage to the knee (as assessed by clinicians experienced in investigating knee cartilage damage using a validated measure for knee osteoarthritis)
|
||
•the defect is over 2 cm2 and
|
||
•the procedure is done at a tertiary referral centre.
|
||
|
||
"
|
||
761,TA478,2017/18,STA,Brentuximab vedotin ,Pharmaceutical,Relapsed or refractory systemic anaplastic large cell lymphoma,Optimised,"Optimised recommendation for brentuximab vedotin as an option for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if:
|
||
•they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and
|
||
•the company provides brentuximab vedotin according to the commercial access agreement with NHS England."
|
||
762,TA479,2017/18,STA,"Reslizumab, as an add-on therapy",Pharmaceutical,Severe eosinophilic asthma,Optimised,"Optimised recommendation for reslizumab, as an add-on therapy, as an option for the treatment of severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids plus another drug, only if:
|
||
|
||
•the blood eosinophil count has been recorded as 400 cells per microlitre or more
|
||
•the person has had 3 or more severe asthma exacerbations needing systemic corticosteroids in the past 12 months and
|
||
•the company provides reslizumab with the discount agreed in the patient access scheme."
|
||
763,TA480,2017/18,STA,Tofacitinib with methotrexate,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for tofacitinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if:
|
||
• disease is severe (a disease activity score [DAS28] of more than 5.1) and
|
||
• the company provides tofacitinib with the discount agreed in the patient access scheme.
|
||
"
|
||
764,TA480,2017/18,STA,Tofacitinib with methotrexate,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for tofacitinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot have, other DMARDs, including at least 1 biological DMARD, only if:
|
||
• disease is severe (a DAS28 of more than 5.1) and
|
||
• they cannot have rituximab and
|
||
• the company provides tofacitinib with the discount agreed in the patient access scheme.
|
||
"
|
||
765,TA480,2017/18,STA,Tofacitinib monotherapy,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for tofacitinib as monotherapy for adults who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in sections 1.1 and 1.2 are met."
|
||
766,TA481,2017/18,MTA,Basiliximab,Pharmaceutical,Kidney transplant in adults,Recommended,Recommended in line with clinical practice
|
||
767,TA481,2017/18,MTA,Immediate-release tacrolimus,Pharmaceutical,Kidney transplant in adults,Recommended,Recommended in line with clinical practice.
|
||
768,TA481,2017/18,MTA,Mycophenolate mofetil,Pharmaceutical,Kidney transplant in adults,Recommended,Recommended in line with marketing authorisation.
|
||
769,TA481,2017/18,MTA,Rabbit anti-human thymocyte immunoglobulin,Pharmaceutical,Kidney transplant in adults,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
770,TA481,2017/18,MTA,Prolonged-release tacrolimus,Pharmaceutical,Kidney transplant in adults,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
771,TA481,2017/18,MTA,Mycophenolate sodium,Pharmaceutical,Kidney transplant in adults,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
772,TA481,2017/18,MTA,Sirolimus,Pharmaceutical,Kidney transplant in adults,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
773,TA481,2017/18,MTA,Everolimus ,Pharmaceutical,Kidney transplant in adults,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
774,TA481,2017/18,MTA,Belatacept,Pharmaceutical,Kidney transplant in adults,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
775,TA482,2017/18,MTA,Basiliximab,Pharmaceutical,Kidney transplant in children and young people,Recommended,Recommended in line with clinical practice
|
||
776,TA482,2017/18,MTA,Immediate-release tacrolimus,Pharmaceutical,Kidney transplant in children and young people,Recommended,Recommended in line with clinical practice.
|
||
777,TA482,2017/18,MTA,Mycophenolate mofetil,Pharmaceutical,Kidney transplant in children and young people,Recommended,Recommended in line with marketing authorisation.
|
||
778,TA482,2017/18,MTA,Rabbit anti-human thymocyte immunoglobulin,Pharmaceutical,Kidney transplant in children and young people,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
779,TA482,2017/18,MTA,Prolonged-release tacrolimus,Pharmaceutical,Kidney transplant in children and young people,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
780,TA482,2017/18,MTA,Mycophenolate sodium,Pharmaceutical,Kidney transplant in children and young people,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
781,TA482,2017/18,MTA,Sirolimus,Pharmaceutical,Kidney transplant in children and young people,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
782,TA482,2017/18,MTA,Everolimus ,Pharmaceutical,Kidney transplant in children and young people,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
783,TA482,2017/18,MTA,Belatacept,Pharmaceutical,Kidney transplant in children and young people,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
784,TA483,2017/18,STA,Nivolumab ,Pharmaceutical,Previously treated squamous non-small-cell lung cancer,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer in adults after chemotherapy, only if:
|
||
•nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and
|
||
•the conditions in the managed access agreement are followed.
|
||
"
|
||
785,TA484,2017/18,STA,Nivolumab ,Pharmaceutical,Previously treated non-squamous non-small-cell lung cancer,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer in adults after chemotherapy, only if:
|
||
•their tumours are PD‑L1 positive and
|
||
•nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression, and
|
||
•the conditions in the managed access agreement are followed."
|
||
786,TA485,2017/18,STA,Sarilumab with methotrexate,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for sarilumab, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if:
|
||
•disease is severe (a disease activity score [DAS28] of more than 5.1) and
|
||
•the company provides sarilumab with the discount agreed in the patient access scheme.
|
||
"
|
||
787,TA485,2017/18,STA,Sarilumab with methotrexate,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for sarilumab, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if:
|
||
•disease is severe (a DAS28 of more than 5.1) and
|
||
•they cannot have rituximab and
|
||
•the company provides sarilumab with the discount agreed in the patient access scheme."
|
||
788,TA485,2017/18,STA,Sarilumab with methotrexate,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for sarilumab, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to rituximab and at least 1 biological DMARD, only if:
|
||
•disease is severe (a DAS28 of more than 5.1) and
|
||
•the company provides sarilumab with the discount agreed in the patient access scheme."
|
||
789,TA485,2017/18,STA,Sarilumab monotherapy,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for sarilumab as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in sections 1.1 and 1.2 are met."
|
||
790,TA486,2017/18,STA,Aflibercept ,Pharmaceutical,Choroidal neovascularisation,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
791,TA487,2017/18,STA,Venetoclax ,Pharmaceutical,Chronic lymphocytic leukaemia,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating chronic lymphocytic leukaemia, that is, in adults:
|
||
•with a 17p deletion or TP53 mutation and when a B‑cell receptor pathway inhibitor is unsuitable, or whose disease has progressed after a B‑cell receptor pathway inhibitor or
|
||
•without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo‑immunotherapy and a B‑cell receptor pathway inhibitor and
|
||
•only if the conditions in the managed access agreement are followed
|
||
"
|
||
792,TA488,2017/18,STA,Regorafenib ,Pharmaceutical,Previously treated unresectable or metastatic gastrointestinal stromal tumours,Optimised,"Optimised recommendation for regorafenib as an option for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib, only if:
|
||
•their Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1 and
|
||
•the company provides regorafenib with the discount agreed in the patient access scheme."
|
||
793,TA489,2017/18,STA,Vismodegib,Pharmaceutical,Basal cell carcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
794,TA490,2017/18,STA,Nivolumab,Pharmaceutical,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy ,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating squamous cell carcinoma of the head and neck in adults whose disease has progressed on platinum-based chemotherapy, only if:
|
||
•the disease has progressed within 6 months of having chemotherapy
|
||
•nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression and
|
||
•the conditions in the managed access agreement are followed."
|
||
795,TA491,2017/18,STA,Ibrutinib ,Pharmaceutical,Waldenstrom’s macroglobulinaemia,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 prior therapy, only if the conditions in the managed access agreement for ibrutinib are followed."
|
||
796,TA492,2017/18,STA,Atezolizumab,Pharmaceutical,Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed."
|
||
797,TA493,2017/18,STA,Cladribine tablets ,Pharmaceutical,Relapsing–remitting multiple sclerosis,Optimised,"Optimised recommendation for cladribine tablets as an option for treating highly active multiple sclerosis in adults, only if the person has:
|
||
•rapidly evolving severe relapsing–remitting multiple sclerosis, that is, at least 2 relapses in the previous year and at least 1 T1 gadolinium-enhancing lesion at baseline MRI or
|
||
•relapsing–remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as 1 relapse in the previous year and MRI evidence of disease activity.
|
||
"
|
||
798,TA494,2017/18,STA,Naltrexone–bupropion ,Pharmaceutical,Managing overweight and obesity,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
799,TA495,2017/18,STA,"Palbocicli, with an aromatase inhibitor",Pharmaceutical,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
800,TA496,2017/18,STA,Ribociclib with an aromatase inhibitor,Pharmaceutical,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
801,TA497,2017/18,STA,Golimumab ,Pharmaceutical,Non-radiographic axial spondyloarthritis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
802,TA498,2017/18,STA,Lenvatinib plus everolimus ,Pharmaceutical,Previously treated advanced renal cell carcinoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
803,TA499,2017/18,STA,Glecaprevir–pibrentasvir ,Pharmaceutical,Chronic hepatitis C,Recommended,Recommended in line with marketing authorisation and if the company provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit.
|
||
804,TA500,2017/18,STA,Ceritinib,Pharmaceutical,Untreated ALK-positive non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
805,TA501,2017/18,MTA,Intrabeam radiotherapy system ,Pharmaceutical,Adjuvant treatment of early breast cancer,Only in Research,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available. Use of the Intrabeam radiotherapy system is recommended only using machines that are already available and in conjunction with NHS England specified clinical governance, data collection and submission arrangements."
|
||
806,TA502,2017/18,STA,Ibrutinib,Pharmaceutical,Relapsed or refractory mantle cell lymphoma,Optimised,"Optimised recommendation for ibrutinib as an option for treating relapsed or refractory mantle cell lymphoma in adults, only if:
|
||
•they have had only 1 previous line of therapy and
|
||
•the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England.
|
||
"
|
||
807,TA503,2017/18,STA,Fulvestrant ,Pharmaceutical,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
|
||
808,TA504,2017/18,STA, Pirfenidone ,Pharmaceutical,Idiopathic pulmonary fibrosis,Optimised,"Optimised recommendation for pirfenidone for treating idiopathic pulmonary fibrosis in adults only if:
|
||
•the person has a forced vital capacity (FVC) between 50% and 80% predicted
|
||
•the company provides pirfenidone with the discount agreed in the patient access scheme and
|
||
•treatment is stopped if there is evidence of disease progression (an absolute decline of 10% or more in predicted FVC within any 12‑month period).
|
||
|
||
"
|
||
809,TA505,2017/18,STA,Ixazomib with lenalidomide and dexamethasone,Pharmaceutical,Relapsed or refractory multiple myeloma,Optimised (CDF),"Optimised recommendation for ixazomib, with lenalidomide and dexamethasone, for use within the Cancer Drugs Fund as an option for treating multiple myeloma in adults only if:
|
||
•they have already had 2 or 3 lines of therapy and
|
||
•the conditions in the managed access agreement for ixazomib are followed."
|
||
810,TA506,2017/18,STA,Lesinurad,Pharmaceutical,Chronic hyperuricaemia in people with gout,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
|
||
811,TA507,2017/18,STA,Sofosbuvir–velpatasvir–voxilaprevir ,Pharmaceutical,Chronic hepatitis C,Optimised,"Optimised recommendation for sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C based on HCV genotype, liver disease stage, treatment history and only if the company provides the drug with the discount agreedwith the Commercial Medicines Unit. Please see the final guidance section 1 for the detailed recommendations."
|
||
812,TA508,2017/18,STA,Autologous chondrocyte implantation using chondrosphere ,Pharmaceutical,Symptomatic articular cartilage defects of the knee,Optimised,"Optimised recommendation for autologous chondrocyte implantation (ACI) using chondrosphere as an option for treating symptomatic articular cartilage defects of the femoral condyle and patella of the knee (International Cartilage Repair Society grade III or IV) in adults, only if:
|
||
•the person has not had previous surgery to repair articular cartilage defects
|
||
•there is minimal osteoarthritic damage to the knee (as assessed by clinicians experienced in investigating knee cartilage damage using a validated measure for knee osteoarthritis) and
|
||
•the defect is over 2 cm2."
|
||
813,TA509,2017/18,STA,Pertuzumab in combination with trastuzumab and docetaxel,Pharmaceutical,HER2-positive breast cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
814,TA510,2017/18,STA, Daratumumab monotherapy ,Pharmaceutical,Relapsed and refractory multiple myeloma,Optimised (CDF),"Optimised recommendation for daratumumab monotherapy for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults whose previous therapy included a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last therapy, only if:
|
||
•they have daratumumab after 3 previous therapies and
|
||
•the conditions in the managed access agreement are followed."
|
||
815,TA511,2017/18,STA,Brodalumab,Pharmaceutical,Moderate to severe plaque psoriasis,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
816,TA512,2017/18,STA,Tivozanib ,Pharmaceutical,Advanced renal cell carcinoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
817,TA513,2017/18,STA,Obinutuzumab ,Pharmaceutical,Untreated advanced follicular lymphoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
818,TA514,2017/18,STA,Regorafenib ,Pharmaceutical,Previously treated advanced hepatocellular carcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
|
||
819,TA515,2017/18,STA,Eribulin ,Pharmaceutical,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
|
||
820,TA516,2017/18,STA,Cabozantinib ,Pharmaceutical,Medullary thyroid cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
821,TA517,2018/19,STA,Avelumab (second-line and beyond treatment),Pharmaceutical,Metastatic Merkel cell carcinoma,Recommended,Recommended in line with marketing authorisation
|
||
822,TA517,2018/19,STA,Avelumab (first-line),Pharmaceutical,Metastatic Merkel cell carcinoma,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating metastatic Merkel cell carcinoma in adults, only if:
|
||
•they have not had chemotherapy for metastatic disease and
|
||
•the conditions in the managed access agreement for avelumab are followed."
|
||
823,TA518,2018/19,STA,Tocilizumab when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids),Pharmaceutical,Giant cell arteritis,Optimised,"Optimised recommendation for tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), as an option for treating giant cell arteritis in adults, only if:
|
||
•they have relapsing or refractory disease
|
||
•they have not already had tocilizumab
|
||
•tocilizumab is stopped after 1 year of uninterrupted treatment at most and
|
||
•the company provides it with the discount agreed in the patient access scheme.
|
||
|
||
"
|
||
824,TA519,2018/19,STA,Pembrolizumab,Pharmaceutical,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy, only if:
|
||
•pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier in the event of disease progression and
|
||
•the conditions in the managed access agreement for pembrolizumab are followed."
|
||
825,TA520,2018/19,STA,Atezolizumab ,Pharmaceutical,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,Optimised,"Optimised recommendation for atezolizumab as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour), only if:
|
||
•atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and
|
||
•the company provides atezolizumab with the discount agreed in the patient access scheme."
|
||
826,TA521,2018/19,STA,Guselkumab ,Pharmaceutical,Moderate to severe plaque psoriasis,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
827,TA522,2018/19,STA,Pembrolizumab,Pharmaceutical,Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable, only if:
|
||
•pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and
|
||
•the conditions of the managed access agreement for pembrolizumab are followed."
|
||
828,TA523,2018/19,STA,Midostaurin ,Pharmaceutical,Untreated acute myeloid leukaemia,Recommended,Recommended in line withmarketing authorisation and following agreement of a patient access scheme.
|
||
829,TA524,2018/19,STA,Brentuximab vedotin ,Pharmaceutical,CD30-positive Hodgkin lymphoma,Optimised,"Optimised recommendation for brentuximab vedotin as an option for treating CD30‑positive Hodgkin lymphoma in adults with relapsed or refractory disease, only if:
|
||
•they have already had autologous stem cell transplant or
|
||
•they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable and
|
||
•the company provides brentuximab vedotin according to the patient access scheme"
|
||
830,TA525,2018/19,STA,Atezolizumab ,Pharmaceutical,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
831,TA526,2018/19,STA,Arsenic trioxide ,Pharmaceutical,Acute promyelocytic leukaemia,Recommended,Recommended in line with marketing authorisation.
|
||
832,TA527,2018/19,MTA,Interferon beta‑1a ,Pharmaceutical,Multiple sclerosis,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
833,TA527,2018/19,MTA,Interferon beta‑1b (Extavia) ,Pharmaceutical,Multiple sclerosis,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
834,TA527,2018/19,MTA,Interferon beta‑1b (Betaferon),Pharmaceutical,Multiple sclerosis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
|
||
835,TA527,2018/19,MTA,Glatiramer acetate ,Pharmaceutical,Multiple sclerosis,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
836,TA528,2018/19,STA,Niraparib,Pharmaceutical,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",Optimised (CDF),"Optimised recommendation for niraparib for use within the Cancer Drugs Fund as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults, only if:
|
||
•they have a germline BRCA mutation and have had 2 courses of platinum-based chemotherapy or
|
||
•they do not have a germline BRCA mutation and have had 2 or more courses of platinum-based chemotherapy and
|
||
•the conditions in the managed access agreement for niraparib are followed."
|
||
837,TA529,2018/19,STA,Crizotinib,Pharmaceutical,ROS1-positive advanced non-small-cell lung cancer,Recommended (CDF),"Recommended for use within the Cancer Drugs Fund as an option for treating ROS1‑positive advanced non-small-cell lung cancer (NSCLC) in adults, only if the conditions in the managed access agreement are followed."
|
||
838,TA530,2018/19,STA,Nivolumab,Pharmaceutical,Locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
|
||
839,TA531,2018/19,STA,Pembrolizumab,Pharmaceutical,Untreated PD-L1-positive metastatic non-small-cell lung cancer,Recommended,Recommended in line with clinical practice and following agreement of a commercial access agreement.
|
||
840,TA532,2018/19,STA,Cenegermin,Pharmaceutical,Neurotrophic keratitis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
|
||
841,TA533,2018/19,STA,Ocrelizumab,Pharmaceutical,Relapsing–remitting multiple sclerosis ,Optimised,"Optimised recommendation for ocrelizumab as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features, only if:
|
||
alemtuzumab is contraindicated or otherwise unsuitable and
|
||
the company provides ocrelizumab according to the commercial arrangement."
|
||
842,TA534,2018/19,STA,Dupilumab,Pharmaceutical,Severe atopic dermatitis,Optimised,"Optimised recommendation for dupilumab as an option for treating moderate to severe atopic dermatitis in adults, only if: the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated
|
||
the company provides dupilumab according to the commercial arrangement"
|
||
843,TA535,2018/19,MTA,Lenvatinib,Pharmaceutical,Thyroid cancer,Optimised,"Optimised recommendation for lenvatinib as an option for treating thyroid cancer in adults whose disease does not respond to radioactive iodine, only if:
|
||
• they have not had a tyrosine kinase inhibitor before or
|
||
• they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification)
|
||
• the company provides lenvatinib according to the patient access scheme
|
||
"
|
||
844,TA535,2018/19,MTA,Sorafenib,Pharmaceutical,Thyroid cancer,Optimised,"Optimised recommendation for sorafenib as an option for treating thyroid cancer in adults whose disease does not respond to radioactive iodine, only if:
|
||
• they have not had a tyrosine kinase inhibitor before or
|
||
• they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification)
|
||
• the compay provides sorafenib according to the commercial access agreement
|
||
"
|
||
845,TA536,2018/19,STA,Alectinib,Pharmaceutical,Non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
846,TA537,2018/19,STA,Ixekizumab,Pharmaceutical,Psoriatic arthritis after inadequate response to DMARDs,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
847,TA537,2018/19,STA,Ixekizumab,Pharmaceutical,Psoriatic arthritis after inadequate response to DMARDs,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
848,TA537,2018/19,STA,Ixekizumab,Pharmaceutical,Psoriatic arthritis after inadequate response to DMARDs,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
849,TA538,2018/19,STA,Dinutuximab,Pharmaceutical,Neuroblastoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
850,TA539,2018/19,MTA,Lutetium (177Lu) oxodotreotide,Pharmaceutical,Unresectable or metastatic pancreatic neuroendocrine tumours,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
851,TA539,2018/19,MTA,Lutetium (177Lu) oxodotreotide,Pharmaceutical,Unresectable or metastatic gastrointestinal neuroendocrine tumours,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
852,TA540,2018/19,STA,Pembrolizumab,Pharmaceutical,Relapsed or refractory classical Hodgkin lymphoma,Optimised (CDF),"Optimised recommendation for pembrolizumab for use within the Cancer Drugs Fund as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had brentuximab vedotin and cannot have autologous stem cell transplant, only if:
|
||
•pembrolizumab is stopped after 2 years of treatment or earlier if the person has a stem cell transplant or the disease progresses and
|
||
•the conditions in the managed access agreement for pembrolizumab are followed"
|
||
853,TA541,2018/19,STA,Inotuzumab,Pharmaceutical,Relapsed or refractory B-cell acute lymphoblastic leukaemia,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
854,TA542,2018/19,STA,Cabozantinib,Pharmaceutical,Untreated advanced renal cell carcinoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
855,TA543,2018/19,STA,Tofacitinib,Pharmaceutical,Psoriatic arthritis after inadequate response to DMARDs,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
856,TA543,2018/19,STA,Tofacitinib,Pharmaceutical,Psoriatic arthritis after inadequate response to DMARDs,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
857,TA544,2018/19,STA,Dabrafenib with trametinib,Pharmaceutical,Resected BRAF V600 mutation-positive melanoma,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
858,TA545,2018/19,STA,Gemtuzumab ozogamicin with daunorubicin and cytarabine,Pharmaceutical,Untreated de novo CD33-positive acute myeloid leukaemia except acute promyelocytic leukaemia for patients age 15 years and above,Optimised,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
859,TA546,2018/19,STA,Padeliporfin ,Pharmaceutical,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources for routine commissioning based on the data available."
|
||
860,TA547,2018/19,STA,Tofacitinib,Pharmaceutical,Moderately to severely active ulcerative colitis with inadequate response or intolerant to conventional therapy or a biologic agent,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
861,TA548,2018/19,STA,Decitabine,Pharmaceutical,Untreated acute myeloid leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
862,TA549,2018/19,STA,Denosumab,Pharmaceutical,Preventing skeletal-related events in multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
863,TA550,2018/19,STA,Vandetanib,Pharmaceutical,Medullary thyroid cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
864,TA551,2018/19,STA,Lenvatinib,Pharmaceutical,Untreated advance hepatocellular carcinoma,Optimised,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
865,TA552,2018/19,STA,Liposomal cytarabine–daunorubicin ,Pharmaceutical,Untreated acute myeloid leukaemia,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
866,TA553,2018/19,STA,Pembrolizumab ,Pharmaceutical,Melanoma with high risk of recurrence,Recommended (CDF),Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of stage III melanoma with lymph node involvement in adults who have had complete resection. It is recommended only if the conditions in the managed access agreement for pembrolizumab are followed.
|
||
867,TA554,2018/19,STA,Tisagenlecleucel ,Pharmaceutical,Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years,Recommended (CDF),"Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B‑cell acute lymphoblastic leukaemia in people aged up to 25 years, only if the conditions in the managed access agreement are followed."
|
||
868,TA555,2018/19,STA,Regorafenib ,Pharmaceutical,Previously treated advanced hepatocellular carcinoma,Optimised,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
869,TA556,2018/19,STA,Darvadstrocel ,Pharmaceutical,Complex perianal fistulas in Crohn’s disease,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
870,TA557,2018/19,STA,Pembrolizumab ,Pharmaceutical,"Untreated, metastatic, non-squamous non-small-cell lung cancer",Optimised (CDF),"Pembrolizumab, with pemetrexed and platinum chemotherapy is recommended for use within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. It is only recommended if: •pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if disease progresses and
|
||
•the company provides pembrolizumab according to the managed access agreement."
|
||
871,TA558,2018/19,STA,Nivolumab,Pharmaceutical,Completely resected melanoma with lymph node involvement or metastatic disease,Recommended (CDF),Nivolumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease. It is recommended only if the conditions in the managed access agreement are followed.
|
||
872,TA559,2018/19,STA,Axicabtagene ciloleucel ,Pharmaceutical,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,Recommended (CDF),"Axicabtagene ciloleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B‑cell lymphoma or primary mediastinal large B‑cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed."
|
||
873,TA560,2018/19,STA,Bevacizumab ,Pharmaceutical,First recurrence of platinum-sensitive advanced ovarian cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
874,TA561,2018/19,STA,Venetoclax ,Pharmaceutical,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
875,TA562,2018/19,STA,Encorafenib ,Pharmaceutical,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme. There are patient access schemes for encorafenib and binimetinib
|
||
876,TA563,2018/19,STA,Abemaciclib,Pharmaceutical,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",Recommended,Recommended in line with marketing authorisation and only if company provides it according to the commercial agreement
|
||
877,TA564,2018/19,STA,Dabrafenib ,Pharmaceutical,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
878,TA565,2018/19,STA,Benralizumab ,Pharmaceutical,Severe eosinophilic asthma,Optimised,"Optimised recommendation for benralizumab as an add-on therapy, is recommended as an option for treating severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids and long-acting beta-agonists, only if:
|
||
•the person has agreed to and followed the optimised standard treatment plan and
|
||
•the blood eosinophil count has been recorded as 300 cells per microlitre or more and the person has had 4 or more exacerbations needing systemic corticosteroids in the previous 12 months, or has had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous 6 months (that is, the person is eligible for mepolizumab) or
|
||
•the blood eosinophil count has been recorded as 400 cells per microlitre or more with 3 or more exacerbations needing systemic corticosteroids in the past 12 months (that is, the person is eligible for reslizumab).
|
||
Benralizumab is recommended only if the company provides it according to the commercial arrangement."
|
||
879,TA566,2018/19,MTA,Unilateral cochlear implantation,Medical device,Severe to profound deafness in children and adults,Recommended,"Partial update of guidance TA166 (recommendation 1.5). Recommendation in line with clinical practice.
|
||
|
||
Unilateral cochlear implantation is recommended as an option for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids; Simultaneous bilateral cochlear implantation is recommended as an option for the following groups of people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids, including children and adults who are blind or who have other disabilities that increase their reliance on auditory stimuli as a primary sensory mechanism for spatial awareness; Sequential bilateral cochlear implantation is not recommended as an option for people with severe to profound deafness"
|
||
880,TA566,2018/19,MTA,Simultaneous bilateral cochlear implantation,Medical device,Severe to profound deafness in children and adults,Optimised,Partial update of guidance TA166 (recommendation 1.5). Optimised recommendation for use in specific circumstances for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids; or children; or adults who are blind or who have other disabilities that increase their reliance on auditory stimuli as a primary sensory mechanism for spatial awareness.
|
||
881,TA566,2018/19,MTA,Sequential bilateral cochlear implantation,Medical device,Sequential bilateral cochlear implantation,Not recommended,"Partial update of guidance TA166 (recommendation 1.5). At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
882,TA567,2018/19,STA,Tisagenlecleucel ,Pharmaceutical,Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies,Recommended (CDF),"Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed."
|
||
883,TA568,2018/19,STA,Abatacept ,Pharmaceutical,Psoriatic arthritis after DMARDs,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
884,TA569,2018/19,STA,Pertuzumab ,Pharmaceutical,Adjuvant treatment of HER2-positive early stage breast cancer,Optimised,"Pertuzumab, with intravenous trastuzumab and chemotherapy, is recommended for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults, only if:
|
||
•they have lymph node-positive disease
|
||
•the company provides it according to the commercial arrangement.
|
||
"
|
||
885,TA570,2018/19,STA,Pembrolizumab ,Pharmaceutical,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
886,TA571,2018/19,STA,Brigatinib,Pharmaceutical,ALK-positive advanced non-small-cell lung cancer after crizotinib,Recommended,Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
|
||
887,TA572,2018/19,STA,Ertugliflozin ,Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with clinical practice.
|
||
888,TA572,2018/19,STA,Ertugliflozin ,Pharmaceutical,Type 2 diabetes,Recommended,Recommended in line with clinical practice.
|
||
889,TA573,2019/20,STA,Daratumumab,Pharmaceutical,Multiple myeloma,Recommended (CDF),Recommended in the CDF
|
||
890,TA574,2019/20,STA,Certolizumab pegol,Pharmaceutical,Moderate to severe plaque psoriasis,Optimised,"Certolizumab pegol is recommended as an option for treating plaque psoriasis in adults, only if:
|
||
•the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
|
||
•the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and
|
||
•the lowest maintenance dosage of certolizumab pegol is used (200 mg every 2 weeks) after the loading dosage and
|
||
•the company provides the drug according to the commercial arrangement."
|
||
891,TA575,2019/20,STA,Tildrakizuamb,Pharmaceutical,Moderate to severe plaque psoriasis,Recommended,"Tildrakizumab is recommended as an option for treating plaque psoriasis in adults, only if:
|
||
•the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
|
||
•the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and
|
||
•the company provides the drug according to the commercial arrangement.
|
||
"
|
||
892,TA576,2019/20,STA,Bosutinib,Pharmaceutical,Chronic myeloid leukaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
893,TA577,2019/20,STA,Brentuximab vedotin ,Pharmaceutical,CD30-positive cutaneous T-cell lymphoma,Optimised,"Optimised recommendation for brentuximab vedotin for treating CD30‑positive cutaneous T‑cell lymphoma after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome "
|
||
894,TA578,2019/20,STA,Durvalumab ,Pharmaceutical,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,Recommended (CDF),"Durvalumab monotherapy is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express PD‑L1 on at least 1% of tumour cells and whose disease has not progressed after platinum-based chemoradiation only if:
|
||
•they have had concurrent platinum-based chemoradiation
|
||
•the conditions in the managed access agreement are followed.
|
||
"
|
||
895,TA579,2019/20,STA,Abemaciclib ,Pharmaceutical,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Recommended (CDF),"Abemaciclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in people who have had endocrine therapy only if:
|
||
•exemestane plus everolimus would be the most appropriate alternative and
|
||
•the conditions in the managed access agreement for abemaciclib with fulvestrant are followed.
|
||
"
|
||
896,TA580,2019/20,STA,Enzalutamide ,Pharmaceutical,Hormone-relapsed non-metastatic prostate cancer,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
897,TA581,2019/20,STA,Nivolumab with ipilimumab,Pharmaceutical,Untreated advanced renal cell carcinoma,Recommended (CDF),Nivolumab with ipilimumab is recommended for use within the Cancer Drugs Fund as an option for adults with untreated advanced renal cell carcinoma that is intermediate- or poor-risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria. It is recommended only if the conditions in the managed access agreement for nivolumab with ipilimumab are followed.
|
||
898,TA582,2019/20,STA,Cabozantinib ,Pharmaceutical,Previously treated advanced hepatocellular carcinoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
899,TA583,2019/20,STA,Ertugliflozin,Pharmaceutical,Type 2 diabetes mellitus ,Optimised,"Optimised recommendation for ertugliflozin with metformin and a dipeptidyl peptidase‑4 (DPP‑4) inhibitor as an option for treating type 2 diabetes in adults when diet and exercise alone do not provide adequate glycaemic control, only if: the disease is uncontrolled with metformin and a DPP‑4 inhibitor, and a sulfonylurea or pioglitazone is not appropriate."
|
||
900,TA584,2019/20,STA,"Atezolizmab with bevacizumab, paclitaxel and carboplatin",Pharmaceutical,First-line treatment of metastatic non-squamous non-small cell lung cancer ,Recommended,"Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults:
|
||
•who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is between 0% and 49% or
|
||
•when targeted therapy for epidermal growth factor receptor (EGFR)‑positive or anaplastic lymphoma kinase (ALK)‑positive NSCLC has failed.
|
||
It is only recommended if:
|
||
•atezolizumab and bevacizumab are stopped at 2 years of uninterrupted treatment, or earlier if there is loss of clinical benefit (for atezolizumab) or if the disease progresses (for bevacizumab) and
|
||
•he company provides atezolizumab and bevacizumab according to the commercial arrangements
|
||
"
|
||
901,TA585,2019/20,STA,Ocrelizumab,Pharmaceutical,Early primary progressive multiple sclerosis,Recommended,"Ocrelizumab is recommended, within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. It is recommended only if the company provides it according to the commercial arrangement."
|
||
902,TA586,2019/20,STA,Lenalidomide with dexamethasone,Pharmaceutical,Multiple myeloma in adults who have hade at least one prior therapy,Optimised,"Optimised recommendation for lenalidomide plus dexamethasone for treating multiple myeloma in adults only if: they have only 1 previous therapy, which included bortezomib"
|
||
903,TA587,2019/20,STA,Lenalidomide with dexamethasone,Pharmaceutical,Previously untreated multiple myeloma who are not eligible for transplant,Optimised,"Optimised recommendation for lenalidomide plus dexamethasone for previously untreated multiple myeloma in adults who are not eligible for a stem cell transplant, only if:
|
||
•thalidomide is contraindicated (including for pre-existing conditions that it may aggravate) or
|
||
•the person cannot tolerate thalidomide"
|
||
904,TA588,2019/20,STA,Nusinersen,Pharmaceutical,Spinal muscular atrophy,Optimised,"Optimised recommendation for nusinersen for treating 5q spinal muscular atrophy (SMA) only if:
|
||
• people have pre-symptomatic SMA, or SMA types 1, 2 or 3 and
|
||
• the conditions in the managed access agreement are followed.
|
||
"
|
||
905,TA589,2019/20,STA,Blinatumomab ,Pharmaceutical,Acute lymphoblastic leukaemia in remission with minimal residual disease activity,Optimised,"Optimised recommendation for blinatumomab for treating Philadelphia-chromosome-negative CD19‑positive B‑precursor acute lymphoblastic leukaemia in adults with minimal residual disease (MRD) of at least 0.1%, only if:
|
||
• the disease is in first complete remission and
|
||
• the company provides blinatumomab according to the commercial arrangement
|
||
"
|
||
906,TA590,2019/20,STA,Fluocinolone acetonide,Pharmaceutical,Recurrent non-infectious uveitis,Recommended,Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
|
||
907,TA591,2019/20,STA,Letermovir,Pharmaceutical,Preventing cytomegalovirus disease after a stem cell transplant,Recommended,Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
|
||
908,TA592,2019/20,STA,Cemiplimab ,Pharmaceutical,Metastatic or locally advanced cutaneous squamous cell carcinoma,Recommended (CDF),"Cemiplimab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not appropriate. It is recommended only if the conditions in the managed access agreement are followed.
|
||
|
||
Treatment with cemiplimab should be continued until disease progression or for up to 24 months (whichever is sooner)."
|
||
909,TA593,2019/20,STA,Ribociclib with fulvestrant,Pharmaceutical,"Hormone receptor-positive, HER2-negative, advanced breast cancer",Optimised (CDF),"Ribociclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in people who have had previous endocrine therapy only if:
|
||
• exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor and
|
||
• the conditions in the managed access agreement for ribociclib with fulvestrant are followed.
|
||
"
|
||
910,TA594,2019/20,STA,Brentuximab vedotin ,Pharmaceutical,Untreated advanced Hodgkin lymphoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
911,TA595,2019/20,STA,Dacomitinib ,Pharmaceutical,Untreated EGFR mutation-positive non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
|
||
912,TA596,2019/20,STA,Risankizumab ,Pharmaceutical,Moderate to severe plaque psoriasis,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
913,TA597,2019/20,STA,Dapagliflozin with insulin,Pharmaceutical,Type 1 diabetes,Optimised,"Optimised recommendation for dapagliflozin with insulin only if:
|
||
• they are on insulin doses of more than 0.5 units/kg of body weight/day and
|
||
• they have completed a structured education programme that is evidence based, quality assured, delivered by trained educators and includes information about diabetic ketoacidosis, such as:
|
||
◦how to recognise its risk factors, signs and symptoms
|
||
◦how and when to monitor blood ketone levels
|
||
◦what actions to take for elevated blood ketones, and
|
||
• treatment is started and supervised by a consultant physician specialising in endocrinology and diabetes.
|
||
"
|
||
914,TA598,2019/20,STA,Olaparib ,Pharmaceutical,"Advanced ovarian, fallopian tube or peritoneal cancer",Recommended (CDF),"Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of BRCA mutation‑positive, advanced (FIGO stages 3 and 4), high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for olaparib are followed."
|
||
915,TA599,2019/20,STA,Sodium zirconium cyclosilicate,Pharmaceutical, Hyperkalaemia,Optimised,"Optimised recommendation Sodium zirconium cyclosilicate is recommended as an option for treating hyperkalaemia in adults only if used:
|
||
•in emergency care for acute life-threatening hyperkalaemia alongside standard care or
|
||
•in outpatient care for people with persistent hyperkalaemia and chronic kidney disease stage 3b to 5 or heart failure, if they:
|
||
◦have a confirmed serum potassium level of at least 6.0 mmol/litre
|
||
◦are not taking an optimised dosage of renin-angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia and
|
||
◦are not on dialysis.
|
||
Sodium zirconium cyclosilicate is recommended only if the company provides it according to the commercial arrangement.
|
||
|
||
"
|
||
916,TA600,2019/20,STA,Pembrolizumab with carboplatin and paclitaxel,Pharmaceutical,Untreated metastatic squamous non-small-cell lung cancer,Recommended (CDF),"Pembrolizumab, with carboplatin and paclitaxel, is recommended for use within the Cancer Drugs Fund as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults only if:
|
||
•pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and
|
||
•the company provides pembrolizumab according to the managed access agreement
|
||
"
|
||
917,TA601,2019/20,STA,Bezlotoxumab,Pharmaceutical,Preventing recurrent Clostridium difficile infection,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
918,TA602,2019/20,STA,Pomalidomide with bortezomib and dexamethasone ,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
919,TA603,2019/20,STA,Lenalidomide with bortezomib and dexamethasone,Pharmaceutical,Untreated multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
920,TA604,2019/20,STA,Idelalisib ,Pharmaceutical,Refractory follicular lymphoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
921,TA605,2019/20,STA,Xeomin (botulinum neurotoxin type A) ,Pharmaceutical,Chronic sialorrhoea,Recommended,Recommended in line with marketing authorisation and only if company provides it according to the patient access scheme
|
||
922,TA606,2019/20,STA,Lanadelumab,Pharmaceutical,Preventing recurrent attacks of hereditary angioedema,Optimised,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
923,TA607,2019/20,STA,Rivaroxabn,Pharmaceutical,Preventing atherothrombotic events in people with coronary or peripheral artery disease,Recommended,Recommended in line with clinical practice
|
||
924,TA608,2019/20,STA,Ibrutinib with rituximab ,Pharmaceutical, Waldenstrom’s macroglobulinaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
925,TA609,2019/20,STA,Ramucirumab ,Pharmaceutical,Unresectable hepatocellular carcinoma after sorafenib,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
926,TA610,2019/20,STA,Pentosan polysulfate sodium ,Pharmaceutical,Badder pain syndrome,Optimised,"Optimised recommendation for pentosan polysulfate for treating bladder pain syndrome with glomerulations or Hunner's lesions in adults with urinary urgency and frequency, and moderate to severe pain, only if:
|
||
• their condition has not responded to an adequate trial of standard oral treatments
|
||
•it is not offered in combination with bladder instillations
|
||
•any previous treatment with bladder instillations was not stopped because of lack of response
|
||
•it is used in secondary care and
|
||
•the company provides pentosan polysulfate sodium according to the commercial arrangement.
|
||
"
|
||
927,TA611,2019/20,STA,Rucaparib,Pharmaceutical,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",Recommended (CDF),"Rucaparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of relapsed platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, only if the conditions in the managed access agreement for rucaparib are followed."
|
||
928,TA612,2019/20,STA,Neratinib ,Pharmaceutical,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",Optimised,"Optimised recommendation for neratinib for the extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)‑positive early stage breast cancer in adults who completed adjuvant trastuzumab-based therapy less than 1 year ago only if:
|
||
•trastuzumab is the only HER2‑directed adjuvant treatment they have had, and
|
||
•if they had neoadjuvant chemotherapy-based regimens, they still had residual invasive disease in the breast or axilla following the neoadjuvant treatment, and
|
||
•the company provides neratinib according to the commercial arrangement.
|
||
"
|
||
929,TA613,2019/20,STA,Fluocinolone acetonide intravitreal implant ,Pharmaceutical,Chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
930,TA614,2019/20,STA,Cannabidiol with clobazam,Pharmaceutical,Seizures associated with Dravet syndrome,Optimised,"Optimised recommendation for cannabidiol with clobazam for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if:
|
||
•the frequency of convulsive seizures is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment
|
||
•the company provides cannabidiol according to the commercial arrangement."
|
||
931,TA615,2019/20,STA,Cannabidiol with clobazam ,Pharmaceutical,Seizures associated with Lennox–Gastaut syndrome,Optimised,"Cannabidiol with clobazam is recommended as an option for treating seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older, only if:
|
||
•the frequency of drop seizures is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment
|
||
•the company provides cannabidiol according to the commercial arrangement"
|
||
932,TA616,2019/20,STA,Cladribine ,Pharmaceutical,Relapsing–remitting multiple sclerosis,Optimised,"Reissue of TA493 with the addition of 'or a significant increase in T2 lesion load compared with a previous MRI' to the recommendations.
|
||
Optimised recommendation for cladribine for treating highly active multiple sclerosis in adults, only if the person has:
|
||
•rapidly evolving severe relapsing–remitting multiple sclerosis, that is with at least:
|
||
◦2 relapses in the previous year and
|
||
◦1 T1 gadolinium-enhancing lesion at baseline MRI or a significant increase in T2‑lesion load compared with a previous MRI, or
|
||
•relapsing–remitting multiple sclerosis that has responded inadequately to treatment with disease-modifying therapy, defined as 1 relapse in the previous year and MRI evidence of disease activity.
|
||
"
|
||
933,TA617,2019/20,MTA,Lusutrombopag ,Pharmaceutical,Trombocytopenia in people with chronic liver disease needing a planned invasive procedure,Recommended,"Recommended in line with the marketing authorisation
|
||
NB No recommendation could be made for avatrombopag since the company hadn't agreed a list price in the UK"
|
||
934,TA618,2019/20,STA,Atezolizumab with carboplatin and nab-paclitaxel ,Pharmaceutical,Untreated advanced non-squamous non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
935,TA619,2019/20,STA,Palbociclib with fulvestrant,Pharmaceutical," Hormone receptor-positive, HER2-negative, advanced breast cancer",Recommended (CDF),"Palbociclib with fulvestrant is recommended for use within the Cancer Drugs Fund as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in people who have had previous endocrine therapy only if:
|
||
•exemestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor and
|
||
•the conditions in the managed access agreement for palbociclib with fulvestrant are followed."
|
||
936,TA620,2019/20,STA,Olaparib ,Pharmaceutical,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",Optimised,"Optimised recommendation for olaparib for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose disease has responded to platinum-based chemotherapy only if:
|
||
•they have a BRCA1 or BRCA2 mutation
|
||
•they have had 3 or more courses of platinum-based chemotherapy and
|
||
•the company provides olaparib according to the commercial arrangement."
|
||
937,TA620,2019/20,STA,Olaparib,Pharmaceutical,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",Optimised (CDF),"Olaparib is recommended for use within the Cancer Drugs Fund as an option for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose disease has responded to platinum-based chemotherapy only if:
|
||
•they have a BRCA1 or BRCA2 mutation
|
||
•they have had 2 courses of platinum-based chemotherapy and
|
||
•the conditions in the managed access agreement for olaparib are followed.
|
||
"
|
||
938,TA621,2019/20,STA,Osimertinib,Pharmaceutical,Untreated EGFR mutation-positive non-small-cell lung cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
939,TA622,2019/20,STA,Sotagliflozin with insulin ,Pharmaceutical,Type 1 diabetes,Recommended,Recommended in line with clinical practice
|
||
940,TA623,2019/20,STA,Patiromer ,Pharmaceutical,Hyperkalaemia,Optimised,Recommended in line with clinical practice
|
||
941,TA624,2019/20,STA,Peginterferon beta-1a ,Pharmaceutical,Relapsing–remitting multiple sclerosis,Recommended,Recommended in line with clinical practice
|
||
942,TA625,2019/20,STA,Recombinant human parathyroid hormone,Pharmaceutical,Hypoparathyroidism,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
943,TA627,2020/21,STA,Lenalidomide with rituximab,Pharmaceutical,Previously treated follicular lymphoma,Recommended,Recommmended in line with marketing autorisation
|
||
944,TA628,2020/21,STA,Lorlatinib ,Pharmaceutical,Previously treated ALK-positive advanced non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
|
||
945,TA629,2020/21,STA,Obinutuzumab with bendamustine ,Pharmaceutical,Follicular lymphoma after rituximab,Recommended,Recommended in line with marketing autorisation
|
||
946,TA630,2020/21,STA,Larotrectinib ,Pharmaceutical,NTRK fusion-positive solid tumours,Recommended (CDF),"Larotrectinib is recommended for use within the Cancer Drugs Fund as an option for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children if:
|
||
•the disease is locally advanced or metastatic or surgery could cause severe health problems and
|
||
•they have no satisfactory treatment options.
|
||
It is recommended only if the conditions in the managed access agreement for larotrectinib are followed.
|
||
"
|
||
947,TA626,2020/21,STA,Avatrombopag,Pharmaceutical,Severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure,Recommended,"Avatrombopag is recommended, within its marketing authorisation, as an option for treating severe thrombocytopenia (that is, a platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having a planned invasive procedure. Avatrombopag and lusutrombopag need to be taken more than a week before a procedure, so cannot be used for emergency procedures.
|
||
|
||
The economic modelling does not fully account for the benefits for patients and service delivery when using avatrombopag and lusutrombopag"
|
||
948,TA631,2020/21,STA,Fremanezumab,Pharmaceutical,Prophylaxis of migraine in adults who have at least 4 migraine days per month,Optimised,"Optimsed recommendation for preventing migraine in adults, only if: the migraine is chronic, that is, 15 or more headache days a month for more than 3 months with at least 8 of those having features of migraine; at least 3 preventive drug treatments have failed and the company provides it according to the commercial arrangement. 1.2 Stop fremanezumab if the migraine frequency does not reduce by at least 30% after 12 weeks of treatment."
|
||
949,TA632,2020/21,STA,Trastuzumab emtansine,Pharmaceutical,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",Recommended,"Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy. It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement"
|
||
950,TA633,2020/21,STA,Ustekinumab,Pharmaceutical,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",Optimised,"Ustekinumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if:
|
||
a tumour necrosis factor‑alpha inhibitor has failed (that is the disease has responded inadequately or has lost response to treatment) or
|
||
a tumour necrosis factor‑alpha inhibitor cannot be tolerated or is not suitable, and
|
||
the company provides ustekinumab at the same price or lower than that agreed with the Commercials Medicines Unit"
|
||
951,TA634,2020/21,STA,Daratumumab with lenalidomide and dexamethasone,Pharmaceutical,Untreated multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
952,TA635,2020/21,STA,Ramucirumab with erlotinib,Pharmaceutical,Untreated EGFR mutation-positive non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
953,TA636,2020/21,STA,Eculizumab,Pharmaceutical,Refractory myasthenia gravis,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
954,TA637,2020/21,STA,Ranibuzimab,Pharmaceutical,Diabetic retinopathy,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
955,TA638,2020/21,STA,Atezolizumab with carboplatin and etoposide ,Pharmaceutical,Untreated extensive-stage small-cell lung cancer,Optimised,"Optimised recommendation for untreated extensive-stage small-cell lung cancer in adults, only if:
|
||
•they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and
|
||
• the company provides atezolizumab according to the commercial arrangement.
|
||
"
|
||
956,TA639,2020/21,STA,Atezolizumab with nab-paclitaxel ,Pharmaceutical,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",Recommended,Recommended in line with marketing autorisation
|
||
957,TA640,2020/21,STA,Treosulfan with fludarabine ,Pharmaceutical,Malignant disease before allogeneic stem cell transplant,Optimised,"Optimsed recommendation for conditioning treatment before allogeneic haematopoietic stem cell transplant (allo-HSCT) for people with malignant diseases for whom a reduced intensity regimen, such as low-dose busulfan with fludarabine, would be suitable."
|
||
958,TA641,2020/21,STA,Brentuximab vedotin in combination ,Pharmaceutical,Untreated systemic anaplastic large cell lymphoma,Recommended,Recommended in line with marketing authorisation
|
||
959,TA642,2020/21,STA,Gilteritinib ,Pharmaceutical,Relapsed or refractory acute myeloid leukaemia,Optimised,"Optimsed recommendation for treating relapsed or refractory FLT3‑mutation-positive acute myeloid leukaemia (AML) in adults only if the company provides gilteritinib according to the commercial arrangement.
|
||
Gilteritinib should not be given as maintenance therapy after a haematopoietic stem cell transplant."
|
||
960,TA643,2020/21,STA,Entrectinib ,Pharmaceutical,ROS1-positive advanced non-small-cell lung cancer,Recommended,Recommended in line with marketing autorisation
|
||
961,TA644,2020/21,STA,Entrectinib ,Pharmaceutical,NTRK fusion-positive solid tumours,Recommended (CDF),"Entrectinib is recommended for use within the Cancer Drugs Fund as an option for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children 12 years and older if:
|
||
•the disease is locally advanced or metastatic or surgery could cause severe health problems and
|
||
•they have not had an NTRK inhibitor before and
|
||
•they have no satisfactory treatment options.
|
||
It is recommended only if the conditions in the managed access agreement for entrectinib are followed.
|
||
"
|
||
962,TA645,2020/21,STA,Avelumab with axitinib for untreated advanced renal cell carcinoma,Pharmaceutical,Untreated advanced renal cell carcinoma,Recommended (CDF),Avelumab with axitinib is recommended for use within the Cancer Drugs Fund as an option for untreated advanced renal cell carcinoma in adults. It is recommended only if the conditions in the managed access agreement for avelumab with axitinib are followed.
|
||
963,TA646,2020/21,STA,Glasdegib,Pharmaceutical,Untreated acute myeloid leukaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
964,TA647,2020/21,STA,Eculizumab ,Pharmaceutical,Relapsing neuromyelitis optica ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
965,TA648,2020/21,STA,Dupilumab ,Pharmaceutical,Chronic rhinosinusitis with nasal polyps,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
966,TA649,2020/21,STA,Polatuzumab vedotin with rituximab and bendamustine,Pharmaceutical,Relapsed or refractory diffuse large B-cell lymphoma,Recommended,Recommended in line with marketing autorisation
|
||
967,TA650,2020/21,STA,Pembrolizumab with axitinib ,Pharmaceutical,Untreated advanced renal cell carcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
968,TA651,2020/21,STA,Naldemedine ,Pharmaceutical,Treating opioid-induced constipation,Recommended,Recommended in line with marketing authorisation
|
||
969,TA652,2020/21,STA,Alpelisib with fulvestrant ,Pharmaceutical,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
970,TA653,2020/21,STA,Osimertinib,Pharmaceutical,EGFR T790M mutation-positive advanced non-small-cell lung cancer,Optimised,"Optimised recommendation for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults, only if:
|
||
• their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor and
|
||
• the company provides osimertinib according to the commercial arrangement."
|
||
971,TA654,2020/21,STA,Osimertinib ,Pharmaceutical,Untreated EGFR mutation-positive non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
|
||
972,TA655,2020/21,STA,Nivolumab,Pharmaceutical, Advanced squamous non-small-cell lung cancer after chemotherapy,Optimised,"Optimsed recommendation for treating locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if:
|
||
• it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses and
|
||
• they have not had a PD‑1 or PD‑L1 inhibitor before.
|
||
It is recommended only if the company provides nivolumab according to the commercial arrangement.
|
||
"
|
||
973,TA656,2020/21,STA,Siponimod,Pharmaceutical,Secondary progressive multiple sclerosis,Recommended,Recommended in line with the marketing authorisation and only if company provides it according to the patient access scheme
|
||
974,TA657,2020/21,STA,Carfilzomib for previously treated multiple myeloma,Pharmaceutical,Previously treated multiple myeloma,Recommended,"Reissue of TA457 to allow previous treatment with bortezomib since clincial practiac has changed. Recommendations now read:
|
||
Carfilzomib with dexamethasone is recommended as an option for treating multiple myeloma in adults, only if:
|
||
•they have had only 1 previous therapy and
|
||
•the company provides carfilzomib according to the commercial arrangement."
|
||
975,TA658,2020/21,STA,Isatuximab with pomalidomide and dexamethasone ,Pharmaceutical,Relapsed and refractory multiple myeloma,Recommended (CDF),"Isatuximab, plus pomalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults who have had lenalidomide and a proteasome inhibitor, and whose disease has progressed on their last treatment, only if:
|
||
•they have had 3 previous lines of treatment
|
||
•the conditions in the managed access agreement for isatuximab plus pomalidomide and dexamethasone are followed.
|
||
"
|
||
976,TA659,2020/21,STA,Galcanezumab,Pharmaceutical,Preventing migraine,Optimised,"Optimised recommendation for preventing migraine in adults, only if:
|
||
•they have 4 or more migraine days a month
|
||
•at least 3 preventive drug treatments have failed and
|
||
•the company provides it according to the commercial arrangement.
|
||
"
|
||
977,TA660,2020/21,STA,Darolutamide with androgen deprivation therapy ,Pharmaceutical,Hormone-relapsed non-metastatic prostate cancer,Recommended,Recommended in line with the marketing autorisation and only if company provides it according to the patient access scheme
|
||
978,TA661,2020/21,STA,Pembrolizumab ,Pharmaceutical,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,Optimised,"Optimised recommendation for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD‑L1 with a combined positive score (CPS) of 1 or more. This is only if:
|
||
•pembrolizumab is given as a monotherapy
|
||
•pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and
|
||
•the company provides pembrolizumab according to the commercial arrangement.
|
||
"
|
||
979,TA662,2020/21,STA,Durvalumab in combination ,Pharmaceutical,Untreated extensive-stage small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
980,TA663,2020/21,STA,Venetoclax with obinutuzumab ,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Optimised,"Optimised recommendation for adults only if:
|
||
•there is a 17p deletion or TP53 mutation, or
|
||
•there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR), is unsuitable, and
|
||
•the companies provide the drugs according to the commercial arrangements."
|
||
981,TA663,2020/21,STA,Venetoclax with obinutuzumab ,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Recommended (CDF),"Venetoclax plus obinutuzumab is recommended for use within the Cancer Drugs Fund as an option for untreated CLL in adults, only if:
|
||
•there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and
|
||
•the conditions in the managed access agreement for venetoclax plus obinutuzumab are followed."
|
||
982,TA664,2020/21,STA,Liraglutide,Pharmaceutical,Managing overweight and obesity,Optimised,"Optimised recommendation for Liraglutide for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, only if:
|
||
•they have a body mass index (BMI) of at least 35 kg/m2 (or at least 32.5 kg/m2 for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) and
|
||
•they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre) and
|
||
•they have a high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia and
|
||
•it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service and
|
||
•the company provides it according to the commercial arrangement.
|
||
"
|
||
983,TA665,2020/21,STA,Upadacitinib with methotrexate ,Pharmaceutical,Severe rheumatoid arthritis,Optimised,"Optimised recommendation for upadacitinib with methotrexate for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if:
|
||
•disease is severe (a disease activity score [DAS28] of more than 5.1) and
|
||
•the company provides upadacitinib according to the commercial arrangement.
|
||
"
|
||
984,TA665,2020/21,STA,Upadacitinib with methotrexate,Pharmaceutical,Severe rheumatoid arthritis,Optimised,"Optimised recommendation for upadacitinib with methotrexate for treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if:
|
||
•disease is severe (a DAS28 of more than 5.1) and
|
||
•they cannot have rituximab and
|
||
•the company provides upadacitinib according to the commercial arrangement.
|
||
"
|
||
985,TA665,2020/21,STA,Upadacitinib with methotrexate,Pharmaceutical,Severe rheumatoid arthritis,Optimised,"Optimised recommendation for upadacitinib with methotrexate for treating active rheumatoid arthritis in adults whose disease has responded inadequately to rituximab and at least 1 biological DMARD, only if:
|
||
•disease is severe (a DAS28 of more than 5.1) and
|
||
•the company provides upadacitinib according to the commercial arrangement.
|
||
"
|
||
986,TA665,2020/21,STA,Upadacitinib monotherapy,Pharmaceutical,Severe rheumatoid arthritis,Optimised,"Optimised recommendation for upadacitinib monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance, when the criteria in sections 1.1, 1.2 or 1.3 are met."
|
||
987,TA666,2020/21,STA,Atezolizumab with bevacizumab ,Pharmaceutical,Advanced or unresectable hepatocellular carcinoma,Optimised,"Optimsed recommendation for Atezolizumab plus bevacizumab for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment, only if:
|
||
•they have Child‑Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and
|
||
•the company provides it according to the commercial arrangement.
|
||
"
|
||
988,TA667,2020/21,STA,Caplacizumab,Pharmaceutical,Acute acquired thrombotic thrombocytopenic purpura,Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
|
||
989,TA668,2020/21,STA,Encorafenib plus cetuximab ,Pharmaceutical,Previously treated BRAF V600E mutation-positive metastatic colorectal cancer,Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the commercial access agreement
|
||
990,TA669,2020/21,STA,Trifluridine–tipiracil ,Pharmaceutical,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies,Not Recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
991,TA670,2020/21,STA,Brigatinib ,Pharmaceutical,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor ,Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
|
||
992,TA671,2020/21,STA,Mepolizumab ,Pharmaceutical,Severe eosinophilic asthma,Optimised,"Optimised recommendation for mepolizumab, as an add-on therapy for treating severe refractory eosinophilic asthma, only if:
|
||
•it is used for adults who have agreed to and followed the optimised standard treatment plan and
|
||
•the blood eosinophil count has been recorded as 300 cells per microlitre or more and the person has had at least 4 exacerbations needing systemic corticosteroids in the previous 12 months, or has had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous 6 months or
|
||
•the blood eosinophil count has been recorded as 400 cells per microlitre or more and the person has had at least 3 exacerbations needing systemic corticosteroids in the previous 12 months (so they are also eligible for either benralizumab or reslizumab).
|
||
Mepolizumab is recommended only if the company provides it according to the commercial arrangement.
|
||
"
|
||
993,TA672,2020/21,STA,Brolucizumab ,Pharmaceutical,Wet age-related macular degeneration ,Optimised,"Optimised recommendation for brolucizumab for treating wet age-related macular degeneration in adults, only if, in the eye to be treated:
|
||
•the best-corrected visual acuity is between 6/12 and 6/96
|
||
•there is no permanent structural damage to the central fovea
|
||
•the lesion size is less than or equal to 12 disc areas in greatest linear dimension and
|
||
•there is recent presumed disease progression (for example, blood vessel growth, as shown by fluorescein angiography, or recent visual acuity changes).
|
||
It is recommended only if the company provides brolucizumab according to the commercial arrangement.
|
||
"
|
||
994,TA673,2020/21,STA,Niraparib ,Pharmaceutical,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",Recommended (CDF),"Niraparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment for advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults. It is recommended only if the conditions in the managed access agreement for niraparib are followed."
|
||
995,TA674,2020/21,STA,Pembrolizumab,Pharmaceutical,"Untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable",Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
996,TA675,2020/21,STA,Vernakalant ,Pharmaceutical,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
997,TA676,2020/21,STA,Filgotinib with methotrexate,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for filgotinib with methotrexate for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs), only if:
|
||
•disease is moderate or severe (a disease activity score [DAS28] of 3.2 or more) and
|
||
•the company provides filgotinib according to the commercial arrangement.
|
||
"
|
||
998,TA676,2020/21,STA,Filgotinib with methotrexate,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised recommendation for filgotinib, with methotrexate, treating active rheumatoid arthritis in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if:
|
||
•disease is severe (a DAS28 of more than 5.1) and
|
||
•they cannot have rituximab and
|
||
•the company provides filgotinib according to the commercial arrangement.
|
||
"
|
||
999,TA676,2020/21,STA,Filgotinib with methotrexate,Pharmaceutical,Severe rheumatoid arthritis,Optimised,"Optimised recommendation for filgotinib, with methotrexate, as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to rituximab and at least 1 biological DMARD, only if:
|
||
•disease is severe (a DAS28 of more than 5.1) and
|
||
•the company provides filgotinib according to the commercial arrangement.
|
||
"
|
||
1000,TA676,2020/21,STA,Filgotinib monotherapy,Pharmaceutical,Moderate to severe rheumatoid arthritis,Optimised,"Optimised reccomendation for filgotinib monotherapy when methotrexate is contraindicated or if people cannot tolerate it, when the criteria in sections 1.1, 1.2 or 1.3 are met."
|
||
1001,TA677,2020/21,STA,Autologous anti-CD19-transduced CD3+ cells,Pharmaceutical,Relapsed or refractory mantle cell lymphoma ,Recommended (CDF),Treatment with autologous anti-CD19-transduced CD3+ cells is recommended for use within the Cancer Drugs Fund as an option for relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton's tyrosine kinase (BTK) inhibitor. It is only recommended if the conditions in the managed access agreement for autologous anti‑CD19‑transduced CD3+ cells treatment are followed.
|
||
1002,TA678,2020/21,STA,Omalizumab ,Pharmaceutical,Chronic rhinosinusitis with nasal polyps,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1003,TA679,2020/21,STA,Dapagliflozin ,Pharmaceutical,Chronic heart failure with reduced ejection fraction ,Optimised,"Optimised recommendation for Dapagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:
|
||
•angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor blockers (ARBs), with beta blockers, and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or
|
||
•sacubitril valsartan, with beta blockers, and, if tolerated, MRAs.
|
||
"
|
||
1004,TA680,2020/21,STA,Lenalidomide ,Pharmaceutical,Maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,Optimised,"Optimised recommendation for lenalidomide as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults, only if:
|
||
•the dosage schedule is 10 mg per day on days 1 to 21 of a 28‑day cycle and
|
||
•the company provides lenalidomide according to the commercial arrangement.
|
||
NOTE: The use of lenalidomide as a maintenance treatment after an autologous stem cell transplant at a dosage of 10 mg per day on days 1 to 21 of a 28-day cycle is outside the terms of the marketing authorisation for lenalidomide. Consequently, the statutory funding requirement does not apply to this recommendation. "
|
||
1005,TA681,2020/21,STA,Baricitinib for treating moderate to severe atopic dermatitis,Pharmaceutical,Moderate to severe atopic dermatitis,Optimised,"Optimised recommendation for baricitinib for treating moderate to severe atopic dermatitis in adults, only if:
|
||
•the disease has not responded to at least 1 systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are not suitable, and
|
||
•the company provides it according to the commercial arrangement.
|
||
"
|
||
1006,TA682,2020/21,STA,Erenumab,Pharmaceutical,Migraine,Optimised,"Optimised recommendation for erenumab for preventing migraine in adults, only if:
|
||
•they have 4 or more migraine days a month
|
||
•at least 3 preventive drug treatments have failed
|
||
•the 140 mg dose of erenumab is used and
|
||
•the company provides it according to the commercial arrangement.
|
||
"
|
||
1007,TA683,2020/21,STA,Pembrolizumab with pemetrexed and platinum chemotherapy ,Pharmaceutical,"Untreated, metastatic, non-squamous non-small-cell lung cancer",Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the commerical access agreement
|
||
1008,TA684,2020/21,STA,Nivolumab ,Pharmaceutical,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
|
||
1009,TA685,2020/21,STA,Anakinra,Pharmaceutical,Still’s disease,Optimised,"Optimised recommendation for anakinra ifor treating Still's disease with moderate to high disease activity, or continued disease activity after non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. It is only recommended for:
|
||
•adult-onset Still's disease that has responded inadequately to 2 or more conventional disease‑modifying antirheumatic drugs (DMARDs)
|
||
•systemic juvenile idiopathic arthritis in people 8 months and older with a body weight of 10 kg or more that has not responded to at least 1 conventional DMARD.
|
||
"
|
||
1010,TA686,2020/21,STA,Blinatumomab,Pharmaceutical, Previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1011,TA687,2020/21,STA,Ribociclib with fulvestrant ,Pharmaceutical,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Recommended,CDF review of TA593
|
||
1012,TA688,2020/21,MTA,Selective internal radiation therapy SIR-Spheres,Pharmaceutical,Hepatocellular carcinoma,Optimised,"Optimsed recommendation selective internal radiation therapy (SIRT) SIR‑Spheres for treating unresectable advanced hepatocellular carcinoma (HCC) in adults, only if:
|
||
•used for people with Child–Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and
|
||
•the company provides SIR‑Spheres according to the commercial arrangement.
|
||
"
|
||
1013,TA688,2020/21,MTA,Selective internal radiation therapy TheraSphere,Pharmaceutical,Hepatocellular carcinoma,Optimised,"Olptimised recommendation for SIRT TheraSphere for treating unresectable advanced HCC in adults, only if:
|
||
•used for people with Child–Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and
|
||
•the company provides TheraSphere according to the commercial arrangement.
|
||
"
|
||
1014,TA688,2020/21,MTA,Selective internal radiation therapy QuiremSpheres,Pharmaceutical,Hepatocellular carcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1015,TA689,2021/22,STA,Acalabrutinib ,Pharmaceutical,Chronic lymphocytic leukaemia,Optimised,"Optimised recommendation for untreated chronic lymphocytic leukaemia (CLL) in adults, only if:
|
||
• there is a 17p deletion or TP53 mutation, or
|
||
• there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is unsuitable, and
|
||
• the company provides the drug according to the commercial arrangement.
|
||
"
|
||
1016,TA689,2021/22,STA,Acalabrutinib ,Pharmaceutical,Chronic lymphocytic leukaemia,Optimised,"Optimised recommendation: as monotherapy is recommended, within its marketing authorisation, as an option for previously treated CLL in adults. It is recommended only if the company provides the drug according to the commercial arrangement."
|
||
1017,TA690,2021/22,STA,Teduglutide ,Pharmaceutical,Short bowel syndrome,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1018,TA691,2021/22,STA,Avelumab,Pharmaceutical, Untreated metastatic Merkel cell carcinoma,Recommended,CDF review of recommendation 1.2 of TA517: for treating metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease
|
||
1019,TA692,2021/22,STA,Pembrolizumab ,Pharmaceutical,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,Not recommended,"CDF review of TA519. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1020,TA693,2021/22,STA,Olaparib plus bevacizumab,Pharmaceutical,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",Optimised (CDF),"Optimised CDF recommendation for maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when:
|
||
•there has been a complete or partial response after first-line platinum-based chemotherapy plus bevacizumab, and
|
||
•the cancer is associated with homologous recombination deficiency (HRD).
|
||
It is recommended only if the conditions in the managed access agreement for olaparib are followed.
|
||
"
|
||
1021,TA694,2021/22,STA,Bempedoic acid with ezetimibe ,Pharmaceutical,Primary hypercholesterolaemia or mixed dyslipidaemia ,Optimised,"Optimised recommendation for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if:
|
||
•statins are contraindicated or not tolerated,
|
||
•ezetimibe alone does not control low-density lipoprotein cholesterol well enough, and
|
||
•the company provides bempedoic acid and bempedoic acid with ezetimibe according to the commercial arrangement.
|
||
Bempedoic acid with ezetimibe can be used as separate tablets or a fixed-dose combination.
|
||
"
|
||
1022,TA695,2021/22,STA,Carfilzomib with dexamethasone and lenalidomide,Pharmaceutical,Previously treated multiple myeloma,Optimised,"Optimised recommenation for treating multiple myeloma in adults, only if:
|
||
•they have had only 1 previous therapy, which included bortezomib, and
|
||
•the company provides carfilzomib according to the commercial arrangement.
|
||
"
|
||
1023,TA696,2021/22,STA,Tafamidis for treating transthyretin amyloidosis with cardiomyopathy,Pharmaceutical,Transthyretin amyloidosis with cardiomyopathy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1024,TA697,2021/22,STA,Andexanet alfa ,Pharmaceutical,Reversing anticoagulation from apixaban or rivaroxaban,Optimised,"Optimiised recommendation for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding, only if:
|
||
• the bleed is in the gastrointestinal tract, and
|
||
•the company provides andexanet alfa according to the commercial arrangement.
|
||
"
|
||
1025,TA697,2021/22,STA,Andexanet alfa ,Pharmaceutical,Reversing anticoagulation from apixaban or rivaroxaban,Only in research,"Only in research recommenation for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding in the skull (intracranial haemorrhage; ICH), in the form of an ongoing randomised trial mandated by the regulator.
|
||
"
|
||
1026,TA698,2021/22,STA,Ravulizumab ,Pharmaceutical,Paroxysmal nocturnal haemoglobinuria,Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
|
||
1027,TA699,2021/22,STA,Ofatumumab for treating relapsing multiple sclerosis,Pharmaceutical,Relapsing multiple sclerosis,Recommended,Recommmended in line with the marketing autorisation and only if company provides it according to the patient access scheme
|
||
1028,TA700,2021/22,STA,Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ,Pharmaceutical,Refractory multiple myeloma ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1029,TA701,2021/22,STA,Crisaborole ,Pharmaceutical,Mild to moderate atopic dermatitis in people 2 years and older ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1030,TA702,2021/22,STA,Ibrutinib with obinutuzumab ,Pharmaceutical,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1031,TA703,2021/22,STA,Ibrutinib with rituximab ,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1032,TA704,2021/22,STA,Trastuzumab deruxtecan ,Pharmaceutical,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,Recommended (CDF),Trastuzumab deruxtecan is recommended for use within the Cancer Drugs Fund as an option for treating HER2‑positive unresectable or metastatic breast cancer in adults after 2 or more anti‑HER2 therapies. It is recommended only if the conditions in the managed access agreement are followed.
|
||
1033,TA705,2021/22,STA,Atezolizumab ,Pharmaceutical,Untreated advanced non-small-cell lung cancer,Recommended,Recommmended in line with the marketing authorisation and only if company provides it according to the patient access scheme
|
||
1034,TA706,2021/22,STA,Ozanimod ,Pharmaceutical,Relapsing–remitting multiple sclerosis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1035,TA707,2021/22,STA,Nivolumab ,Pharmaceutical,Previously treated unresectable advanced or recurrent oesophageal cancer,Recommended,Recommmended in line with the marketing auhtorisation and only if company provides it according to the commerical access agreement
|
||
1036,TA708,2021/22,STA,Budesonide orodispersible tablet,Pharmaceutical,Inducing remission of eosinophilic oesophagitis,Optimised,"Optimised recommendation for inducing remission of eosinophilic oesophagitis in adults. This is an optimised recommendation because although the licence was extended during the course of the appraisal, the company submission covered only induction. "
|
||
1037,TA709,2021/22,STA,Pembrolizumab ,Pharmaceutical,Untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency,Optimised,"Optimised recommendation for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults, only if:
|
||
•pembrolizumab is stopped after 2 years and no documented disease progression, and
|
||
•the company provides pembrolizumab according to the commercial arrangement."
|
||
1038,TA710,2021/22,STA,Ravulizumab ,Pharmaceutical,Atypical haemolytic uraemic syndrome,Recommended,Recommmended in line with the marketing authorisation and only if company provides it according to the patient access scheme
|
||
1039,TA711,2021/22,STA,Guselkumab ,Pharmaceutical,Active psoriatic arthritis after inadequate response to DMARDs,Optimised,"Optimised recommendation for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them, only if they have:
|
||
• peripheral arthritis with 3 or more tender joints and 3 or more swollen joints
|
||
•moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10)
|
||
•had 2 conventional DMARDs and at least 1 biological DMARD.
|
||
Guselkumab is recommended only if the company provides it according to the commercial arrangement."
|
||
1040,TA712,2021/22,STA,Enzalutamide,Pharmaceutical,Hormone-sensitive metastatic prostate cancer,Recommended,Recommended in line with the marketing authorisation and only if company provides it according to the patient access scheme
|
||
1041,TA713,2021/22,STA,Nivolumab ,Pharmaceutical,Advanced non-squamous non-small-cell lung cancer after chemotherapy,Optimised,"CDF review of TA484. locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if:
|
||
•their tumours are PD-L1 positive, and
|
||
•it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses, and
|
||
• they have not had a PD-1 or PD-L1 inhibitor before.
|
||
It is recommended only if the company provides nivolumab according to the commercial arrangement.
|
||
"
|
||
1042,TA714,2021/22,STA,Dasatinib ,Pharmaceutical,Philadelphia-chromosome-positive acute lymphoblastic leukaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1043,TA715,2021/22,MTA,Adalimumab with methotrexate,Pharmaceutical,Moderate rheumatoid arthritis after conventional DMARDs have failed,Optimised,"Optimised recommendation for adalimumab with methotrexate for treating active rheumatoid arthritis in adults, only if:
|
||
• intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and
|
||
•disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and
|
||
•the company provides adalimumab at the same or lower prices than those agreed with the Commercial Medicines Unit.
|
||
"
|
||
1044,TA715,2021/22,MTA,Etanercept with methotrexate,Pharmaceutical,Moderate rheumatoid arthritis after conventional DMARDs have failed,Optimised,"Optimised recommendation for etanercept with methotrexate for treating active rheumatoid arthritis in adults, only if:
|
||
• intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and
|
||
•disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and
|
||
•the company provides etanercept at the same or lower prices than those agreed with the Commercial Medicines Unit.
|
||
"
|
||
1045,TA715,2021/22,MTA,Infliximab with methotrexate,Pharmaceutical,Moderate rheumatoid arthritis after conventional DMARDs have failed,Optimised,"Optimised recommendation for infliximab with methotrexate for treating active rheumatoid arthritis in adults, only if:
|
||
• intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and
|
||
•disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and
|
||
•the company provides infliximab at the same or lower prices than those agreed with the Commercial Medicines Unit.
|
||
"
|
||
1046,TA715,2021/22,MTA,Abatacept with methotrexate,Pharmaceutical,Moderate rheumatoid arthritis after conventional DMARDs have failed,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1047,TA715,2021/22,MTA,Adalimumab monotherapy,Pharmaceutical,Moderate rheumatoid arthritis after conventional DMARDs have failed,Optimised,"Optimised recommendation for adalimumab monotherapy for treating active rheumatoid arthritis in adults, only if:
|
||
• intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and
|
||
•disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and
|
||
•the company provides adalimumab at the same or lower prices than those agreed with the Commercial Medicines Unit. "
|
||
1048,TA715,2021/22,MTA,Etanercept monotherapy,Pharmaceutical,Moderate rheumatoid arthritis after conventional DMARDs have failed,Optimised,"Optimised recommendation for etanercept monotherpay for treating active rheumatoid arthritis in adults, only if:
|
||
• intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs) has not controlled the disease well enough and
|
||
•disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and
|
||
•the company provides etanercept at the same or lower prices than those agreed with the Commercial Medicines Unit. "
|
||
1049,TA716,2021/22,STA,Nivolumab with ipilimumab,Pharmaceutical,Previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency,Recommended,Recommmended in line with the marketing auhtorisation and only if company provides it according to the commerical access agreements
|
||
1050,TA717,2021/22,STA,Duvelisib,Pharmaceutical,Relapsed follicular lymphoma after 2 or more systemic therapies,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1051,TA718,2021/22,STA,Ixekizumab,Pharmaceutical,Axial spondyloarthritis,Optimised,"Optimised recommendation for reating active ankylosing spondylitis that is not controlled well enough with conventional therapy, or active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs), in adults. It is recommended only if:
|
||
tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough, and
|
||
the company provides ixekizumab according to the commercial arrangement."
|
||
1052,TA719,2021/22,STA,Secukinumab ,Pharmaceutical,Non-radiographic axial spondyloarthritis,Optimised,"Optimsed recommendation for reating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. It is recommended only if:
|
||
tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and
|
||
the company provides secukinumab according to the commercial arrangement."
|
||
1053,TA720,2021/22,STA,Chlormethine gel,Pharmaceutical,Mycosis fungoides-type cutaneous T-cell lymphoma,Optimised,"Optimised recommendation for treating early stage (stage 1A, 1B, and 2A) mycosis fungoides-type cutaneous T‑cell lymphoma (MF‑CTCL) in adults, only if the company provides chlormethine gel according to the commercial arrangement."
|
||
1054,TA721,2021/22,STA,Abiraterone ,Pharmaceutical,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1055,TA722,2021/22,STA,Pemigatinib ,Pharmaceutical,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,Recommended,Recommmended in line with the marketing auhtorisation and only if company provides it according to the patient access scheme
|
||
1056,TA723,2021/22,STA,Bimekizumab ,Pharmaceutical,Moderate to severe plaque psoriasis,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
1057,TA724,2021/22,STA,Nivolumab with ipilimumab and chemotherapy ,Pharmaceutical,Untreated metastatic non-small-cell lung cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1058,TA725,2021/22,STA,Abemaciclib with fulvestrant ,Pharmaceutical,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
1059,TA726,2021/22,STA,Daratumumab with pomalidomide and dexamethasone ,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1060,TA727,2021/22,STA,Isatuximab with carfilzomib and dexamethasone,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1061,TA728,2021/22,STA,Midostaurin ,Pharmaceutical,Advanced systemic mastocytosis,Recommended,Recommended in line with clinical practice and following agreement of acommerical access agreement.
|
||
1062,TA729,2021/22,STA,Sapropterin ,Pharmaceutical,Hyperphenylalaninaemia in phenylketonuria,Optimised,"Optimised recommendation for treating hyperphenylalaninaemia that responds to sapropterin (response as defined in the summary of product characteristics) in people with phenylketonuria (PKU), only if they are:
|
||
•under 18 and a dose of 10 mg/kg is used, only using a higher dose if target blood phenylalanine levels cannot be achieved at 10 mg/kg
|
||
•aged 18 to 21 inclusive, continuing the dose they were having before turning 18 or at a maximum dose of 10 mg/kg
|
||
• pregnant (from a positive pregnancy test until birth). Sapropterin is recommended only if the company provides it according to the commercial arrangement.
|
||
"
|
||
1063,TA730,2021/22,STA,Avapritinib ,Pharmaceutical,Unresectable or metastatic gastrointestinal stromal tumours,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1064,TA731,2021/22,STA,Vericiguat ,Pharmaceutical,Chronic heart failure with reduced ejection fraction,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1065,TA732,2021/22,STA,Baloxavir marboxil,Pharmaceutical,Acute uncomplicated influenza,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1066,TA733,2021/22,STA,Inclisiran,Pharmaceutical,Primary hypercholesterolaemia or mixed dyslipidaemia,Optimised,"Optimised recommendation for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if:
|
||
•there is a history of any of the following cardiovascular events:
|
||
◦acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
|
||
◦coronary or other arterial revascularisation procedures
|
||
◦coronary heart disease
|
||
◦ischaemic stroke or
|
||
◦peripheral arterial disease, and
|
||
• low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is:
|
||
◦maximum tolerated statins with or without other lipid-lowering therapies or,
|
||
◦other lipid-lowering therapies when statins are not tolerated or are contraindicated, and
|
||
•the company provides inclisiran according to the commercial arrangement.
|
||
"
|
||
1067,TA733,2021/22,STA,Inclisiran ,Pharmaceutical,Primary hypercholesterolaemia or mixed dyslipidaemia,Only in research,"Only in research recommendatio fort reating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults who have no history of cardiovascular events. This research is in the form of a clinical trial currently in development.
|
||
"
|
||
1068,TA734,2021/22,STA,Secukinumab,Pharmaceutical,Moderate to severe plaque psoriasis in children and young people ,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
1069,TA735,2021/22,STA,Tofacitinib ,Pharmaceutical,Juvenile idiopathic arthritis,Optimised,"Optimised recommendation for for treating active polyarticular juvenile idiopathic arthritis (JIA; rheumatoid factor positive or negative polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis in people 2 years and older. This is if their condition has responded inadequately to previous treatment with disease-modifying antirheumatic drugs (DMARDs), and only if:
|
||
•a tumour necrosis factor (TNF)‑alpha inhibitor is not suitable or does not control the condition well enough, and
|
||
•the company provides tofacitinib according to the commercial arrangement.
|
||
"
|
||
1070,TA736,2021/22,STA,Nivolumab ,Pharmaceutical,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
1071,TA737,2021/22,STA,Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy ,Pharmaceutical,Untreated advanced oesophageal and gastro-oesophageal junction cancer,Recommended,Recommended in line with clinical practice and following agreement of a commerical access agreement.
|
||
1072,TA738,2021/22,STA,Berotralstat for preventing recurrent attacks of hereditary angioedema,Pharmaceutical,Recurrent attacks of hereditary angioedema,Optimised,"Optimised recommenation for preventing recurrent attacks of hereditary angioedema in people 12 years and older, only if:
|
||
•they have at least 2 attacks per month, and
|
||
•it is stopped if the number of attacks per month does not reduce by at least 50% after 3 months.
|
||
It is only recommended if the company provides berotralstat according to the commercial arrangement.
|
||
|
||
"
|
||
1073,TA739,2021/22,STA,Atezolizumab,Pharmaceutical,Untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
1074,TA740,2021/22,STA,Apalutamide with androgen deprivation therapy,Pharmaceutical,High-risk hormone-relapsed non-metastatic prostate cancer,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
1075,TA741,2021/22,STA,Apalutamide with androgen deprivation therapy ,Pharmaceutical,Hormone-sensitive metastatic prostate cancer ,Optimised,"Optimised recommendation for treating hormone-sensitive metastatic prostate cancer in adults, only if:
|
||
• docetaxel is not suitable
|
||
• the company provides apalutamide according to the commercial arrangement "
|
||
1076,TA742,2021/22,STA,Selpercatinib,Pharmaceutical,Advanced thyroid cancer with RET alterations,Recommended (CDF),"Selpercatinib is recommended for use within the Cancer Drugs Fund, as an option for treating:
|
||
advanced RET fusion-positive thyroid cancer in adults who need systemic therapy after sorafenib or lenvatinib
|
||
advanced RET-mutant medullary thyroid cancer in people 12 years and older who need systemic therapy after cabozantinib or vandetanib.
|
||
It is recommended only if the conditions in the managed access agreement are followed."
|
||
1077,TA743,2021/22,STA,Crizanlizumab ,Pharmaceutical,Preventing sickle cell crises in sickle cell disease,Optimised,Crizanlizumab is recommended as an option for preventing recurrent sickle cell crises (vaso-occlusive crises) in people aged 16 or over with sickle cell disease only if the conditions in the managed access agreement are followed.
|
||
1078,TA744,2021/22,STA,Upadacitinib with methotrexate,Pharmaceutical,Moderate rheumatoid arthritis,Optimised,"Optimised recommendation for upadacitinib, with methotrexate, for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease‑modifying antirheumatic drugs (DMARDs), only if:
|
||
disease is moderate (a disease activity score [DAS28] of 3.2 to 5.1) and the company provides upadacitinib according to the commercial arrangement. The scope for this technology appraisal also included severe rheumatoid arthritis. This is covered by TA665."
|
||
1079,TA744,2021/22,STA,Upadacitinib monotherapy,Pharmaceutical,Moderate rheumatoid arthritis,Optimised,"Optimsed recommendation for upadacitinib monotherapy when methotrexate is contraindicated or if people cannot tolerate it, when the criteria in section 1.1 are met. The scope for this technology appraisal also included severe rheumatoid arthritis. This is covered by TA665."
|
||
1080,TA745,2021/22,STA,NBTXR-3 ,Pharmaceutical,Advanced soft tissue sarcoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1081,TA746,2021/22,STA,Nivolumab ,Pharmaceutical,Resected oesophageal or gastro-oesophageal junction cancer,Recommended,Recommended in line with clinical practice and following agreement of a commerical access agreement.
|
||
1082,TA747,2021/22,STA,Nintedanib for treating progressive fibrosing interstitial lung diseases,Pharmaceutical,Progressive fibrosing interstitial lung diseases,Recommended,Recommended in line with clinical practice and following agreement of a patient access scheme.
|
||
1083,TA748,2021/22,STA,Mexiletine ,Pharmaceutical,Myotonia in non-dystrophic myotonic disorders,Recommended,Recommended in line with the marketing authorisation and only if company provides it according to the patient access scheme
|
||
1084,TA749,2021/22,STA,Liraglutide,Pharmaceutical,Managing obesity in people aged 12 to 17 years,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1085,TA750,2021/22,STA,Olaparib ,Pharmaceutical,Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1086,TA751,2021/22,STA,Dupilumab ,Pharmaceutical,Severe asthma with type 2 inflammation,Optimised,"Optimised recommendation for dupilumab as add-on maintenance therapy for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over, despite maintenance therapy with high-dose inhaled corticosteroids and another maintenance treatment, only if:
|
||
• the dosage used is 400 mg initially and then 200 mg subcutaneously every other week
|
||
• the person has agreed to and follows an optimised standard treatment plan
|
||
• the person has a blood eosinophil count of 150 cells per microlitre or more and fractional exhaled nitric oxide of 25 parts per billion or more, and has had at least 4 or more exacerbations in the previous 12 months
|
||
• the person is not eligible for mepolizumab, reslizumab or benralizumab, or has asthma that has not responded adequately to these biological therapies
|
||
• the company provides dupilumab according to the commercial arrangement."
|
||
1087,TA752,2021/22,STA,Belimumab ,Pharmaceutical,Active autoantibody-positive systemic lupus erythematosus,Optimised,"Optimised recommendation for belimumab as add-on treatment for active autoantibody-positive systemic lupus erythematosus in people with high disease activity despite standard treatment, only if:
|
||
• high disease activity is defined as at least 1 serological biomarker (positive anti-double-stranded DNA or low complement) and a SELENA‑SLEDAI score of greater than or equal to 10
|
||
• treatment is continued beyond 24 weeks only if the SELENA‑SLEDAI score has improved by 4 points or more
|
||
• the company provides belimumab according to the commercial arrangement. This guidance reviews the additional evidence collected as part of the MAA for TA397 and replaces TA397."
|
||
1088,TA753,2021/22,STA,Cenobamate,Pharmaceutical,Focal onset seizures in epilepsy,Optimised,"Optimsed recommendation for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines. It is recommended only if:
|
||
• it is used as an add-on treatment, after at least 1 other add-on treatment has not controlled seizures, and
|
||
• treatment is started in a tertiary epilepsy service."
|
||
1089,TA754,2021/22,STA,Mogamulizumab ,Pharmaceutical,Previously treated Sézary syndrome,Recommended,"Optimised recommendation for treating Sézary syndrome in adults who have had at least 1 systemic treatment. It is recommended only if the company provides mogamulizumab according to the commercial arrangement.
|
||
"
|
||
1090,TA754,2021/22,STA,Mogamulizumab ,Pharmaceutical,Previously treated mycosis fungoides ,Optimised,"Optimised recommendation for treating mycosis fungoides in adults, only if:
|
||
• their condition is stage 2B or above and they have had at least 2 systemic treatments and
|
||
• the company provides mogamulizumab according to the commercial arrangement."
|
||
1091,TA755,2021/22,STA,Risdiplam ,Pharmaceutical,Spinal muscular atrophy,Optimised,"Optimised recommendation for risdiplam for treating 5q spinal muscular atrophy (SMA) in people 2 months and older with a clinical diagnosis of SMA types 1, 2 or 3 or with pre-symptomatic SMA and 1 to 4 SMN2 copies. It is recommended only if the conditions of the managed access agreement are followed."
|
||
1092,TA756,2021/22,STA,Fedratinib,Pharmaceutical,Disease-related splenomegaly or symptoms in myelofibrosis,Recommended (CDF),"Fedratinib is recommended for use within the Cancer Drugs Fund as an option for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults. It is recommended only if:
|
||
they have previously had ruxolitinib and
|
||
the conditions in the managed access agreement for fedratinib are followed."
|
||
1093,TA757,2021/22,STA,Cabotegravir with rilpivirine,Pharmaceutical,Treating HIV-1 ,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1094,TA758,2021/22,STA,Solriamfetol ,Pharmaceutical,Excessive daytime sleepiness caused by narcolepsy,Optimised,Optimised recommendation for soiriamfetol for treating excessive daytime sleepiness in adults with narcolepsy with or without cataplexy. This is only if modafinil and either dexamfetamine or methylphenidate have not worked well enough or are not suitable.
|
||
1095,TA759,2021/22,STA,Fostamatinib ,Pharmaceutical,Refractory chronic immune thrombocytopenia,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1096,TA760,2021/22,STA,Selpercatinib ,Pharmaceutical,Previously treated RET fusion-positive advanced non-small-cell lung cancer,Recommended (CDF),"Selpercatinib is recommended for use within the Cancer Drugs Fund as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults who need systemic therapy after immunotherapy, platinum-based chemotherapy or both. It is recommended only if the conditions in the managed access agreement are followed."
|
||
1097,TA761,2021/22,STA,Osimertinib ,Pharmaceutical,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,Optimised (CDF),"Osimertinib is recommended for use within the Cancer Drugs Fund as adjuvant treatment after complete tumour resection in adults with stage 1b to 3a non‑small‑cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. It is recommended only if:
|
||
•osimertinib is stopped at 3 years, or earlier if there is disease recurrence or unacceptable toxicity and
|
||
•the company provides osimertinib according to the managed access agreement."
|
||
1098,TA762,2021/22,STA,Olaparib ,Pharmaceutical,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1099,TA763,2021/22,STA,Daratumumab in combination ,Pharmaceutical,Multiple myeloma when a stem cell transplant is suitable,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1100,TA764,2021/22,STA,Fremanezumab,Pharmaceutical,Preventing migraine,Optimised,"Optimised recommendation for fremanezumab for preventing migraine in adults, only if:
|
||
•they have 4 or more migraine days a month
|
||
•at least 3 preventive drug treatments have failed and
|
||
•the company provides it according to the commercial arrangement.
|
||
Stop fremanezumab after 12 weeks of treatment if:
|
||
•in episodic migraine (fewer than 15 headache days a month), the frequency does not reduce by at least 50%
|
||
•in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine), the frequency does not reduce by at least 30%.
|
||
Updates and replaces TA631"
|
||
1101,TA765,2021/22,STA,Venetoclax with azacitidine,Pharmaceutical, Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1102,TA766,2021/22,STA,Pembrolizumab,Pharmaceutical,Adjuvant treatment of completely resected stage 3 melanoma,Recommended,"Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
Replaces TA553"
|
||
1103,TA767,2021/22,STA,Ponesimod ,Pharmaceutical,Relapsing–remitting multiple sclerosis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1104,TA768,2021/22,STA,Upadacitinib ,Pharmaceutical,Active psoriatic arthritis after inadequate response to DMARDs,Optimised,"Optimised recommendation for upadacitinib, alone or with methotrexate, for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and:
|
||
they have had 2 conventional DMARDs and at least 1 biological DMARD or
|
||
TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
|
||
Upadacitinib is recommended only if the company provides it according to the commercial arrangement."
|
||
1105,TA769,2021/22,STA,Palforzia ,Pharmaceutical,Peanut allergy in children and young people,Recommended,Recommended in line with marketing authorisation.
|
||
1106,TA770,2021/22,STA,Pembrolizumab with carboplatin and paclitaxel ,Pharmaceutical,Untreated metastatic squamous non-small-cell lung cancer,Optimised,"Optimised recommendation for Pembrolizumab with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if
|
||
their tumours express PD‑L1 with a tumour proportion score of 0% to 49%
|
||
their tumours express PD‑L1 with a tumour proportion score of 50% or more and they need urgent clinical intervention
|
||
it is stopped at 2 years of uninterrupted treatment or earlier if their disease progresses and
|
||
the company provides pembrolizumab according to the commercial arrangement.
|
||
CDF review of TA600 "
|
||
1107,TA771,2021/22,STA,"Daratumumab with bortezomib, melphalan and prednisone",Pharmaceutical, Untreated multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1108,TA772,2021/22,STA,Pembrolizumab ,Pharmaceutical,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,Recommended,"Recommendded in line with marketing authorisation and following agreemenet of a commerical access agreement.
|
||
Extension to the MA in TA540"
|
||
1109,TA773,2021/22,STA,Empagliflozin,Pharmaceutical,Chronic heart failure with reduced ejection fraction,Optimised,"Optimised recommendation for empagliflozin for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:
|
||
an angiotensin-converting enzyme (ACE) inhibitor or angiotensin 2 receptor blocker (ARB), with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA), or
|
||
sacubitril valsartan with a beta blocker and, if tolerated, an MRA."
|
||
1110,TA774,2021/22,STA,Lenalidomide ,Pharmaceutical,Relapsed or refractory mantle cell lymphoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1111,TA775,2021/22,STA,Dapagliflozin ,Pharmaceutical,Chronic kidney disease,Optimised,"Optimised recommendation for dapagliflozin for treating chronic kidney disease (CKD) in adults. It is recommended only if:
|
||
it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and
|
||
people have an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 to 75 ml/min/1.73 m2 at the start of treatment and:
|
||
have type 2 diabetes or
|
||
have a urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more. "
|
||
1112,TA776,2021/22,STA,Pitolisant hydrochloride ,Pharmaceutical,Excessive daytime sleepiness caused by obstructive sleep apnoea,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1113,TA777,2021/22,STA,Solriamfetol ,Pharmaceutical,Excessive daytime sleepiness caused by obstructive sleep apnoea,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1114,TA778,2021/22,STA,Pegcetacoplan,Pharmaceutical,Paroxysmal nocturnal haemoglobinuria,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1115,TA779,2021/22,STA,Dostarlimab,Pharmaceutical,Previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,Recommended (CDF),Dostarlimab is recommended for use within the Cancer Drugs Fund as an option for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy. It is recommended only if the conditions in the managed access agreement are followed.
|
||
1116,TA780,2021/22,STA,Nivolumab with ipilimumab ,Pharmaceutical,Untreated advanced renal cell carcinoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1117,TA781,2021/22,STA,Sotorasib ,Pharmaceutical,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,Recommended (CDF),"Sotorasib is recommended for use within the Cancer Drugs Fund as an option for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy. It is recommended only if the conditions in the managed access agreement for sotorasib are followed."
|
||
1118,TA782,2021/22,STA,Tagraxofusp,Pharmaceutical, Treating blastic plasmacytoid dendritic cell neoplasm ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1119,TA783,2022/23,STA,Daratumumab monotherapy for treating relapsed and refractory multiple myeloma,Pharmaceutical,Relapsed and refractory multiple myeloma,Optimised,"CDF review of TA510 Optimised recommenation for daratumumab monotherapy is recommended as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment, only if:
|
||
they have daratumumab after 3 treatments and
|
||
the company provides daratumumab according to the commercial arrangement."
|
||
1120,TA784,2022/23,STA,Niraparib,Pharmaceutical,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",Optimised,"CDF review of TA528. Optimised recommendation for niraparib for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults. It is recommended only if:
|
||
they have a BRCA mutation and have had 2 courses of platinum-based chemotherapy, or they do not have a BRCA mutation and have had 2 or more courses of platinum-based chemotherapy, and
|
||
the company provides it according to the commercial arrangement."
|
||
1121,TA785,2022/23,STA,Nivolumab with cabozantinib ,Pharmaceutical,Untreated advanced renal cell carcinoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1122,TA786,2022/23,STA,Tucatinib with trastuzumab and capecitabine ,Pharmaceutical,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1123,TA787,2022/23,STA,Venetoclax with low dose cytarabine ,Pharmaceutical,Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,Optimised,"Optimised recommendation for venetoclax with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable, only if:
|
||
they have over 30% bone marrow blasts
|
||
the company provides venetoclax according to the commercial arrangement."
|
||
1124,TA788,2022/23,STA,Avelumab ,Pharmaceutical,Maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy,Optimised,"Optimised recommendation for avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer that has not progressed after platinum-based chemotherapy in adults, only if:
|
||
avelumab is stopped at 5 years of uninterrupted treatment or earlier if the disease progresses and
|
||
the company provides avelumab according to the commercial arrangement."
|
||
1125,TA789,2022/23,STA,Tepotinib ,Pharmaceutical,Advanced non-small-cell lung cancer with MET gene alterations,Recommended,Recommended in line with the marketing authorisation and following agreement of a patient access scheme.
|
||
1126,TA790,2022/23,STA,TYRX Absorbable Antibacterial Envelope ,Medical Device,Preventing infection from cardiac implantable electronic devices,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1127,TA791,2022/23,STA,Romosozumab,Pharmaceutical,Treating severe osteoporosis,Optimised,"Optimised recommendation for reating severe osteoporosis in people after menopause who are at high risk of fracture, only if:
|
||
they have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture) and
|
||
the company provides romosozumab according to the commercial arrangement."
|
||
1128,TA792,2022/23,STA,Filgotinib,Pharmaceutical,Moderately to severely active ulcerative colitis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1129,TA793,2022/23,STA,Anifrolumab ,Pharmaceutical,Active autoantibody-positive systemic lupus erythematosus,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1130,TA794,2022/23,STA,Diroximel fumarate ,Pharmaceutical,Relapsing–remitting multiple sclerosis,Optimised,"Optimised recommendation for diroximel fumarate for treating active relapsing–remitting multiple sclerosis (normally defined as 2 clinically significant relapses in the previous 2 years) in adults, only if:
|
||
they do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis and
|
||
the company provides diroximel fumarate according to the commercial arrangement."
|
||
1131,TA795,2022/23,STA,Ibrutinib ,Pharmaceutical,Waldenstrom’s macroglobulinaemia,Not recommended,"CDF review of TA491. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1132,TA796,2022/23,STA,Venetoclax ,Pharmaceutical,Chronic lymphocytic leukaemia,Recommended,CDF review of TA487 Recommended in line with the martketing authorisation and following agreement of a patient access schemem
|
||
1133,TA797,2022/23,STA,Enfortumab vedotin ,Pharmaceutical,Previously treated locally advanced or metastatic urothelial cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1134,TA798,2022/23,STA,Durvalumab ,Pharmaceutical,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,Optimised,"CDF review of TA578 Optimised recommendation for durvalumab for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD‑L1) on 1% or more of cells and whose disease has not progressed after platinum-based chemoradiation, only if:
|
||
they have had concurrent platinum-based chemoradiation
|
||
the company provides durvalumab according to the commercial arrangement."
|
||
1135,TA799,2022/23,STA,Faricimab,Pharmaceutical,Diabetic macular oedema,Optimised,"Optimised recommendation for faricimab for faricimab is recommended as an option for treating visual impairment due to diabetic macular oedema in adults, only if:
|
||
the eye has a central retinal thickness of 400 micrometres or more at the start of treatment
|
||
the company provides faricimab according to the commercial arrangement."
|
||
1136,TA800,2022/23,STA,Faricimab ,Pharmaceutical,Wet age-related macular degeneration,Optimised,"Optimised recommendation for aricimab for treating wet age-related macular degeneration in adults, only if:
|
||
the eye has a best-corrected visual acuity between 6/12 and 6/96
|
||
there is no permanent structural damage to the central fovea
|
||
the lesion size is 12 disc areas or less in greatest linear dimension
|
||
there are signs of recent disease progression (for example, blood vessel growth as shown by fluorescein angiography, or recent visual acuity changes)
|
||
the company provides faricimab according to the commercial arrangement."
|
||
1137,TA801,2022/23,STA,Pembrolizumab plus chemotherapy,Pharmaceutical," Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",Optimised,"Optimised recommendation for pembrolizumab plus chemotherapy (paclitaxel or nab‑paclitaxel) for treating triple‑negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease. It is recommended only if:
|
||
the tumours express PD‑L1 with a combined positive score (CPS) of 10 or more and an immune cell staining (IC) of less than 1%, and
|
||
the company provides pembrolizumab according to the commercial arrangement."
|
||
1138,TA802,2022/23,STA,Cemiplimab,Pharmaceutical,Advanced cutaneous squamous cell carcinoma,Optimised,"CDF review of TA592 Optimised recommendation for cemiplimabn for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults when curative surgery or curative radiotherapy is not suitable, only if:
|
||
it is stopped at 24 months, or earlier if their disease progresses, and
|
||
the company provides cemiplimab according to the commercial arrangement."
|
||
1139,TA803,2022/23,STA,Risankizumab,Pharmaceutical,Psoriatic arthritis after inadequate response to DMARDs,Optimised,"Optimised recommendation for risankizumab, alone or with methotrexate for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have:
|
||
peripheral arthritis with 3 or more tender joints and 3 or more swollen joints
|
||
moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10)
|
||
had 2 conventional DMARDs and at least 1 biological DMARD.
|
||
Risankizumab is recommended only if the company provides it according to the commercial arrangement."
|
||
1140,TA804,2022/23,STA,Teduglutide,Pharmaceutical,Short bowel syndrome,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1141,TA805,2022/23,STA,Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides,Pharmaceutical,Reducing the risk of cardiovascular events in people with raised triglycerides,Optimised,"Optimised recommendation for Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have:
|
||
established cardiovascular disease (secondary prevention), defined as a history of any of the following:
|
||
acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
|
||
coronary or other arterial revascularisation procedures
|
||
coronary heart disease
|
||
ischaemic stroke
|
||
peripheral arterial disease, and
|
||
low-density lipoprotein cholesterol (LDL‑C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre."
|
||
1142,TA806,2022/23,STA,Belimumab ,Pharmaceutical,Lupus nephritis,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1143,TA807,2022/23,STA,Roxadustat,Pharmaceutical,Symptomatic anaemia in chronic kidney disease,Optimised,"Optimised recommendation for roxadustat for treating symptomatic anaemia associated with chronic kidney disease (CKD) in adults only if:
|
||
they have stage 3 to 5 CKD with no iron deficiency and
|
||
they are not on dialysis at the start of treatment and
|
||
the company provides roxadustat according to the commercial arrangement."
|
||
1144,TA808,2022/23,STA,Fenfluramine,Pharmaceutical,Treating seizures associated with Dravet syndrome,Optimised,"Optimised recommendation for fenfluramine as an add‑on to other antiseizure medicines for treating seizures associated with Dravet syndrome in people aged 2 years and older, only if:
|
||
seizures have not been controlled after trying 2 or more antiseizure medicines
|
||
the frequency of convulsive seizures is checked every 6 months, and fenfluramine is stopped if it has not fallen by at least 30% compared with the 6 months before starting treatment
|
||
the company provides fenfluramine according to the commercial arrangement."
|
||
1145,TA809,2022/23,STA,Imlifidase ,Pharmaceutical,Desensitisation treatment before kidney transplant in people with chronic kidney disease,Optimised,"Optimised recommendation for desensitisation treatment option for adults who:
|
||
are waiting for a kidney transplant from a deceased donor
|
||
are highly sensitised to human leukocyte antigens (HLA)
|
||
have a positive crossmatch with the donor and are unlikely to have a transplant under the available kidney allocation system (including prioritisation programmes for highly sensitised people).
|
||
It is recommended only if:
|
||
a maximum of 1 dose is given
|
||
it is given in a specialist centre with experience of treating high sensitisation to HLA
|
||
the company provides imlifidase according to the commercial arrangement."
|
||
1146,TA810,2022/23,STA,Abemaciclib with endocrine therapy ,Pharmaceutical,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",Recommended,"Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
NB The MA is confuisng and split across section 4.1 and 5.1.
|
||
"
|
||
1147,TA811,2022/23,STA,Duvelisib ,Pharmaceutical,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1148,TA812,2022/23,STA,Pralsetinib ,Pharmaceutical,RET fusion-positive advanced non-small-cell lung cancer,Not recommended," At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1149,TA813,2022/23,STA,Asciminib ,Pharmaceutical,Chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1150,TA814,2022/23,MTA,Abrocitinib,Pharmaceutical,Moderate to severe atopic dermatitis,Optimised,"Optimsed recommendation for abrocitinib treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over, only if:
|
||
the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable
|
||
the company provides abrocitinib according to the commercial arrangement."
|
||
1151,TA814,2022/23,MTA,Upadacitinib,Pharmaceutical,Moderate to severe atopic dermatitis,Optimised,"Optimsed recommendation for upadacitinib are recommended as options for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over, only if:
|
||
the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable
|
||
the company provides upadacitinib according to the commercial arrangement."
|
||
1152,TA814,2022/23,MTA,Tralokinumab,Pharmaceutical,Moderate to severe atopic dermatitis,Optimised,"Optimsed recommendation for ralokinumab is recommended as an option for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults, only if:
|
||
the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable
|
||
the company provides tralokinumab according to the commercial arrangement."
|
||
1153,TA815,2022/23,STA,Guselkumab ,Pharmaceutical,Active psoriatic arthritis after inadequate response to DMARDs,Optimised,"Rapid review of TA711. Optimised recommendation for guselkumab, alone or with methotrexate, for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have had 2 conventional DMARDs and:have had at least 1 biological DMARD, or
|
||
tumour necrosis factor (TNF)-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
|
||
Guselkumab is recommended only if the company provides it according to the commercial arrangement. Active psoriatic arthritis is defined as peripheral arthritis with 3 or more tender joints and 3 or more swollen joints."
|
||
1154,TA816,2022/23,STA,Alpelisib with fulvestrant ,Pharmaceutical,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",Optimised,"Replaces TA652 Optimised recommendation for alpelisib plus fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults, only if:
|
||
their cancer has progressed after a CDK4/6 inhibitor plus an aromatase inhibitor and
|
||
the company provides alpelisib according to the commercial arrangement)."
|
||
1155,TA817,2022/23,STA,Nivolumab,Pharmaceutical,Invasive urothelial cancer at high risk of recurrence,Optimised,"Optimsed recommendation for nivolumab for the adjuvant treatment of muscle-invasive urothelial cancer that is at high risk of recurrence after radical resection in adults whose tumours express PD-L1 at a level of 1% or more. It is recommended only if:
|
||
adjuvant treatment with platinum‑based chemotherapy is unsuitable, and
|
||
the company provides nivolumab according to the commercial arrangement."
|
||
1156,TA818,2022/23,STA,Nivolumab with ipilimumab ,Pharmaceutical,Untreated unresectable malignant pleural mesothelioma,Optimised,"Optimised recommendation for nivolumab plus ipilimumab is recommended as an option for untreated unresectable malignant pleural mesothelioma in adults, only if:
|
||
they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
|
||
the company provides it according to the commercial arrangement."
|
||
1157,TA819,2022/23,STA,Sacituzumab govitecan ,Pharmaceutical,Unresectable triple-negative advanced breast cancer after 2 or more therapies,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1158,TA820,2022/23,STA,Brolucizumab,Pharmaceutical,Diabetic macular oedema,Optimised,"Optimised recommendation for brolucizumab for treating visual impairment due to diabetic macular oedema in adults, only if:
|
||
the eye has a central retinal thickness of 400 micrometres or more at the start of treatment
|
||
the company provides brolucizumab according to the commercial arrangement."
|
||
1159,TA821,2022/23,STA,Avalglucosidase alfa ,Pharmaceutical,Pompe disease,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1160,TA822,2022/23,STA,Melphalan ,Pharmaceutical,Haematological diseases before allogeneic haematopoietic stem cell transplant,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1161,TA823,2022/23,STA,Atezolizumab,Pharmaceutical,Adjuvant treatment of resected non-small-cell lung cancer,Recommended (CDF),"Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for adjuvant treatment after complete tumour resection in adults with stage 2 to 3a non-small-cell lung cancer (NSCLC) whose:
|
||
tumours have the programmed cell death ligand‑1 (PD‑L1) biomarker expression on 50% or more of their tumour cells and
|
||
whose disease has not progressed after platinum-based adjuvant chemotherapy.
|
||
It is recommended only if the company provides atezolizumab according to the managed access agreement."
|
||
1162,TA824,2022/23,STA,Dexamethasone intravitreal implant,Pharmaceutical,Diabetic macular oedema,Optimised,"Replaces TA349. Optimised recommendation for dexamethasone intravitreal implant for treating visual impairment caused by diabetic macular oedema in adults only if their condition has not responded well enough to, or if they cannot have non-corticosteroid therapy."
|
||
1163,TA825,2022/23,STA,Avacopan,Pharmaceutical,Severe active granulomatosis with polyangiitis or microscopic polyangiitis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1164,TA826,2022/23,STA,Vedolizumab,Pharmaceutical,Chronic refractory pouchitis after surgery for ulcerative colitis,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1165,TA827,2022/23,STA,Oral azacitidine ,Pharmaceutical,Maintenance treatment of acute myeloid leukaemia after induction therapy,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1166,TA828,2022/23,STA,Ozanimod ,Pharmaceutical,Moderately to severely active ulcerative colitis,Optimised,"Optimised recommendation for eating moderately to severely active ulcerative colitis in adults, only if:
|
||
conventional treatment cannot be tolerated or is not working well enough and infliximab is not suitable, or
|
||
biological treatment cannot be tolerated or is not working well enough, and
|
||
the company provides it according to the commercial arrangement."
|
||
1167,TA829,2022/23,STA,Upadacitinib ,Pharmaceutical,Active ankylosing spondylitis,Optimised,"Optimised recommendation for upadacitinib for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if:
|
||
tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and
|
||
the company provides upadacitinib according to the commercial arrangement."
|
||
1168,TA830,2022/23,STA,Pembrolizumab ,Pharmaceutical,Adjuvant treatment of renal cell carcinoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme.
|
||
1169,TA831,2022/23,STA,Olaparib ,Pharmaceutical,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,Not recommended," At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1170,TA832,2022/23,STA,Relugolix–estradiol–norethisterone acetate,Pharmaceutical,Moderate to severe symptoms of uterine fibroids,Recommended,Recommended in line with the marketing authorisation
|
||
1171,TA833,2022/23,STA,Zanubrutinib ,Pharmaceutical,Waldenstrom’s macroglobulinaemia,Optimised,"Optimised recommendation for zanubrutinib for treating Waldenstrom's macroglobulinaemia in adults who have had at least 1 treatment, only if:
|
||
bendamustine plus rituximab is also suitable and
|
||
the company provides it according to the commercial arrangement."
|
||
1172,TA834,2022/23,STA,SQ HDM SLIT ,Pharmaceutical,Allergic rhinitis and allergic asthma caused by house dust mites,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1173,TA835,2022/23,STA,Fostamatinib ,Pharmaceutical,Refractory chronic immune thrombocytopenia,Optimised,"Rapid review of TA759. Optimised recommendation for treating refractory chronic immune thrombocytopenia (ITP) in adults, only if:
|
||
they have previously had a thrombopoietin receptor agonist (TPO‑RA), or a TPO‑RA is unsuitable
|
||
the company provides fostamatinib according to the commercial arrangement.
|
||
"
|
||
1174,TA836,2022/23,STA,Palbociclib with fulvestrant ,Pharmaceutical,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",Recommended,CDF review of TA619. Recommended in line with clincial practice and following agreement of a patient access scheme.
|
||
1175,TA837,2022/23,STA,Pembrolizumab ,Pharmaceutical,Adjuvant treatment of resected stage 2B or 2C melanoma,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1176,TA838,2022/23,STA,Slow-release potassium bicarbonate–potassium citrate,Pharmaceutical,Distal renal tubular acidosis,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1177,TA839,2022/23,STA,Ruxolitinib,Pharmaceutical,Acute graft versus host disease refractory to corticosteroids,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1178,TA840,2022/23,STA,Ruxolitinib,Pharmaceutical,Chronic graft versus host disease refractory to corticosteroids,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1179,TA841,2022/23,STA,Carfilzomib with daratumumab and dexamethasone,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1180,TA842,2022/23,STA,Tisagenlecleucel ,Pharmaceutical,Follicular lymphoma after 2 or more therapies ,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1181,TA843,2022/23,STA,Luspatercept ,Pharmaceutical,Anaemia caused by beta-thalassaemia,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1182,TA844,2022/23,STA,Luspatercept,Pharmaceutical,Anaemia caused by myelodysplastic syndromes,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1183,TA845,2022/23,STA,Mepolizumab ,Pharmaceutical,Eosinophilic granulomatosis with polyangiitis,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1184,TA846,2022/23,STA,Mepolizumab,Pharmaceutical,Severe hypereosinophilic syndrome,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1185,TA847,2022/23,STA,Mepolizumab,Pharmaceutical,Severe chronic rhinosinusitis with nasal polyps,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1186,TA848,2022/23,STA,Cemiplimab,Pharmaceutical,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the manufacturer’s submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1187,TA849,2022/23,STA,Cabozantinib,Pharmaceutical, Previously treated advanced hepatocellular carcinoma,Optimised,"Replaces TA582. Optimised recommendation for cabozantinib for treating advanced hepatocellular carcinoma (HCC) in adults who have had sorafenib, only if:
|
||
they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and
|
||
the company provides it according to the commercial arrangement.
|
||
"
|
||
1188,TA850,2022/23,STA,Amivantamab,Pharmaceutical,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1189,TA851,2022/23,STA,Pembrolizumab ,Pharmaceutical,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a commerical access arrangement
|
||
1190,TA852,2022/23,STA,Trifluridine–tipiracil,Pharmaceutical,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments,Recommended,Rapide review of TA669. Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1191,TA853,2022/23,STA,Avatrombopag,Pharmaceutical,Primary chronic immune thrombocytopenia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1192,TA854,2022/23,STA,Esketamine nasal spray,Pharmaceutical,Treatment-resistant depression,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1193,TA855,2022/23,STA,Mobocertinib,Pharmaceutical,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1194,TA856,2022/23,STA,Upadacitinib ,Pharmaceutical,Moderately to severely active ulcerative colitis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1195,TA857,2022/23,STA,Nivolumab with platinum- and fluoropyrimidine-based chemotherapy,Pharmaceutical," Untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma",Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1196,TA858,2022/23,MTA,Lenvatinib,Pharmaceutical, Untreated advanced renal cell carcinoma,Optimised,"Optimised recommendation for lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma in adults, only if:
|
||
their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and
|
||
nivolumab with ipilimumab would otherwise be offered and
|
||
the companies provide lenvatinib and pembrolizumab according to the commercial arrangements."
|
||
1197,TA858,2022/23,MTA,Pembrolizumab,Pharmaceutical,Untreated advanced renal cell carcinoma,Optimised,"Optimised recommendation for lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma in adults, only if:
|
||
their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria and
|
||
nivolumab with ipilimumab would otherwise be offered and
|
||
the companies provide lenvatinib and pembrolizumab according to the commercial arrangements."
|
||
1198,TA859,2022/23,STA,Angiotensin II ,Pharmaceutical,Vasosuppressor-resistant hypotension caused by septic or distributive shock,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1199,TA860,2022/23,STA,Maribavir ,Pharmaceutical,Refractory cytomegalovirus infection after transplant,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1200,TA861,2022/23,STA,Upadacitinib ,Pharmaceutical,Active non-radiographic axial spondyloarthritis,Optimised,"Optimised recommendation for upadacitinib for treating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. It is recommended only if:
|
||
tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and
|
||
the company provides upadacitinib according to the commercial arrangement."
|
||
1201,TA862,2022/23,STA,Trastuzumab deruxtecan ,Pharmaceutical,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,Recommended (CDF),Trastuzumab deruxtecan is recommended with managed access as an option for treating HER2‑positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. It is only recommended if the conditions in the managed access agreement for trastuzumab deruxtecan are followed.
|
||
1202,TA863,2022/23,STA,Somatrogon ,Pharmaceutical,Growth disturbance in people 3 years and over,Recommended,Recommended in line with marketing authorisation
|
||
1203,TA864,2022/23,STA,Nintedanib ,Pharmaceutical,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,Recommended,"Part review of TA379 which did not recommend people with a forced vital capacity above 80% predicted . Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis in adults, only if:
|
||
they have a forced vital capacity of above 80% predicted
|
||
the company provides it according to the commercial arrangement."
|
||
1204,TA865,2022/23,STA,Nivolumab with fluoropyrimidine- and platinum-based chemotherapy ,Pharmaceutical,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",Optimised,"Optimised recommendation for nivolumab with fluoropyrimidine-based and platinum-based combination chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD‑L1 at a level of 1% or more. It is recommended only if:
|
||
- pembrolizumab plus chemotherapy is not suitable
|
||
- the company provides nivolumab according to the commercial arrangement."
|
||
1205,TA866,2022/23,STA,Regorafenib ,Pharmaceutical,Previously treated metastatic colorectal cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1206,TA867,2022/23,STA,Mitapivat ,Pharmaceutical,Pyruvate kinase deficiency ,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1207,TA868,2022/23,STA,Vutrisiran ,Pharmaceutical,Hereditary transthyretin-related amyloidosis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1208,TA869,2022/23,STA,Teclistamab ,Pharmaceutical,Relapsed or refractory multiple myeloma after 3 or more therapies,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1209,TA870,2022/23,STA,Ixazomib with lenalidomide and dexamethasone,Pharmaceutical,Relapsed or refractory multiple myeloma,Optimised,"Review of TA505. Optimised recommendation for ixazomib, with lenalidomide and dexamethasone, as an option for treating multiple myeloma in adults, only if:
|
||
they have had 2 or 3 lines of therapy and
|
||
the company provides ixazomib according to the commercial arrangement."
|
||
1210,TA871,2022/23,STA,Eptinezumab ,Pharmaceutical,Preventing migraine,Optimised,"Optimised recommendation for eptinezumab for preventing migraine in adults, only if:
|
||
they have 4 or more migraine days a month
|
||
at least 3 preventive drug treatments have failed and
|
||
the company provides it according to the commercial arrangement."
|
||
1211,TA872,2022/23,STA,Axicabtagene ciloleucel ,Pharmaceutical,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,Recommended,CDF review of TA559. Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1212,TA873,2022/23,STA,Cannabidiol ,Pharmaceutical,Treating seizures caused by tuberous sclerosis complex,Optimised,"Optimised recommendation for cannabidiol as an add-on treatment option for seizures caused by tuberous sclerosis complex in people aged 2 years and over, only if:
|
||
their seizures are not controlled well enough by 2 or more antiseizure medications (either used alone or in combination) or these treatments were not tolerated
|
||
seizure frequency is checked every 6 months, and cannabidiol is stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment
|
||
the company provides cannabidiol according to the commercial arrangement."
|
||
1213,TA874,2022/23,STA,Polatuzumab vedotin in combination ,Pharmaceutical,Untreated diffuse large B-cell lymphoma,Optimised,"Optimised recommendation for polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisolone (R‑CHP) for untreated diffuse large B-cell lymphoma (DLBCL) in adults, only if
|
||
they have an International Prognostic Index (IPI) score of 2 to 5
|
||
the company provides it according to the commercial arrangement."
|
||
1214,TA875,2022/23,STA,Semaglutide ,Pharmaceutical,Managing overweight and obesity,Optimised,"Optimised recommendation for semaglutide for weight management, including weight loss and weight maintenance, alongside a reduced-calorie diet and increased physical activity in adults, only if:
|
||
it is used for a maximum of 2 years, and within a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4), and
|
||
they have at least 1 weight-related comorbidity and:
|
||
a body mass index (BMI) of at least 35.0 kg/m2, or
|
||
a BMI of 30.0 kg/m2 to 34.9 kg/m2 and meet the criteria for referral to specialist weight management services in NICE's guideline on obesity: identification, assessment and management.
|
||
Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds."
|
||
1215,TA876,2022/23,STA,Nivolumab with chemotherapy ,Pharmaceutical,Neoadjuvant treatment of resectable non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1216,TA877,2022/23,STA,Finerenone ,Pharmaceutical,Treating chronic kidney disease in type 2 diabetes,Optimised,"Optimised recommendation for finerenone as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults. It is recommended only if:
|
||
it is an add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of:
|
||
angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and
|
||
sodium–glucose cotransporter‑2 (SGLT2) inhibitors and
|
||
the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 or more."
|
||
1217,TA878,2022/23,MTA,Nirmatrelvir plus ritonavir,Pharmaceutical,Treating COVID-19,Optimised,"Optimised recommendation for nirmatrelvir plus ritonavir for treating COVID‑19 in adults, only if they:
|
||
do not need supplemental oxygen for COVID‑19 and
|
||
have an increased risk for progression to severe COVID‑19, as defined in section 5."
|
||
1218,TA878,2022/23,MTA,Sotrovimab,Pharmaceutical,Treating COVID-19,Optimised,"Optimised recommendation for sotrovimab for treating COVID‑19 in adults and young people aged 12 years and over and weighing at least 40 kg, only if:
|
||
they do not need supplemental oxygen for COVID‑19 and
|
||
they have an increased risk for progression to severe COVID‑19, as defined in the independent advisory group report commissioned by the Department of Health and Social Care and
|
||
nirmatrelvir plus ritonavir is contraindicated or unsuitable.
|
||
Sotrovimab is only recommended if the company provides it according to the commercial arrangement."
|
||
1219,TA878,2022/23,MTA,Tocilizumab,Pharmaceutical,Treating COVID-19,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1220,TA878,2022/23,MTA,Casirivimab plus imdevimab ,Pharmaceutical,Treating COVID-19,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1221,TA879,2023/24,STA,Trastuzumab deruxtecan ,Pharmaceutical,HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1222,TA880,2023/24,STA,Tezepelumab ,Pharmaceutical,Severe asthma ,Optimised,"Optimised recommendation for tezepelumab as an add-on maintenance treatment for severe asthma in people 12 years and over, when treatment with high-dose inhaled corticosteroids plus another maintenance treatment has not worked well enough. It is recommended only if people:
|
||
have had 3 or more exacerbations in the previous year, or
|
||
are having maintenance oral corticosteroids.
|
||
Tezepelumab is recommended only if the company provides it according to the commercial arrangement."
|
||
1223,TA881,2023/24,STA,Ripretinib ,Pharmaceutical,Advanced gastrointestinal stromal tumour after 3 or more treatments,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1224,TA882,2023/24,STA,Voclosporin with mycophenolate mofetil ,Pharmaceutical,Lupus nephritis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1225,TA883,2023/24,STA,Tafasitamab with lenalidomide ,Pharmaceutical,Relapsed or refractory diffuse large B-cell lymphoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1226,TA884,2023/24,STA,Capmatinib,Pharmaceutical,Advanced non-small-cell lung cancer with MET exon 14 skipping,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1227,TA885,2023/24,STA,Pembrolizumab plus chemotherapy with or without bevacizumab,Pharmaceutical,"Persistent, recurrent or metastatic cervical cancer",Recommended (CDF),"Pembrolizumab plus chemotherapy with or without bevacizumab is recommended for use within the Cancer Drugs Fund as an option for treating persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD‑L1 with a combined positive score (CPS) of at least 1. It is recommended only if:
|
||
pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and
|
||
the conditions in the managed access agreement for pembrolizumab are followed."
|
||
1228,TA886,2023/24,STA,Olaparib ,Pharmaceutical,Adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1229,TA887,2023/24,STA,Olaparib,Pharmaceutical,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,Recommended,Rapid review of TA831. Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1230,TA888,2023/24,STA,Risankizumab ,Pharmaceutical,Previously treated moderately to severely active Crohn's disease,Optimised,"Optimised recommendation for risankizumab for treating moderately to severely active Crohn's disease in people 16 years and over, only if:
|
||
the disease has not responded well enough or lost response to a previous biological treatment, or
|
||
a previous biological treatment was not tolerated, or
|
||
tumour necrosis factor (TNF)-alpha inhibitors are not suitable.
|
||
Risankizumab is only recommended if the company provides it according to the commercial arrangement."
|
||
1231,TA889,2023/24,STA,Ciltacabtagene autoleucel ,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1232,TA890,2023/24,STA,Difelikefalin,Pharmaceutical,Pruritus in people having haemodialysis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1233,TA891,2023/24,STA,Ibrutinib with venetoclax ,Pharmaceutical,Untreated chronic lymphocytic leukaemia,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1234,TA892,2023/24,STA,Mosunetuzumab ,Pharmaceutical,Relapsed or refractory follicular lymphoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1235,TA893,2023/24,STA,Brexucabtagene autoleucel ,Pharmaceutical,Relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over,Recommended (CDF),Brexucabtagene autoleucel is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B‑cell acute lymphoblastic leukaemia in people 26 years and over. It is recommended only if the conditions in the managed access agreement for brexucabtagene autoleucel are followed.
|
||
1236,TA894,2023/24,STA,Axicabtagene ciloleucel,Pharmaceutical,Relapsed or refractory follicular lymphoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1237,TA895,2023/24,STA,Axicabtagene ciloleucel ,Pharmaceutical,Relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy,Recommended (CDF),"Axicabtagene ciloleucel is recommended for use within the Cancer Drugs Fund as an option for treating diffuse large B‑cell lymphoma in adults when an autologous stem cell transplant is suitable if it:
|
||
has relapsed within 12 months after first-line chemoimmunotherapy or
|
||
is refractory to first-line chemoimmunotherapy.
|
||
It is recommended only if the conditions in the managed access agreement for axicabtagene ciloleucel are followed."
|
||
1238,TA896,2023/24,STA,Bulevirtide ,Pharmaceutical,Chronic hepatitis D,Optimised,"Optimised recommendation for bulevirtide for treating chronic hepatitis D in adults with compensated liver disease only if:
|
||
there is evidence of significant fibrosis (METAVIR stage F2 or above or Ishak stage 3 or above) and
|
||
their hepatitis has not responded to peginterferon alfa‑2a (PEG‑IFN) or they cannot have interferon-based therapy.
|
||
Bulevirtide is only recommended if the company provides it according to the commercial arrangement."
|
||
1239,TA897,2023/24,STA,Daratumumab with bortezomib and dexamethasone,Pharmaceutical,Previously treated multiple myeloma,Optimised,"Managed access review of TA573. Optimised recommendation for daratumumab with bortezomib and dexamethasone for treating multiple myeloma in adults, only if they have had just 1 previous line of treatment and:
|
||
it included lenalidomide or
|
||
lenalidomide is unsuitable as a second-line treatment and
|
||
the company provides it according to the commercial arrangement."
|
||
1240,TA898,2023/24,STA,Dabrafenib plus trametinib,Pharmaceutical,BRAF V600 mutation-positive advanced non-small-cell lung cancer,Optimised,"Review of TA564. Optimised recommendation for dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if:
|
||
it is used as first-line treatment of advanced stage cancer, and
|
||
the company provides it according to the commercial arrangement."
|
||
1241,TA899,2023/24,STA,Esketamine ,Pharmaceutical,Major depressive disorder in adults at imminent risk of suicide ,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1242,TA900,2023/24,STA,Tixagevimab plus cilgavimab,Pharmaceutical,Preventing COVID-19,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1243,TA901,2023/24,STA,Cemiplimab ,Pharmaceutical,Recurrent or metastatic cervical cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1244,TA902,2023/24,STA,Dapagliflozin,Pharmaceutical,Chronic heart failure with preserved or mildly reduced ejection fraction,Recommended,Recommended in line with marketing authorisation
|
||
1245,TA903,2023/24,STA,Darolutamide with androgen deprivation therapy and docetaxel ,Pharmaceutical,Hormone-sensitive metastatic prostate cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1246,TA904,2023/24,STA,Pembrolizumab with lenvatinib ,Pharmaceutical,Previously treated advanced or recurrent endometrial cancer,Recommended,0
|
||
1247,TA905,2023/24,STA,Upadacitinib,Pharmaceutical,Previously treated moderately to severely active Crohn’s disease,Optimised,"Optimised recommendation for upadacitinib for treating moderately to severely active Crohn's disease in adults, only if:
|
||
the disease has not responded well enough or lost response to a previous biological treatment or
|
||
a previous biological treatment was not tolerated or
|
||
tumour necrosis factor (TNF)-alpha inhibitors are contraindicated.
|
||
Upadacitinib is only recommended if the company provides it according to the commercial arrangement."
|
||
1248,TA906,2023/24,STA,Rimegepant ,Pharmaceutical,Preventing migraine,Optimised,"Optimised recommendation for rimegepant for preventing episodic migraine in adults who have at least 4 and fewer than 15 migraine attacks per month, only if at least 3 preventative treatments have not worked."
|
||
1249,TA907,2023/24,STA,Deucravacitinib for treating moderate to severe plaque psoriasis,Pharmaceutical,Moderate to severe plaque psoriasis,Optimised,"Optimised recommendation for deucravacitinib for treating moderate to severe plaque psoriasis in adults, only if:
|
||
the Psoriasis Area and Severity Index (PASI) score is 10 or more and the Dermatology Life Quality Index (DLQI) score is more than 10
|
||
the condition has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated
|
||
the company provides deucravacitinib according to the commercial arrangement."
|
||
1250,TA908,2023/24,STA,Olaparib ,Pharmaceutical," Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy",Optimised,"Replaces TA620. Optimised recommendation for olaparib for the maintenance treatment of relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults whose cancer has responded to platinum-based chemotherapy, only if:
|
||
they have a BRCA1 or BRCA2 mutation
|
||
they have had 2 or more courses of platinum-based chemotherapy
|
||
the company provides olaparib according to the commercial arrangement."
|
||
1251,TA909,2023/24,STA,Lorlatinib,Pharmaceutical,Untreated ALK-positive advanced non-small-cell lung cancer,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1252,TA910,2023/24,STA,Semaglutide ,Pharmaceutical,Managing overweight and obesity in young people aged 12 to 17 years,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1253,TA911,2023/24,STA,Selpercatinib,Pharmaceutical,Untreated RET fusion-positive advanced non-small-cell lung cancer,Optimised (CDF),"Optimised recommendation for selpercatinib for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if:
|
||
it is untreated
|
||
the conditions in the managed access agreement for selpercatinib are followed."
|
||
1254,TA912,2023/24,STA,Cipaglucosidase alfa with miglustat ,Pharmaceutical,Late-onset Pompe disease,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1255,TA913,2023/24,STA,Mavacamten ,Pharmaceutical,Symptomatic obstructive hypertrophic cardiomyopathy,Optimised,"Optimised recommendation for mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3. It is recommended only if:
|
||
it is an add‑on to individually optimised standard care that includes beta‑blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated, and
|
||
the company provides it according to the commercial arrangement."
|
||
1256,TA914,2023/24,STA,Pembrolizumab ,Pharmaceutical,"Previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency",Optimised,"Optimised recommendation for pembrolizumab for treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults with:
|
||
advanced or recurrent endometrial cancer that has progressed during or after a platinum-based therapy, who cannot have curative surgery or radiotherapy
|
||
unresectable or metastatic gastric, small intestine or biliary cancer that has progressed during or after 1 therapy
|
||
colorectal cancer after fluoropyrimidine combination therapy, only if they cannot have nivolumab with ipilimumab.
|
||
It is only recommended if:
|
||
pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if the cancer progresses, and
|
||
the company provides it according to the commercial arrangement."
|
||
1257,TA915,2023/24,STA,Pegunigalsidase alfa ,Pharmaceutical,Fabry disease,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1258,TA916,2023/24,STA,Bimekizumab ,Pharmaceutical,Active psoriatic arthritis,Optimised,"Optimised recommendation for bimekizumab alone or with methotrexate for treating active psoriatic arthritis (defined as peripheral arthritis with 3 or more tender joints and 3 or more swollen joints) in adults whose condition has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have had 2 conventional DMARDs and:
|
||
at least 1 biological DMARD or
|
||
tumour necrosis factor (TNF)-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
|
||
Bimekizumab is recommended only if the company provides it according to the commercial arrangement.
|
||
This appraisal followed the cost comparison process."
|
||
1259,TA917,2023/24,STA,Daratumumab with lenalidomide and dexamethasone ,Pharmaceutical,Untreated multiple myeloma when a stem cell transplant is unsuitable,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1260,TA918,2023/24,STA,Bimekizumab ,Pharmaceutical,Axial spondyloarthritis,Optimised,"Optimised recommendation for bimekizumab in adults for treating active ankylosing spondylitis (AS) when conventional therapy has not worked well enough or is not tolerated, or active non‑radiographic axial spondyloarthritis (nr‑axSpA) with objective signs of inflammation (shown by elevated C‑reactive protein or MRI) when non-steroidal anti‑inflammatory drugs (NSAIDs), have not worked well enough or are not tolerated. It is recommended only if:
|
||
tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough, and
|
||
the company provides it according to the commercial arrangement.
|
||
"
|
||
1261,TA919,2023/24,STA,Rimegepant,Pharmaceutical,Acute migraine with or without aura,Optimised,"Optimised recommendation for rimegepant for the acute treatment of migraine with or without aura in adults, only if for previous migraines:
|
||
at least 2 triptans were tried and they did not work well enough or
|
||
triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough."
|
||
1262,TA920,2023/24,STA,Tofacitinib ,Pharmaceutical,Active ankylosing spondylitis,Optimised,"Optimised recommendation for tofacitinib for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if:
|
||
tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and
|
||
the company provides tofacitinib according to the commercial arrangement.
|
||
This appraisal followed the cost comparison process."
|
||
1263,TA921,2023/24,STA,Ruxolitinib ,Pharmaceutical,Polycythaemia vera,Recommended,Replaces TA356. Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1264,TA922,2023/24,STA,Daridorexant ,Pharmaceutical,Long-term insomnia,Optimised,"Optimised recommendation for daridorexant for treating insomnia in adults with symptoms lasting for 3 nights or more per week for at least 3 months, and whose daytime functioning is considerably affected, only if:
|
||
cognitive behavioural therapy for insomnia (CBTi) has been tried but not worked, or
|
||
CBTi is not available or is unsuitable."
|
||
1265,TA923,2023/24,STA,Tabelecleucel ,Pharmaceutical,Treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1266,TA924,2023/24,STA,Tirzepatide ,Pharmaceutical,Treating type 2 diabetes,Optimised,"Optimised recommendation for Tirzepatide for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if:
|
||
triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and
|
||
they have a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or
|
||
they have a BMI of less than 35 kg/m2, and:
|
||
insulin therapy would have significant occupational implications, or
|
||
weight loss would benefit other significant obesity-related complications.
|
||
Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds."
|
||
1267,TA925,2023/24,STA,Mirikizumab ,Pharmaceutical,Treating moderately to severely active ulcerative colitis,Optimised,"Optimised recommendation for mirikizumab for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment, only if:
|
||
a tumour necrosis factor (TNF)‑alpha inhibitor has not worked (that is the condition has not responded well enough or has lost response to treatment) or
|
||
a TNF-alpha inhibitor cannot be tolerated or is not suitable and
|
||
the company provides it according to the commercial arrangement.
|
||
This appraisal followed the cost comparison process."
|
||
1268,TA926,2023/24,STA,Baricitinib,Pharmaceutical,Treating severe alopecia areata,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1269,TA927,2023/24,STA,Glofitamab,Pharmaceutical,Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1270,TA928,2023/24,STA,Cabozantinib,Pharmaceutical,Previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1271,TA929,2023/24,STA,Empagliflozin,Pharmaceutical,Treating chronic heart failure with preserved or mildly reduced ejection fraction,Recommended,"Recommended in line with marketing authorisation.
|
||
This appraisal followed the cost comparison process."
|
||
1272,TA930,2023/24,STA,Lutetium-177 vipivotide tetraxetan,Pharmaceutical,Treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1273,TA931,2023/24,STA,Zanubrutinib,Pharmaceutical,Treating chronic lymphocytic leukaemia,Optimised,"Optimised recommendation for zanubrutinib for treating chronic lymphocytic leukaemia (CLL) in adults. It is only recommended if the CLL is:
|
||
untreated and
|
||
there is a 17p deletion or tumour protein 53 (TP53) mutation or
|
||
there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR) is unsuitable, or
|
||
relapsed or refractory.
|
||
Zanubrutinib is recommended only if the company provides it according to the commercial arrangement."
|
||
1274,TA932,2023/24,STA,Decitabine–cedazuridine,Pharmaceutical,Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1275,TA933,2023/24,STA,Tisagenlecleucel,Pharmaceutical,Treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1276,TA934,2023/24,STA,Foslevodopa–foscarbidopa ,Pharmaceutical,Treating advanced Parkinson’s with motor symptoms,Optimised,"Optimised recommendation for Foslevodopa–foscarbidopa is recommended as an option for treating advanced levodopa-responsive Parkinson's in adults whose symptoms include severe motor fluctuations and hyperkinesia or dyskinesia, when available medicines are not working well enough, only if:
|
||
they cannot have apomorphine or deep brain stimulation, or these treatments no longer control symptoms, and
|
||
the company provides foslevodopa–foscarbidopa according to the commercial arrangement."
|
||
1277,TA935,2023/24,STA,Secukinumab,Pharmaceutical,Moderate to severe hidradenitis suppurativa,Optimised,"Optimised recommendation for secukinumab for treating active moderate to severe hidradenitis suppurativa (acne inversa) in adults when it has not responded well enough to conventional systemic treatment, only if:
|
||
adalimumab is not suitable, did not work or has stopped working
|
||
the company provides secukinumab according to the commercial arrangements."
|
||
1278,TA936,2023/24,STA,Idecabtagene vicleucel,Pharmaceutical,Treating relapsed and refractory multiple myeloma after 3 or more treatments,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1279,TA937,2023/24,STA,Targeted-release budesonide ,Pharmaceutical,Treating primary IgA nephropathy,Optimised,"Optimised recommendation for targeted-release budesonide for treating primary immunoglobulin A nephropathy (IgAN) when there is a risk of rapid disease progression in adults with a urine protein-to-creatinine ratio of 1.5 g/g or more. Targeted-release budesonide is recommended only if:
|
||
it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated
|
||
the company provides it according to the commercial arrangement."
|
||
1280,TA938,2023/24,STA,Dupilumab ,Pharmaceutical,Treating eosinophilic oesophagitis in people 12 years and over,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1281,TA939,2023/24,STA,Pembrolizumab plus chemotherapy with or without bevacizumab,Pharmaceutical,"Persistent, recurrent or metastatic cervical cancer",Optimised,"Rapid review of TA885. Optimised recommendation for pembrolizumab plus chemotherapy with or without bevacizumab for treating persistent, recurrent or metastatic cervical cancer in adults whose tumours express PD‑L1 with a combined positive score of at least 1. It is recommended only if:
|
||
pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if the cancer progresses, and
|
||
the company provides it according to the commercial arrangements."
|
||
1282,TA940,2023/24,STA,Ravulizumab,Pharmaceutical,Treating generalised myasthenia gravis,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1283,TA941,2023/24,STA,Ravulizumab ,Pharmaceutical,Treating AQP4 antibody-positive neuromyelitis optica spectrum disorder,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1284,TA942,2023/24,STA,Empagliflozin,Pharmaceutical,Treating chronic kidney disease,Optimised,"Optimised recommendation for empagliflozin for treating chronic kidney disease (CKD) in adults, only if:
|
||
- it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and
|
||
- people have an estimated glomerular filtration rate of:
|
||
20 ml/min/1.73 m2 to less than 45 ml/min/1.73 m2 or
|
||
45 ml/min/1.73 m2 to 90 ml/min/1.73 m2 and either:
|
||
a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more, or
|
||
type 2 diabetes."
|
||
1285,TA943,2023/24,MTA,Hybrid closed loop systems ,Pharmaceutical,Managing blood glucose levels in type 1 diabetes,Optimised,"Optimised recommendation for hybrid closed loop (HCL) systems for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling hypoglycaemia, despite best possible management with at least 1 of the following:
|
||
continuous subcutaneous insulin infusion (CSII)
|
||
real-time continuous glucose monitoring
|
||
intermittently scanned continuous glucose monitoring.
|
||
HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following NHS England's and NHS Wales' implementation plans."
|
||
1286,TA943,2023/24,MTA,Hybrid closed loop systems ,Pharmaceutical,Managing blood glucose levels in type 1 diabetes,Optimised,"Optimised recommendation for HCL systems for managing blood glucose levels in type 1 diabetes for children and young people. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following NHS England's and NHS Wales' implementation plans."
|
||
1287,TA943,2023/24,MTA,Hybrid closed loop systems ,Pharmaceutical,Managing blood glucose levels in type 1 diabetes,Optimised,"Optimised recommendation for HCL systems for managing blood glucose levels in type 1 diabetes for women, trans men and non-binary people who are pregnant or planning to become pregnant. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following NHS England's and NHS Wales' implementation plans."
|
||
1288,TA944,2023/24,STA,Durvalumab with gemcitabine and cisplatin ,Pharmaceutical,Unresectable or advanced biliary tract cancer,Recommended, Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1289,TA945,2023/24,STA,Treosulfan with fludarabine ,Pharmaceutical,before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1290,TA946,2023/24,STA,Olaparib with bevacizumab ,Pharmaceutical,"Maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Recommended,CDF review of TA693. Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1291,TA947,2023/24,STA,Loncastuximab tesirine ,Pharmaceutical,Relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments,Optimised,"Optimised recommendation for loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) after 2 or more systemic treatments in adults, only if:
|
||
they have previously had polatuzumab vedotin, or if polatuzumab vedotin is contraindicated or not tolerated, and
|
||
the company provides it according to the commercial arrangement."
|
||
1292,TA948,2023/24,STA,Ivosidenib,Pharmaceutical,Advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1293,TA949,2023/24,STA,Belumosudil ,Pharmaceutical,Chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1294,TA950,2023/24,STA,Nivolumab–relatlimab ,Pharmaceutical,Untreated unresectable or metastatic melanoma in people 12 years and over,Optimised,"Optimised recommendation for nivolumab–relatlimab for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over, only if:
|
||
nivolumab–relatlimab is stopped after 2 years of treatment, or earlier if the cancer progresses, and
|
||
the company provides it according to the commercial arrangement."
|
||
1295,TA951,2023/24,STA,Olaparib with abiraterone,Pharmaceutical, Untreated hormone-relapsed metastatic prostate cancer,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1296,TA952,2023/24,STA,Talazoparib ,Pharmaceutical,Treating HER2-negative advanced breast cancer with germline BRCA mutations,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1297,TA953,2023/24,STA,Fluocinolone acetonide intravitreal implant,Pharmaceutical,Chronic diabetic macular oedema,Recommended,Replaces TA613 and TA301. Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1298,TA954,2023/24,STA,Epcoritamab,Pharmaceutical,Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments,Optimised,"Optimised recommendation for epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults after 2 or more systemic treatments, only if:
|
||
they have had polatuzumab vedotin, or if polatuzumab vedotin is contraindicated or not tolerated, and
|
||
the company provides epcoritamab according to the commercial arrangement."
|
||
1299,TA955,2023/24,STA,Dupilumab ,Pharmaceutical,Moderate to severe prurigo nodularis,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1300,TA956,2023/24,STA,Etrasimod ,Pharmaceutical,Treating moderately to severely active ulcerative colitis in people aged 16 and over,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1301,TA957,2023/24,STA,Momelotinib ,Pharmaceutical,Myelofibrosis-related splenomegaly or symptoms,Optimised,"Optimised recommendation for momelotinib as an option for treating myelofibrosis-related splenomegaly or symptoms in adults with moderate to severe anaemia who have not had a JAK inhibitor or have had ruxolitinib, only if:
|
||
they have intermediate‑2 or high-risk myelofibrosis, and
|
||
the company provides momelotinib according to the commercial arrangement."
|
||
1302,TA958,2023/24,STA,Ritlecitinib ,Pharmaceutical,Severe alopecia areata in people 12 years and over,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1303,TA959,2023/24,STA,Daratumumab in combination,Pharmaceutical,Newly diagnosed systemic amyloid light-chain amyloidosis,Optimised,"Optimised recommendation for daratumumab plus bortezomib, cyclophosphamide and dexamethasone for treating newly diagnosed systemic amyloid light-chain (AL) amyloidosis in adults. It is recommended only if:
|
||
daratumumab is stopped after 24 cycles of treatment, or earlier if the condition progresses, and
|
||
the company provides daratumumab according to the commercial arrangement."
|
||
1304,TA960,2023/24,STA,Satralizumab ,Pharmaceutical,Preventing relapses in neuromyelitis optica spectrum disorders,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1305,TA961,2023/24,STA,Sebelipase alfa,Pharmaceutical,Lysosomal acid lipase deficiency that is not Wolman disease,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1306,TA962,2023/24,STA,Olaparib ,Pharmaceutical,"Maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy",Recommended,Replaces TA598. Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1307,TA963,2024/25,STA,Dostarlimab with platinum-based chemotherapy,Pharmaceutical,Advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,Recommended (CDF),Dostarlimab with platinum-based chemotherapy is recommended with managed access as an option for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who are candidates for systemic therapy. It is only recommended if the conditions in the managed access agreement for dostarlimab are followed.
|
||
1308,TA964,2024/25,STA,Cabozantinib with nivolumab,Pharmaceutical,Untreated advanced renal cell carcinoma,Optimised,"Optimised recommendation for cabozantinib with nivolumab for untreated advanced renal cell carcinoma in adults, only if:
|
||
their disease is intermediate or poor risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria, and
|
||
nivolumab with ipilimumab or lenvatinib with pembrolizumab would otherwise be offered, and
|
||
the companies provide cabozantinib and nivolumab according to their commercial arrangements."
|
||
1309,TA965,2023/24,STA,Human alpha1-proteinase inhibitor ,Pharmaceutical,Treating emphysema,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1310,TA966,2024/25,STA,Pembrolizumab with gemcitabine and cisplatin ,Pharmaceutical,Untreated advanced biliary tract cancer,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1311,TA967,2024/25,STA,Pembrolizumab ,Pharmaceutical,Relapsed or refractory classical Hodgkin lymphoma in people 3 years and over,Optimised,"CDF review of TA540 Optimised recommendation for pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over who have had at least 2 previous treatments and cannot have an autologous stem cell transplant (ASCT). It is recommended only if:
|
||
they have already had brentuximab vedotin and
|
||
pembrolizumab is stopped after 2 years of treatment or earlier if the person has a stem cell transplant or the disease progresses and
|
||
the company provides it according to the commercial arrangement."
|
||
1312,TA968,2024/25,STA,Melphalan flufenamide with dexamethasone,Pharmaceutical,Relapsed or refractory multiple myeloma,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1313,TA969,2024/25,STA,Gefapixant,Pharmaceutical,Refractory or unexplained chronic cough,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1314,TA970,2024/25,STA,Selinexor with dexamethasone ,Pharmaceutical,Relapsed or refractory multiple myeloma after 4 or more treatments,Recommended,Partial update of TA700. Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1315,TA971,2024/25,MTA,Remdesivir ,Pharmaceutical,Treating COVID-19,Optimised,"Optimised recommendation for remdesivir for treating COVID‑19 in hospitals in:
|
||
adults, only if they have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19)
|
||
babies, children and young people, only if they:
|
||
are aged 4 weeks to 17 years and weigh at least 3 kg, and:
|
||
have pneumonia, and
|
||
need supplemental oxygen, or
|
||
weigh at least 40 kg, and have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID‑19).
|
||
Remdesivir is only recommended if the company provides it according to the commercial arrangement."
|
||
1316,TA971,2024/25,MTA,Rixagevimab plus cilgavimab ,Pharmaceutical,Treating COVID-19,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1317,TA972,2024/25,STA,Sirolimus ,Pharmaceutical,Treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1318,TA973,2024/25,STA,Atogepant ,Pharmaceutical,Preventing migraine,Optimised,"Optimised recommendation for atogepant for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventive medicines have failed."
|
||
1319,TA974,2024/25,STA,Selinexor with bortezomib and dexamethasone ,Pharmaceutical,Previously treated multiple myeloma,Optimised,"Partial update of TA700. Optimised recommendation for selinexor plus bortezomib and dexamethasone for treating multiple myeloma in adults, only if:
|
||
they have only had 1 previous line of treatment, and their condition is refractory to both daratumumab and lenalidomide, or
|
||
they have only had 2 previous lines of treatment and their condition is refractory to lenalidomide.
|
||
Selinexor is only recommended if the company provides it according to the commercial arrangement."
|
||
1320,TA975,2024/25,STA,Tisagenlecleucel,Pharmaceutical,Relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under,Recommended,CDF review of TA554. Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1321,TA976,2024/25,STA,Trastuzumab deruxtecan ,Pharmaceutical,Treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1322,TA977,2024/25,STA,Dabrafenib with trametinib ,Pharmaceutical,Treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1323,TA978,2024/25,STA,Zanubrutinib with obinutuzumab ,Pharmaceutical,Treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1324,TA979,2024/25,STA,Ivosidenib with azacitidine ,Pharmaceutical,Untreated acute myeloid leukaemia with an IDH1 R132 mutation,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1325,TA980,2024/25,STA,Nivolumab ,Pharmaceutical,Adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1326,TA981,2024/25,STA,Voxelotor,Pharmaceutical,Haemolytic anaemia caused by sickle cell disease,Optimised,"Optimised recommendation for voxelotor, with or without hydroxycarbamide, as an option for treating haemolytic anaemia caused by sickle cell disease in people 12 years and over. It is recommended only if:
|
||
people are ineligible for, or intolerant of hydroxycarbamide, or
|
||
hydroxycarbamide alone is insufficiently effective.
|
||
Voxelotor is only recommended if the company provides it according to the commercial arrangement."
|
||
1327,TA982,2024/25,STA,Baricitinib ,Pharmaceutical,Juvenile idiopathic arthritis in people 2 years and over,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1328,TA983,2024/25,STA,Pembrolizumab with trastuzumab and chemotherapy ,Pharmaceutical,Untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1329,TA984,2024/25,STA,Tafamidis ,Pharmaceutical,Transthyretin amyloidosis with cardiomyopathy,Recommended,Review of TA696. Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1330,TA985,2024/25,STA,Selective internal radiation therapy with QuiremSpheres ,Pharmaceutical,Unresectable advanced hepatocellular carcinoma,Optimised,"Optimised recommendation for the selective internal radiation therapy (SIRT) QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (HCC) in adults, only if it is:
|
||
used for people with Child–Pugh grade A liver impairment when conventional transarterial therapies are inappropriate, and
|
||
the company provides it according to the commercial arrangement."
|
||
1331,TA986,2024/25,STA,Lebrikizumab,Pharmaceutical,Moderate to severe atopic dermatitis in people 12 years and over,Optimised,"Optimised recommendation for lebrikizumab for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in people 12 years and over with a body weight of 40 kg or more, only if:
|
||
the atopic dermatitis has not responded to at least 1 systemic immunosuppressant or these treatments are not suitable, and
|
||
dupilumab or tralokinumab would otherwise be offered, and
|
||
the company provides it according to the commercial arrangement."
|
||
1332,TA987,2024/25,STA,Lisocabtagene maraleucel ,Pharmaceutical,Relapsed or refractory aggressive B-cell non-Hodgkin lymphoma,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1333,TA988,2024/25,MTA,Ivacaftor–tezacaftor–elexacafto,Pharmaceutical,Treating cystic fibrosis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1334,TA988,2024/25,MTA,Tezacaftor–ivacaftor,Pharmaceutical,Treating cystic fibrosis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1335,TA988,2024/25,MTA,Lumacaftor–ivacaftor ,Pharmaceutical,Treating cystic fibrosis,Recommended,Recommended in line with marketing authorisation and following agreement of a patient access scheme
|
||
1336,TA989,2024/25,STA,Etranacogene dezaparvovec ,Pharmaceutical,Moderately severe or severe haemophilia B,Optimised,Etranacogene dezaparvovec is recommended with managed access as an option for treating moderately severe or severe haemophilia B (congenital factor IX [FIX] deficiency) in adults without anti‑FIX antibodies. It is only recommended if the conditions in the managed access agreement for etranacogene dezaparvovec are followed.
|
||
1337,TA990,2024/25,STA,Tenecteplase ,Pharmaceutical,Treating acute ischaemic stroke,Recommended,"Recommended in line with marketing authorisation.
|
||
This appraisal followed the cost comparison process"
|
||
1338,TA991,2024/25,STA,Abaloparatide,Pharmaceutical, Treating osteoporosis after menopause,Optimised,Optimised recommendation
|
||
1339,TA992,2024/25,STA,Trastuzumab deruxtecan ,Pharmaceutical,Treating HER2-low metastatic or unresectable breast cancer after chemotherapy,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1340,TA993,2024/25,STA,Burosumab,Pharmaceutical,Treating X-linked hypophosphataemia in adults,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1341,TA994,2024/25,STA,Enzalutamide,Pharmaceutical, Treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1342,TA995,2024/25,STA,Relugolix ,Pharmaceutical,Treating hormone-sensitive prostate cancer,Recommended,Recommended in line with marketing authorisation.
|
||
1343,TA996,2024/25,STA,Linzagolix ,Pharmaceutical,Treating moderate to severe symptoms of uterine fibroids,Optimised,"Optimised recommendation for linzagolix for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age only if:
|
||
it is intended to be used for longer-term treatment (normally for more than 6 months and not for people who need short-term treatment, for example, before planned surgery)
|
||
the following dosage is used:
|
||
with hormonal add-back therapy (ABT): 200 mg once daily
|
||
without hormonal ABT: 200 mg once daily for 6 months, then 100 mg once daily."
|
||
1344,TA997,2024/25,STA,Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy,Pharmaceutical, Untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma,Recommended,Recommended in line with marketing authorisation and following agreement of a commercial access arrangement
|
||
1345,TA998,2024/25,STA,Risankizumab ,Pharmaceutical,Treating moderately to severely active ulcerative colitis,Optimised,"Optimised recommendation for risankizumab for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or has lost response to treatment, only if:
|
||
a tumour necrosis factor (TNF)-alpha inhibitor:
|
||
has not worked (that is the condition has not responded well enough or has lost response to treatment), or
|
||
cannot be tolerated or is not suitable, and
|
||
the company provides it according to the commercial arrangement.
|
||
This appraisal followed the cost comparison process"
|
||
1346,TA999,2024/25,STA,Vibegron,Pharmaceutical,Treating symptoms of overactive bladder syndrome,Optimised,"Optimised recommendation for Vibegron as an option for treating the symptoms of overactive bladder syndrome in adults. It is only recommended if antimuscarinic medicines are not suitable, do not work well enough or have unacceptable side effects."
|
||
1347,TA1000,2024/25,STA,Iptacopan,Pharmaceutical,Treating paroxysmal nocturnal haemoglobinuria,Recommended,Recommended in line with marketing authorisation
|
||
1348,TA1001,2024/25,STA,Zanubrutinib,Pharmaceutical,Treating marginal zone lymphoma after anti-CD20-based treatment,Recommended,Recommended in line with marketing authorisation
|
||
1349,TA1002,2024/25,STA,Evinacumab,Pharmaceutical,Treating homozygous familial hypercholesterolaemia in people 12 years and over,Recommended,Recommended in line with marketing authorisation
|
||
1350,TA1003,2024/25,STA,Exagamglogene autotemcel,Pharmaceutical,Treating transfusion-dependent beta-thalassaemia in people 12 years and over,Recommended,"Exagamglogene autotemcel (exa-cel) is recommended with managed access as an option for treating transfusion-dependent beta-thalassaemia in people 12 years and over, when: a haematopoietic stem cell transplant (HSCT) is suitable, and a human leukocyte antigen-matched related haematopoietic stem cell donor is not available. It is only recommended if the conditions in the managed access agreement for exa-cel are followed."
|
||
1351,TA1004,2024/25,STA,Faricimab ,Pharmaceutical,Treating visual impairment caused by macular oedema after retinal vein occlusion,Recommended,Recommended in line with marketing authorisation
|
||
1352,TA1005,2024/25,STA,Futibatinib,Pharmaceutical,Previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,Recommended,Recommended in line with marketing authorisation
|
||
1353,TA1006,2024/25,STA,Empagliflozin,Pharmaceutical,Treating type 2 diabetes in people 10 to 17 years,Terminated Appraisal - non submission,The single technology appraisal process is based on the company's submission. In the absence of a submission from the manufacturer the appraisal was terminated and a recommendation could not be made.
|
||
1354,TA1007,2024/25,STA,Rucaparib ,Pharmaceutical,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",Recommended,Recommended in line with marketing authorisation
|
||
1355,TA1008,2024/25,STA,Trifluridine–tipiracil with bevacizumab,Pharmaceutical,Treating metastatic colorectal cancer after 2 systemic treatments,Recommended,Recommended in line with marketing authorisation
|
||
1356,TA1009,2024/25,STA,Latanoprost–netarsudil ,Pharmaceutical,Previously treated primary open-angle glaucoma or ocular hypertension,Optimised,"Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not reduced IOP enough, only if: • they have then tried a fixed-dose combination treatment and it has not reduced IOP enough, or • a fixed-dose combination treatment containing beta-blockers is unsuitable."
|
||
1357,TA1010,2024/25,STA,Danicopan,Pharmaceutical,Treating paroxysmal nocturnal haemoglobinuria,Optimised,Recommended in line with company positioning
|
||
1358,TA1011,2024/25,STA,Belzutifan,Pharmaceutical,Treating tumours associated with von Hippel-Lindau disease,Recommended (CDF),Recommended in line with marketing authorisation
|
||
1359,TA1012,2024/25,STA,Avapritinib,Pharmaceutical,Treating advanced systemic mastocytosis,Recommended,Recommended in line with marketing authorisation
|
||
1360,TA1013,2024/25,STA,Quizartinib,Pharmaceutical,"For induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia",Recommended,Recommended in line with marketing authorisation
|
||
1361,TA1014,2024/25,STA,Alectinib,Pharmaceutical,Adjuvant treatment of ALK-positive non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
|
||
1362,TA1015,2024/25,STA,Teclistamab,Pharmaceutical,Treating relapsed and refractory multiple myeloma after 3 or more treatments,Optimised,"Review of TA869. Optimised recommendation for teclistamab ifor treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on the last treatment. It is only recommended if the company provides teclistamab according to the commercial arrangement."
|
||
1363,TA1016,2024/25,STA,Elafibranor ,Pharmaceutical,For previously treated primary biliary cholangitis,Recommended,Recommended in line with marketing authorisation
|
||
1364,TA1017,2024/25,STA,Pembrolizumab ,Pharmaceutical,Treating resectable non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
|
||
1365,TA1018,2024/25,STA,Fedratinib,Pharmaceutical,Treating disease-related splenomegaly or symptoms in myelofibrosis,Optimised,"Review of TA756. Optimised recommendation for fedratinib for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis. It is recommended for adults, only if: they have had ruxolitinib, and momelotinib is unsuitable, and the company provides fedratinib according to the commercial arrangement."
|
||
1366,TA1019,2024/25,STA,Crovalimab,Pharmaceutical,Treating paroxysmal nocturnal haemoglobinuria in people 12 years and over,Recommended,Recommended in line with marketing authorisation
|
||
1367,TA1020,2024/25,STA,Eplontersen,Pharmaceutical,Treating hereditary transthyretin-related amyloidosis,Recommended,Recommended in line with marketing authorisation
|
||
1368,TA1021,2024/25,STA,Crizotinib,Pharmaceutical,Treating ROS1-positive advanced non-small-cell lung cancer,Optimised,"Review of TA529. Optimised recommendation for crizotinibfor treating ROS1-positive advanced non-small-cell lung cancer in adults, only if: they have not had ROS1 inhibitors, the company provides it according to the commercial arrangement."
|
||
1369,TA1022,2024/25,STA,Bevacizumab gamma,Pharmaceutical,Treating wet age-related macular degeneration,Recommended,Recommended in line with marketing authorisation
|
||
1370,TA1023,2024/25,STA,Elranatamab,Pharmaceutical,Treating relapsed and refractory multiple myeloma after 3 or more treatments,Optimised (CDF),"Optimised recommendation for elranatamab for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti‑CD38 antibody) when the multiple myeloma has progressed on the last treatment. It is only recommended if the conditions in the managed access agreement for elranatamab are followed."
|
||
1371,TA1024,2024/25,STA,Toripalimab,Pharmaceutical,For untreated advanced oesophageal squamous cell cancer,Terminated Appraisal - non submission,"NICE is unable, at this time, to make a recommendation about the use in the NHS of toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer in adults. This is because Shanghai Junshi Bioscience has requested a delay to the evidence submission."
|
||
1372,TA1025,2024/25,STA,Ublituximab,Pharmaceutical,Treating relapsing multiple sclerosis,Optimised,"Optimised recommendation for ublituximab for treating relapsing forms of multiple sclerosis, defined as active by clinical or imaging features in adults, only if: the multiple sclerosis is relapsing–remitting, and the company provides it according to the commercial arrangement."
|
||
1373,TA1026,2024/25,STA,Tirzepatide,Pharmaceutical,For managing overweight and obesity,Optimised,"Optimised recommendation for tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have:
|
||
an initial body mass index (BMI) of at least 35 kg/m2 and
|
||
at least 1 weight-related comorbidity."
|
||
1374,TA1027,2024/25,STA,Tebentafusp,Pharmaceutical,For treating advanced uveal melanoma,Recommended,Recommended in line with marketing authorisation
|
||
1375,TA1028,2024/25,STA,Bimekizumab ,Pharmaceutical,For treating moderate to severe hidradenitis suppurativa,Terminated Appraisal - non submission,NICE is unable to make a recommendation about the use in the NHS of bimekizumab (Bimzelx) for treating moderate to severe hidradenitis suppurativa in adults. This is because UCB Pharma withdrew from the appraisal.
|
||
1376,TA1029,2024/25,STA,Andexanet alfa,Pharmaceutical,For reversing anticoagulation in people with intracranial haemorrhage ,Terminated Appraisal - non submission,NICE is unable to make a recommendation about the use in the NHS of andexanet alfa (Ondexxya) for reversing anticoagulation in adults with intracranial haemorrhage. This is because AstraZeneca did not provide an evidence submission.
|
||
1377,TA1030,2024/25,STA,Durvalumab,Pharmaceutical,Before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
|
||
1378,TA1031,2024/25,STA,Vamorolone,Pharmaceutical,For treating Duchenne muscular dystrophy in people 4 years and over,Recommended,Recommended in line with marketing authorisation
|
||
1379,TA1032,2024/25,STA,Niraparib,Pharmaceutical,For untreated hormone-relapsed metastatic prostate cancer,Terminated Appraisal - non submission,NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.
|
||
1380,TA1033,2024/25,STA,Ganaxolone,Pharmaceutical,Treating seizures caused by CDKL5 deficiency disorder in people 2 years and over,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1381,TA1034,2024/25,STA,Anhydrous sodium thiosulfate,Pharmaceutical,Preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours,Recommended,Recommended in line with marketing authorisation
|
||
1382,TA1035,2024/25,STA,Vadadustat,Pharmaceutical,For treating symptomatic anaemia in adults having dialysis for chronic kidney disease,Recommended,Recommended in line with marketing authorisation
|
||
1383,TA1036,2024/25,STA,Elacestrant,Pharmaceutical,Treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment,Optimised,"Optimised recommendation. Elacestrant is recommended as an option for treating oestrogen receptor (ER)-positive HER2-negative locally advanced or metastatic breast cancer with an activating ESR1 mutation that has progressed after at least 1 line of endocrine treatment plus a cyclin-dependent kinase (CDK) 4 and 6 inhibitor in:
|
||
women, trans men and non-binary people who have been through the menopause
|
||
trans women and men.
|
||
|
||
Elacestrant is recommended only if:
|
||
the cancer has progressed after at least 12 months of endocrine treatment plus a CDK 4 and 6 inhibitor, and
|
||
the company provides it according to the commercial arrangement."
|
||
1384,TA1037,2024/25,STA,Pembrolizumab,Pharmaceutical,Adjuvant treatment of resected non-small-cell lung cancer,Recommended,Recommended in line with marketing authorisation
|
||
1385,TA1038,2024/25,STA,Selpercatinib,Pharmaceutical,For advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over,Optimised,"Updates and replaces TA742. Optimised recommendation. Selpercatinib is recommended as an option in people 12 years and over for treating:
|
||
advanced RET fusion-positive thyroid cancer that is refractory to radioactive iodine (if radioactive iodine is appropriate), only if systemic treatment is needed after sorafenib or lenvatinib
|
||
advanced RET-mutant medullary thyroid cancer, only if systemic treatment is needed after cabozantinib or vandetanib.
|
||
Selpercatinib is only recommended if the company provides it according to the commercial arrangement."
|
||
1386,TA1039,2024/25,STA,Selpercatinib,Pharmaceutical,For advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over,Recommended,Recommended in line with marketing authorisation
|
||
1387,TA1040,2024/25,STA,Olaparib ,Pharmaceutical,For treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy,Recommended,Updates and replaces TA762. Recommended in line with marketing authorisation
|
||
1388,TA1041,2024/25,STA,Durvalumab,Pharmaceutical,For untreated extensive-stage small-cell lung cancer,Optimised,"Review of TA662. Optimised recommendation to align with comparator. Durvalumab with etoposide and either carboplatin or cisplatin is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if:
|
||
they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and the company provides durvalumab according to the commercial arrangement."
|
||
1389,TA1042,2024/25,STA,Selpercatinib ,Pharmaceutical,For previously treated RET fusion-positive advanced non-small-cell lung cancer,Optimised,"Review of TA760. Optimised recommendation. Selpercatinib is recommended as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults, only if:
|
||
it has been treated before and
|
||
the company provides selpercatinib according to the commercial arrangement"
|
||
1390,TA1043,2024/25,STA,Osimertinib,Pharmaceutical,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,Recommended,Updates and replaces TA761. Recommended in line with marketing authorisation.
|
||
1391,TA1044,2024/25,STA,Exagamglogene autotemcel,Pharmaceutical,For treating severe sickle cell disease in people 12 years and over,Optimised,"Optimised recommendation through Managed Access. Exagamglogene autotemcel (exa‑cel) is recommended with managed access as an option for treating sickle cell disease (SCD) in people 12 years and over:
|
||
who have:
|
||
recurrent vaso-occlusive crises (VOCs) and
|
||
a βS/βS, βS/β+ or βS/β0 genotype and
|
||
when haematopoietic stem cell transplant (HSCT) is suitable, but a human leukocyte antigen-matched related haematopoietic stem cell donor is not available.
|
||
It is only recommended:
|
||
for people who have had at least 2 VOCs (as defined in section 3.4) per year during the 2 previous years and
|
||
if the conditions in the managed access agreement for exa‑cel are followed."
|
||
1392,TA1045,2024/25,STA,12 SQ-HDM SLIT,Pharmaceutical,For treating allergic rhinitis caused by house dust mites,Optimised,"Updates and replaces TA834. Optimised recommendation. 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT) is recommended, within its marketing authorisation, as an option for treating moderate to severe house dust mite allergic rhinitis in people 12 to 65 years that is:
|
||
diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test or specific immunoglobulin E [IgE]) and
|
||
persistent despite use of symptom-relieving medicine."
|
||
1393,TA1045,2024/25,STA,12 SQ-HDM SLIT,Pharmaceutical,For treating allergic asthma caused by house dust mites,Not recommended,"Updates and replaces TA834. At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1394,TA1046,2024/25,STA,Zolbetuximab,Pharmaceutical,For untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1395,TA1047,2024/25,STA,Atezolizumab,Pharmaceutical,For untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable ,Terminated Appraisal - non submission,NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in adults. This is because Roche Products did not provide an evidence submission.
|
||
1396,TA1048,2024/25,STA,Lisocabtagene maraleucel,Pharmaceutical,For treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable,Optimised,"Optimised recommendation. Lisocabtagene maraleucel (liso‑cel) is recommended as an option for treating large B‑cell lymphoma that is refractory to, or has relapsed within 12 months after, first-line chemoimmunotherapy in adults with: diffuse large B‑cell lymphoma, high-grade B‑cell lymphoma, primary mediastinal large B-cell lymphoma, or
|
||
follicular lymphoma grade 3B. Liso-cel is recommended only if: an autologous stem cell transplant would be considered suitable, and the company provides it according to the commercial arrangement."
|
||
1397,TA1049,2024/25,STA,Blinatumomab,Pharmaceutical,For consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia,Optimised,"Optimised recommendation. Blinatumomab with chemotherapy can be used as an option to treat Philadelphia-chromosome-negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in adults, if: the leukaemia is minimal residual disease-negative, it is used at the start of consolidation treatment, the company provides it according to the commercial arrangement."
|
||
1398,TA1050,2024/25,STA,Fenfluramine,Pharmaceutical,For treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over,Not recommended,"At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available."
|
||
1399,TA1051,2025/26,STA,Efanesoctocog alfa,Pharmaceutical,For treating and preventing bleeding episodes in haemophilia A in people 2 years and over,Optimised,"Optimised recommendation. Efanesoctocog alfa is recommended as an option for treating and preventing bleeding episodes in people 2 years and over with haemophilia A (congenital factor VIII deficiency), only if:
|
||
they have a factor VIII activity level of less than 1% (severe haemophilia A)
|
||
the company provides it according to the commercial arrangement."
|
||
1400,TA1052,2025/26,STA,Pegylated liposomal irinotecan,Pharmaceutical,For untreated metastatic pancreatic cancer,Terminated Appraisal - non submission,"NICE is unable to make a recommendation on pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults. This is because the company did not provide an evidence submission."
|
||
1401,TA1053,2025/26,STA,Cladribine,Pharmaceutical,For treating active relapsing forms of multiple sclerosis,Optimised,"Optimised recommendation. Cladribine is recommended as an option for treating active relapsing forms of multiple sclerosis in adults, only:
|
||
if they have active relapsing–remitting multiple sclerosis, and
|
||
when high-efficacy disease-modifying therapies would be offered."
|
||
1402,TA1054,2025/26,STA,Ruxolitinib,Pharmaceutical,For treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over,Recommended,Updates and replaces TA839. Recommended in line with marketing authorisation
|
||
1403,TA1055,2025/26,STA,Rucaparib,Pharmaceutical,"For maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",Optimised,"Optimised recommendation. Rucaparib is recommended as an option for the maintenance treatment of advanced (International Federation of Gynecology and Obstetrics [FIGO] stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy in adults, only if:
|
||
it is BRCA mutation-negative and homologous recombination deficiency (HRD)-positive, or
|
||
it is BRCA mutation-negative, and HRD status is negative or unknown, and bevacizumab is not a treatment option because:
|
||
NHS England's BEV3 and BEV10 commissioning approval criteria for having it are not met, or
|
||
it is contraindicated or not tolerated, and
|
||
the company provides rucaparib according to the commercial arrangemen"
|
||
1404,TA1056,2025/26,STA,Molnupiravir,Pharmaceutical,For treating COVID-19,Optimised,"Optimised recommendation. Molnupiravir is recommended as an option for treating mild to moderate COVID‑19 in adults who have a positive SARS‑CoV‑2 test, only if:
|
||
they have 1 or more risk factors for progression to severe COVID‑19 (as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19) and
|
||
both nirmatrelvir plus ritonavir and sotrovimab are contraindicated or unsuitable."
|
||
1405,TA1057,2025/26,STA,Relugolix–estradiol–norethisterone,Pharmaceutical,For treating symptoms of endometriosis,Recommended,Recommended in line with marketing authorisation
|
||
1406,#N/A,2025/26,#N/A,#N/A,Pharmaceutical,#N/A,#N/A,#N/A
|